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Data on the prevalence or incidence of congenital infections in Namibia are limited. Therefore, this 
study aimed to determine the prevalence and model the incidence of three important vertically 
transmitted infectious diseases: Toxoplasma gondii (T. gondii), rubella and cytomegalovirus (CMV) 
infections in women of childbearing potential in Namibia.   
Methodology: 
Three hundred and forty-four consenting women attending public antenatal care in Windhoek were 
included in the study.  Clotted blood was collected, and a questionnaire included demographic data, 
immunization and obstetric history data as well as information on the exposure to risk factors. 
Seroprevalences of IgG against T. gondii, rubella and CMV and specific IgM antibodies against CMV 
were determined.  T. gondii IgM and T. gondii and CMV IgG avidity were determined with ELISA. 
Statistics: Fisher’s exact test was used for categorical associations and Kruskal Wallis test for 
continuous variables.  
Results: 
Anti-T. gondii IgG was found in 9 (2.61%) pregnant women. There was no association of anti-T. 
gondii IgG with demographic characteristics or exposure to risk factors. Anti-T. gondii IgM was 
positive in 1 (0.3 %) woman while 3 (0.9 %) women had borderline positive results. Specific IgG 
avidity was equivocal and high in 33% and 67% of seropositive women. 
Seroprevalence of rubella did not increase with age and the overall seroprevalence of specific IgG 
was 95.9%. The majority of the participants had never been vaccinated against rubella infection. The 
percentage of women with IgG levels of <10 IU/ml, 10-14.9 IU/ml and > 15 IU/ml were 2.0%, 2.0% 
and 95.9% respectively. An overall anti-rubella IgG mean level of 164.5 IU/ml (95% CI 150.4-178.7) 
was found in five age groups, namely 15-20 (195.8; 159-232); 21-25 (167.8; 143-193); 26-30 (165.2; 





age, gestational age and immunization history did not show significant associations with anti-rubella 
IgG levels.  
Seroprevalence of anti-CMV IgG among pregnant women was 100%. Eleven participants (3.2%) 
had a positive or equivocal anti-CMV IgM result. Specific IgG avidity was high in all of these cases. 
Neither maternal age nor gestational age was associated with a positive or equivocal zone IgM 
result.   
Incidences of infections could not be modelled due to either a very high or very low prevalence 
across age ranges. 
Conclusion: 
Seroprevalence of anti-T. gondii IgG is much lower in central urban Namibia than in other developing 
countries.  Investigation into specific IgM seropositivity and IgG avidity showed that pregnant women 
in the central region of Namibia are at low risk of vertical transmission and development of congenital 
toxoplasmosis.  
A high percentage of pregnant women in the study were immune to rubella virus despite no history 
of vaccination. This is likely due to a high rate of natural infection with rubella of children before 
reaching child-bearing potential. 
This was the first study to investigate seroprevalence of CMV in Namibia. The high seroprevalence 
of CMV suggests a risk of reinfection or reactivation rather than primary CMV infection in pregnancy. 





Data oor die voorkoms of insidensie van aangebore infeksies in Namibië is beperk. Hierdie studie 
het ten doel gehad om die voorkoms te bepaal en die insidensie te modelleer van drie belangrike 
vertikaal oordraagbare aansteeklike siektes: Toksoplasma gondii (T. gondii), rubella en 
sitomegalovirus (CMV) infeksies in vroue van vrugbare potensiaal in Namibië.   
Metodiek: 
Driehonderd vier-en-veertig instemmende vroue wat die openbare voorgeboortekliniek in Windhoek 
besoek het, is in die studie ingesluit. Stolboed is versamel en ‘n vraelys het demografiese data, 
inentingsgeskiedenis en verloskundige geskiedenis sowel as inligting oor blootstelling aan 
risikofaktore ingesluit. Seroprevalensie van IgG teen T. gondii, rubella en CMV en spesifieke IgM 
teenliggampies teen CMV is bepaal.  T. gondii IgM en T. gondii en CMV IgG aviditeit is bepaal met 
‘n ELISA. Statistiek: Fisher se eksakte toets is gebruik vir kategoriese data en die Kruskal Wallis-
toets vir aaneenlopende waardes.  
Resultate: 
Anti-T. gondii IgG is in 9 (2.61%) swanger vroue gevind. Daar was geen assosiasie van anti-T. gondii 
IgG met demografiese eienskappe of blootstelling aan risikofaktore nie. Anti-T. gondii IgM was 
positief in 1 (0.3 %) vrou terwyl 3 (0.9 %) vroue grenslyn anti-T. gondii IgM resultate getoon het. 
Spesifieke IgG aviditeit was dubbelsinnig en hoog in 33% en 67% van seropositiewe vroue. 
Seroprevalensie van rubella het nie met ouderdom toegeneem nie. Die meerderheid van die 
deelnemers het geen rubella-inentingsgeskiedenis gehad nie. Die persentasie vroue met IgG vlakke 
van <10 IU/ml, 10-14.9 IU/ml en > 15 IU/ml was 2.0%, 2.0% en 95.9% respektiewelik. ‘n Algehele 
anti-rubella IgG gemiddelde vlak van 164.5 IU/ml (95% CI 150.4-178.7) is gevind in vyf 
ouderdomsgroepe, naamlik 15-20 (195.8; 159-232); 21-25 (167.8; 143-193); 26-30 (165.2; 136-195); 





ouderdom, swangerskapouderdom en inentingsgeskiedenis het nie beduidende assosiasies met 
hoë vlakke van anti-rubella IgG getoon nie.  
Seroprevalensie van anti-CMV IgG in swanger vroue was 100%. Elf deelnemers (3.2%) het ‘n 
positiewe of dubbelsinnige anti-CMV IgM resultaat getoon. Spesifieke IgG aviditeit was hoog in al 
hierdie gevalle. Moederlike ouderdom of swangerskapouderdom was nie positief geassosieer met 
‘n positiewe of dubbelsinnige IgM resultaat nie.  
Insidensie van infeksies kon nie bepaal word nie weens of baie hoë of baie lae voorkoms oor 
ouderdomskategorieë.  
Gevolgtrekking: 
Seroprevalensie van anti-T. gondii IgG is baie laer in sentraal stedelike Namibië as in ander 
ontwikkelende lande. Ondersoek na spesifieke IgM seropositiwiteit en IgG aviditeit het getoon dat 
swanger vroue in die sentrale streek van Namibië ’n lae risiko vir vertikale oordrag en gevolglike 
aangebore toksoplasmose het.  
‘n Hoë persentasie van swanger vroue in die studie was immuun teen rubella virus ten spyte van 
geen rubella inentingeskiedenis. Dit is waarskynlik as gevolg van ‘n hoë koers van natuurlike 
infeksies met rubella onder kinders voordat vrugbare ouderdom bereik word.  
Hierdie was die eerste studie wat die seroprevalensie van CMV in Namibië ondersoek het. Die hoë 
seroprevalense dui op ‘n groter kans vir herinfeksie of heraktivering as vir primêre CMV infeksie. 
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The gentle silence of the dandelion seed 
floating on 
a wisp of warm air 
 
of the violet 
opening 
to the morning sun 
 
of the motion of 
the butterfly’s wings 
as it sucks the nectar 
of a cherry blossom 
 
The silence is broken  
by the cries 
of all the infants destroyed 
and the anguish of their mothers 
whose tears cannot reverse 
what the organism has wrought 
 
The quiet silence of the womb 
harbouring an unborn child 
awaiting its first breath 
of deserved normality 
 






Nor of the sad silence  
of the grave 
 
How can we silence the sad silence? 
 
Jack (2005)  
 
This poem was published in Infectious diseases of the fetus and newborn infant, Remington JS, 
Klein JO, Wilson CB, Nizet V, Maldonado YA, editors, 7th ed. p vi; Philadelphia: Saunders. Copyright 
Elsevier (2011). 
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Chapter 1: Introduction 
 
1.1 Overview of the study 
 
1.1.1 Background 
This study assessed the prevalence and incidence of three infectious agents, which are associated 
with congenital infection, among pregnant women attending the antenatal clinic at Windhoek Central 
Hospital in 2016. We were initially interested in directly assessing congenital infections among 
neonates born in Central Namibia in 2016. However, this was not regarded as feasible due to 
logistical difficulties and a limited budget not allowing for the testing of neonates shortly after birth.  
The term “congenital infections” refers to those infections that are transmitted vertically with most 
severe complications when occurring during the period of organogenesis – resulting in congenital 
infections associated with abnormal intrauterine development. 
Perinatal infections are infections that are transmitted just before, during or just after birth, resulting 
in neonatal infection that could be acute: e.g. group B Streptococcus; Listeria; E. coli; varicella or 
herpes simplex or result in chronic infection e.g. hepatitis B and C viral infections. 
Congenital infection is a well-described cause of stillbirths, as well as perinatal morbidity.  The 
epidemiology varies in different parts of the world while the burden is greatest in developing 
countries.  Common congenital infections, associated with intrautine tranmission include Treponema 
pallidum, resulting in congenital syphilis, human cytomegalovirus, Toxoplasma gondii, rubella, HIV, 
other herpes viruses such as varicella or herpes simplex viruses and enteroviruses. Recently a newly 
emerging infection in the New World, Zika virus, has been found to cause congenital infections. One 
of the most common congenital infections in sub-Saharan Africa has been congenital syphilis. 
Congenital syphilis has been described as one of the most important congenital infections in 
Southern Africa and is being addressed by maternal screening and treatment. It was rare in most 
developed countries with a slight increase recently in several European countries. Despite screening 





Africa congenital syphilis remains a public health problem although antenatal screening programmes 
for pregnant women are combined with cost-effective treatment with penicillin. In developing 
countries, antenatal care screening needs to be strengthened by implementation of point-of-care 
decentralized screening and treatment and alternative innovative applications to control congenital 
syphilis [155,156]. 
The point of departure for this study was the diagnostic testing for maternal and congenital infections 
which were known in previous years as the TORCH screen. The TORCH screen was well-known in 
clinical laboratories in Namibia and appeared on the repertoire of tests offered to clinicians. The 
acronym “TORCH” was first used in 1971 to indicate Toxoplasma gondii (T. gondii), rubella, 
cytomegalovirus (CMV) and herpes simplex virus. Later the ‘’O’’ indicated other infections like 
hepatitis viruses, human immunodeficiency virus (HIV), varicella and parvovirus B19.  In 1993, it was 
suggested in the United Kingdom (UK) that the term ‘’TORCH’’ be abolished due to the unreliable 
nature of Immunoglobulin M (IgM) results in congenital infections.  Over the last decade there has 
been significant improvement in diagnostic and imaging techniques [1,2].  
This study aimed to investigate the prevalence and incidence of agents listed in the TORCH screen 
and included three infectious agents originating from the initial TORCH screen, namely T. gondii, 
rubella and CMV.  Herpes simplex virus was not included due to the similarity in latency and 
reactivation to CMV which is also in the family of herpes viruses. T. gondii was of interest because 
the Faculty of Health and Applied Sciences at Namibia University of Science and Technology 
(NUST) hosts a niche research area for zoonotic diseases. Rubella is the main vaccine-preventable 
cause of birth defects. Cytomegalovirus is the leading cause of congenital infection and of 
sensorineural hearing loss in neonates. 
Zika virus is the newest maternal infection associated with a high risk of congenital infection and 
complications. The high occurrence of babies born with microcephaly coincided with an outbreak of 
Zika virus in South America and the Caribbean in 2015.  Subsequently systematic epidemiological 






Reduction of the under-five mortality rate by two thirds, between 1990 and 2015, was one of the 
United Nations Millennium Development Goals (Target 4.A). This meant that health systems 
internationally and especially in sub-Saharan Africa had to address factors contributing to the high 
under-five mortality and morbidity.  In Namibia, the under-five mortality rate is 49.8 per 1000 live 
births and the neonatal mortality rate is 21.8 per 1000 live births [6]. Namibia has identified the need 
to enhance the health of pregnant women and children, and to lower rates of perinatal deaths as 
stipulated in the National Development Plan 3 (NDP 3).  So far, the Ministry of Health and Social 
Services (MoHSS) has managed to improve mortality rates of pregnant women and children, by 
mainly focusing on services rendered at primary health care centres.  Much more work in this field 
needs to be done to enable achievement of the goals set by NDP 3. The Faculty of Health and 
Applied Sciences at the Namibia University of Science and Technology (NUST) responded to this 
need by establishing a Centre for Maternal and Child Health.  The aim of this centre is mainly to 
investigate the burden of Group B Streptococcus infections in pregnant women, which is associated 
with high neonatal mortality due to pneumonia and meningitis and high morbidity due to 
neurodevelopmental sequelae in those who survive.  However, infections that can be vertically 
transmitted through early intrauterine infection may also contribute to the burden of infectious 
diseases in pregnant women, the foetus and child after birth when suffering from the complications 
of a congenital infection.   
Transmission of pathogens may occur through the placenta before birth (intrauterine), during the 
birth process through contact with blood and vaginal secretions (perinatally) or postnatally through 
breast milk.  
Early diagnosis of congenital infections may allow for interventions that may modify the outcome or 
prevent complications [1]. Preferably, pre-conception screening programmes should be in place to 
identify pregnancies at risk of transmitting congenital infections, but these are found in developed 
countries only. For example, as part of family planning or before considering infertility treatment, it is 
essential that vaccination of women not immune to rubella or varicella is offered. Aggressive 





and congenital infections [1] but this may be more difficult to achieve in resource-constrained 
settings. Well-managed screening programmes may, however, prove cost-effective in some settings. 
In this project, a pilot study was conducted to determine the prevalence of toxoplasmosis among 
blood donors in Namibia. Results from this study were used to determine sample size for the study 
in the pregnant population. This study focused on pregnant women attending the antenatal clinic at 
Windhoek Central Hospital.  The aim of the study was to establish the exposure to toxoplasmosis 
and CMV infection, as well as anti-rubella immunity in this study group.  Blood samples were taken 
from voluntary, consenting participants in each of the three trimesters of pregnancy. Participants 
were requested to fill a questionnaire with demographic information, history of previous pregnancies 
and information about exposure to risk factors.  
In addition to testing of serum samples for immunoglobulin G (IgG) and IgM antibodies, IgG avidity 
was tested to determine whether IgM positive individuals had recent infections.  The avidity test 
assesses the combined affinity of binding between antibodies and antigens in the assay, and a low 
avidity indicates a recent primary infection, whereas a high avidity indicates a longstanding or 
secondary infection. In pregnant women, it is important to distinguish between older infections and 
new infections since transmission to the foetus is more likely during an early primary infection before 
neutralizing antibodies are present.  In the case of toxoplasmosis, IgM antibodies persist for twelve 
to eighteen months which means that IgM antibodies alone do not indicate a current infection.  This 
challenge can be addressed by implementing the IgG avidity test, which would distinguish a recent 
(low avidity) from a longstanding (high avidity) infection.  
In case of a positive rubella IgM test, rubella IgG avidity is valuable in discriminating recent acute 
infections (low avidity) from re-infections (high avidity), as recent infections hold a much higher risk 
of transmission and may require termination of pregnancy.  
CMV IgM assays are prone to false positivity and unless there is a high pre-test probability have low 
positive predictive values. When used in conjunction with avidity testing it is more informative: a 





and an intermediate IgG avidity may suggest the possibility of re-infection, and a high avidity may 
suggest possible virus reactivation.    
The prevalence of toxoplasmosis in human study groups in Namibia has been documented in one 
previous article [7], with two more articles on toxoplasmosis in groups investigating its zoonotic 
potential [8,9]. Toxoplasmosis in pregnant women has not been reported, neither the prevalence of 
CMV infection in any study group in Namibia. The only information available on rubella immunity in 
Namibia is from a study done on HIV sentinel survey samples collected from pregnant women [10]. 
There is no national surveillance system for rubella in Namibia, but measles negative cases are 
referred for rubella testing as part of the routine screening for measles in the national measles 
surveillance programme of the MoHSS in collaboration with the World Health Organisation (WHO). 
1.1.2 Benefits for Namibia 
This study aimed to shed light on the extent of maternal infectious diseases in central Namibia 
(Khomas region).  This information might guide further interventions in the health care system to 
improve diagnosis and treatment of infectious diseases which affect pregnant women and their 
foetuses. The outcome of the investigation into rubella immunity among pregnant women could 
evaluate vaccine coverage and further guide the immunisation programme of the Ministry of Health 
and Social Services. The ultimate goal would ideally be to enhance screening for infectious diseases 
among pregnant women, should this study identify a need for that. Effective prevention, diagnosis 
and treatment of infections in pregnant women would impact on the prevalence and severity of 
congenital infections.  This may save a lot of money for the health care and social systems in Namibia 
in terms of management of children with disabilities. 
1.1.3 Place of Research 
The study was performed in Windhoek, Namibia.  Samples were collected at the antenatal clinic of 
the Windhoek Central Hospital. This facility serves as a primary health care centre for the 





1.1.4 Research problem / Central research theme 
The screening panel for congenital infections used by local laboratories is only requested in cases 
of symptomatic maternal or congenital infection. Many infections in pregnant women in central 
Namibia may never be diagnosed, resulting in detrimental or fatal effects on the foetus. Except for 
Jacobs & Mason (1978) [7], no recent studies have determined the burden of T.  gondii infection in 
Namibia. No information is available on the prevalence of CMV infection among pregnant women or 
any other population in Namibia. Only one previous study reported on rubella immunity among 





1.2 Overview of infections in pregnant women and congenital 
infections 
 
1.2.1 Concepts in congenital infections 
Pregnant women are constantly exposed to infectious agents circulating in their community. An 
additional risk factor is their association with young children which increases their exposure to 
infectious agents.  Maternal infections are mainly through the oral or respiratory route and resolve 
with or without symptoms in immunocompetent women.  If the infection enters the maternal 
bloodstream it can be transmitted to the foetus [11]. 
When microorganisms invade the maternal blood stream, four consequences are possible: (1) 
placental infection without infection of the foetus; (2) foetal infection without infection of the placenta; 
(3) neither foetal nor placental infection; (4) infection of both placenta and the foetus. Invasion of the 
maternal bloodstream by microorganisms is common, yet in most cases neither foetal nor placental 
infections result. In cases where both placenta and foetus are infected, the infection might spread 
from the placenta by emboli from necrotized placental tissue or through contaminated amniotic fluid 
ingested by the foetus [11]. 
1.2.2 Developmental immunology 
The human foetus and neonate are susceptible to infectious agents which may not cause significant 
disease in immunocompetent more mature individuals, due to underdevelopment of the foetal 
immune system. 
Host defence against specific classes of neonatal pathogens include the interaction between the 
foetal immune system and T. gondii. Information regarding the innate immune response in the foetus 
and neonate against the parasite is limited. Neonatal monocytes can ingest and kill T. gondii, and 
macrophages from neonates can kill or restrict the growth of T. gondii as effectively as adult cells. 
However, it is indicated that other deficiencies in the neonatal innate immune system contribute to 





differences in T lymphocyte (T cell) responses between the foetus or neonate and adults. Foetal and 
neonatal antigen presenting cells produce less cytokines to activate helper T cells [12].  
The underdeveloped immune system of the foetus renders it more susceptible to infections incurred 
intrauterine when transmitted from the mother. The foetus and young child have high susceptibility 
to intracellular pathogens indicating different T cell-mediated immune responses from adults [152]. 
A number of viruses, including CMV, HIV and herpes simplex type 2 cause more severe or rapidly 
progressing disease in early life compared to later life. The immaturity of the neonatal immune 
system could be ascribed to defects in conventional T cells, especially CD4 T cells, and impaired 
dendritic cell responses. Probably in all species, immature T cells develop in the foetus with T cell 
receptors which are different from those found in adults [152]. Vermijlen et. al. (2010) reported that 
CMV infection in utero changes the T cell compartments. Foetal T cells generated in utero during 
CMV infection are equipped with a range of antiviral effector mechanisms, including interferon 
production and granule-mediated cytotoxicity. T cell clones generated from CMV-infected newborns 
killed CMV-infected cells and limited CMV replication in vitro [152]. Interferon and cytokines appear 
to be upregulated in rubella-infected human foetal cells, which could disrupt developing and 
differentiating cells and thus contribute to congenital defects [153].  
1.2.3 Contributing factors to congenital infections and neonatal deaths 
In addition to direct infectious causes of neonatal deaths, a multitude of indirect causes contribute to 
the high neonatal mortality rate in developing countries. These contributing factors may be 
socioeconomic or medical by nature and include lack of clean water and sanitation and inadequate 
access to high-quality medical care. If untreated, infections in newborns can fast become life-
threatening or lead to adverse effects lasting for life [13].  Lack of well-managed vaccination 
programmes with high coverage, also play a role in child mortality and morbidity in developing 





1.2.4. Prevention of congenital complications by maternal and neonatal 
infections 
Prevention of infections in newborns can in some instances be achieved by better maternal care – 
preventive and curative. Furthermore, capacity to diagnose and treat neonatal infections should be 
built. Interventions for prevention of infectious congenital diseases can be classified as follows: 
(1) primary prevention of maternal infection during pregnancy;   
(2) secondary prevention, or reduction of risk of foetal infection and disease once maternal infection 
has been acquired in pregnancy; and  
(3) tertiary prevention, defined as reduction in the risk of neonates being affected by the agent once 
infected [14].  
Approved treatment regimens for pregnant women are not always available, once maternal CMV or 
rubella is diagnosed no treatment has been shown to change the disease course. No therapies have 
been approved to treat intra-uterine CMV infection. In some cases, commonly used medication is 
toxic to the foetus when administered to pregnant women. In other cases, like rubella, congenital 
infections can best be prevented by well-managed vaccination programmes where vaccines are 
available.  Education of pregnant women on lifestyle interventions like good hygiene is sometimes 
the best practice to prevent congenital infections.  In France, reduction of maternal toxoplasmosis 
has greatly been attributed to better education regarding hygiene practices to prevent infection [15]. 
Behavioural strategies are also recommended by Centers for Disease Control and Prevention (CDC) 







1.3 Toxoplasma gondii 
 
1.3.1 Parasite description 
Toxoplasma gondii (T. gondii) is an apicomplexan protozoan parasite with the only definitive hosts 
being cat species. Genetic diversity among T. gondii includes three lineages, namely type I, II and 
III which predominates in different combinations in geographical areas.  T. gondii exists in three 
forms outside the cat intestine, namely the oocysts, the bradyzoites and the tachyzoites [18].  
1.3.2 Morphology and biology  
Tachyzoites are oval with one end pointed and one end rounded. They are 4-8 µm long. Tachyzoites 
require an intracellular habitat to survive and multiply, and very few survive the gastric environment 
of the host. Once in a vacuole in the host cell the parasites multiply by nuclear divisions and form a 
large collection within the host cell. During the acute stage of infection tachyzoites invade every kind 
of mammalian cell [18].  
During the first initial acute phase after ingestion of the parasites, tachyzoites prevail which are 
responsible for parasitaemia and systemic infection. The second phase is characterized by the 
transformation of rapidly dividing tachyzoites in slowly dividing bradyzoites. In the third stage cysts 
in tissues represent the latent phase of infection.  The tissue cyst is formed within the host cell and 
may be up to 200 µm in size. Cysts occur in any type of tissue, but are found mainly in brain, heart 
and skeletal muscle tissue where they persist for life to form a latent infection. Cysts in the brain are 
found within neurons [18].  
Oocysts are shed by cats and excretion may last up to two weeks. In 1-5 days, the oocysts sporulate 
and become infectious. In a favourable environment like warm, moist soil they may remain infectious 
for up to a year [18]. 
1.3.3 Epidemiology in Africa 
Prevalence of toxoplasmosis varies widely in different populations, and this may be due to 
environmental factors or differences in culture and eating habits [19]. While the prevalence of 





35% in recent years and declined in humans and pigs in the United States of America (USA), recent 
reports on seroprevalence in Africa remain scarce [20,21].  Since the first report on the prevalence 
of T. gondii in Africa between 1971 and 2012, there has been a decline in seroprevalence from the 
northern to the southern, and from the western to the eastern regions of the continent. 
Toxoplasmosis rates are highest in the northern part of Africa while there has been a decreasing 
trend over time in northern, southern and eastern Africa [22]. While a considerable reservoir of T. 
gondii prevails among wild animals, toxoplasmosis remains a threat to the health of humans, 
especially immunocompromised individuals like HIV positive patients [23,24]. 











Population Method Reference 












Benin 1995 53.6 Pregnant 
women 
 
ELISA Rodier [28] 
India 2004 IgG 45 
IgM 3.3 




ELISA Singh [27] 
Ethiopia 2007 60 
 
Urban MDAT Negash [32] 
Nigeria 2007 20.8 Healthy 
individuals 
 
 Uneke [36] 
Tanzania 2009 46 Occupationally 
exposed 
 
LAT Swai [39] 













Gabon 2010 56 Pregnant 
women 
 
 Mickoto [33] 
Mozambique 2010 18.7 Pregnant 
women 
 
ELISA Sitoe [34] 







Egypt 2012 IgG 67.5 
IgM 2.8 




ELFA El Deeb [31] 





ELISA De Paschale 
[29] 
Congo 2014 IgG 80.3 
IgM 4.4 




ELFA Doudou [30] 
Ethiopia 2015 18.5 Pregnant 
women 






In 1978 Jacobs and Mason reported seroprevalence of antibodies against T. gondii in 12% of blood 
donors in Windhoek area, while a study in South Africa reported toxoplasmosis in 9.8% and 6.4% of 
HIV-positive and HIV-negative subjects respectively [7,41]. 
Information on the prevalence of congenital toxoplasmosis remains scarce and it is not well-
documented, especially in developing countries. In 2001 data from the New England Regional 
Newborn Screening Program suggested congenital T. gondii infection in 1 in 10 000 live births. Given 
about 4 million births in the USA each year, an estimated 400-4000 infants are born each year with 
congenital toxoplasmosis [42]. Torgerson & Mastroiacovo (2013) used mathematical modelling and 
information from a literature review to estimate the global burden of congenital toxoplasmosis (CT). 
The global estimated incidence of congenital toxoplasmosis (CT) is 1.5 cases per 1000 live births or 
190 100 annual cases. The European CDC reported a rate of 288 cases of CT in Europe in 2015 
[151].  The incidence of CT in the WHO Afro E region is 2.4 per 1000 live births or 37 000 cases 
annually [43].  
1.3.4 Lifecycle and transmission 
T.  gondii is an obligate intracellular parasite with the only definitive hosts being cat species [18]. 
Sexual reproduction only takes place in the intestine of the cat family, where oocysts are produced 
after ingestion of any of the three forms mentioned. Within 3-15 days from infection gametocytes 
appear in the small intestine. After zygote and oocyst formation no further development takes place 
in the intestine of the cat. Oocysts are passed out of the gut with the faeces with peak oocyst 
production between days 5 and 8. Oocysts are shed in the faeces for a period of 7-20 days. Up to 
10 million oocysts might be shed in one day. When sporulated oocysts are ingested they are infective 
to the intermediate hosts and give rise to the extra-intestinal forms. Tissue cysts form in muscle and 
brain tissue of the host, which in the case of rodents might serve as food source for the definitive 
host. Humans can be regarded as accidental dead-end intermediate hosts and could be infected by 
accidently ingesting cat feaces, or through contaminated food.  Proper storage and cooking of meat 
should be effective to prevent infection in humans. Oocysts do not sporulate below 4o C or above 






Infection occurs via contamination of soil and water and the parasite can be found in all mammals, 
some reptiles and even sea otters. Humans are intermediate hosts. Infections in humans occur 
through ingestion of raw or undercooked meat, unpasteurised milk or contaminated water or living 
with cats and inadvertently ingesting eggs from cat faeces. It can also be acquired through organ 
transplant or blood transfusion. Toxoplasmosis can be transmitted from a mother to a foetus and 
cause deafness, blindness, mental retardation, physical impairment or even stillbirth.  If a pregnant 
woman is diagnosed with T. gondii infection, treatment is available although the success of the 
treatment will depend on a number of variables [18].  
Figure 1 depicts the life cycle of T. gondii with the different forms of the parasite and how it can be 
transmitted to a foetus [150]. 
 
 






1.3.5  Immune response to T. gondii infection 
After local invasion through the intestine, the organisms are either phagocytosed or they invade cells 
directly where they form intracellular cysts.  Human monocytes and neutrophils kill the majority of 
parasites, but some may persist within macrophages which move into the tissues. T. gondii invades 
every organ and tissue of the human host. Once there are too many parasites in an intracellular 
vacuole, the cell disrupts. Tissue destruction is limited by cell-mediated, as well as humoral immune 
responses. The intracellular location of parasites mostly protects them against antibodies and cysts 
persist for life [18]. 
In immunocompetent patients T. gondii induces a strong immune response. During infection, T. 
gondii spreads through the blood circulation and establishes in cysts in organs like the brain and 
heart. The first response to acute infection is by the innate immune system and is mediated by cells 
like neutrophils, monocytes, macrophages and dendritic cells which release interleukins (IL-12). This 
is followed by an adaptive immune response where CD4 T cells facilitate a strong response by CD8 
T cells releasing interferons which suppress intracellular parasite replication. The parasites are able 
to evade the host immune response by: (i) modulating host signalling pathways by down-regulating 
interleukin (IL-12) and by blocking up-regulation of genes responsible for production of interferon; 
(ii) inhibition of apoptosis in host cells infected with T. gondii; and (iii) evading intracellular death in 
neutrophils and macrophages [145]. Following acute infection is the latent infection characterized by 
exhaustion of the CD4 T cell and CD8 T cell responses towards the parasite [142], resulting in clinical 
recovery in most individuals. However, the infection is not erradicated and cysts persist as it enters 
a latent stage, which in immunocompetent women would not result in vertical transmission.   
1.3.6  Pathology  
Cysts formed in the brain tissue may rupture and form new cysts in the nearby tissue through the 
“leakage” of bradyzoites. The necrosis of brain tissue seen in newborns with CT is characterised by 
lesions in the cortex and basal ganglia. Zones of necrosis may undergo calcification. In the eye, the 
parasites first lodges in the retina and causes inflammation followed by destruction of the tissues in 





1.3.7  Congenital toxoplasmosis 
The second or subacute stage is considered of importance in the development of congenital 
toxoplasmosis [18]. Congenital transmission of T. gondii from an infected mother to her foetus was 
the first form of vertical transmission of any infection to be described in the literature. 
Immunocompetent and immunocompromised women contracting T. gondii infection for the first time, 
during pregnancy run a risk of transmitting the infection to the foetus due to the parasite crossing the 
placenta from the maternal blood. A host that is immunocompetent acquires life-long immunity 
against toxoplasmosis when infected with T. gondii.  A new T. gondii infection contracted 4 – 6 
months before conception will usually not result in vertical transmission of toxoplasmosis on 
subsequent exposures. In immunocompromised women who are HIV positive, T. gondii infection 
may reactivate with resulting vertical transmission [19,44].  
Only about 30% of infants born to mothers who had seroconversion in pregnancy acquire prenatal 
infection. If the infection in a pregnant woman is not treated, the risk of intrauterine infection increases 
with gestational age, i.e. from 14% for primary maternal infection in the first trimester, to 59% for 
primary maternal infection in the last trimester. [19]. The later in gestation of primary infection, the 
higher the risk of transmission to the foetus. However, when transmission occurs early in gestation 
the risk of symptomatic infection and severe disease is high [45].  
The highest risk for a mother of giving birth to a child with severe congenital infection is when 
maternal infection occurs at 10-20 weeks of gestation. When maternal infection is acquired after the 
24th week of gestation congenital infection is frequent but mainly mild [18]. 
Reactivation of latent infection causes symptoms in immune compromised patients [19]. Given the 
high prevalence of HIV infection in pregnant women in Africa, it is advisable to follow pregnancies 
and CT infections in women who were seropositive at conception as well. A study in Brazil found 
that among 49 foetuses born to HIV-1 infected mothers with chronic T. gondii infection, 3 children 
were diagnosed with CT. It was suggested that the CT could be attributed to reactivation of maternal 
T. gondii infection during pregnancy. However, there was no difference in the rate of vertical 





1.3.8 Symptoms and signs  
Most healthy people, including pregnant women, are asymptomatic. Mild flu-like symptoms may 
occur and may be accompanied by symptoms of infectious mononucleosis-like lymphadenopathy 
[2]. Effects on the foetus vary with different stages of primary maternal infection with T. gondii and 
are more severe when the pregnant woman is infected early in pregnancy. Clinical signs of 
toxoplasmosis in neonates include the classical triad namely intracranial calcification, hydrocephalus 
and chorioretinitis. About 10% of prenatal infections result in abortion or neonatal death.  The 
surviving infants suffer from CT presenting with progressive neurologic complications like mental 
retardation, learning problems, hearing and visual impairment or seizures and require special 
management with regards to residency and education. Most children (70-90%) who have been 
infected before birth might be asymptomatic at birth, but will develop complications associated with 
toxoplasmosis (chorioretinitis, motor and cerebellar dysfunction, microcephaly, seizures, mental 
retardation or sensorineural hearing loss) later in life [1,19,46,47]. More severe signs and symptoms 
usually indicate T. gondii infection early in pregnancy, while infections contracted in the third 
trimester of pregnancy show no symptoms at birth [1]. Clinical trials indicate that early treatment of 
these children can decrease manifestations of disease and improve the quality of life [19]. 
1.3.9 Diagnosis of toxoplasmosis 
Serological screening of pregnant women is an effective way to prevent transmission of 
toxoplasmosis to the foetus and practical approaches based on serologic data have been proposed. 
Villard et. al. (2016) proposed two approaches to serologic testing, with the first including fast or 
automated screening while the second is used for confirmatory testing [48]. In the USA IgG and IgM 
antibodies against T. gondii are determined with enzyme-linked immunosorbent assays (ELISA) and 
in cases of seroconversion followed up with amniocentesis and polymerase chain reaction (PCR) to 
determine whether the foetus had been infected. Laboratory testing for toxoplasmosis in pregnant 
women poses a specific challenge since it is difficult to distinguish a past infection from a new 
infection due to sustained persistence of IgM (up to two years after acute infection) antibodies in 
some persons [1,47]. Additional IgM may be produced when dormant T. gondii is reactivated or when 





gondii antibodies have been evaluated but the recommendation is that determination of T. gondii 
specific IgG avidity in patients with detectable IgM antibodies is the most accurate way to determine 
the stage of infection [50].  
Antibody avidity is the compound value for binding strength among a pool of specific antibodies and 
antigens. It normally increases as an immune response proceeds and matures. Avidity testing has 
diagnostic value, especially when a decision needs to be taken about the risk of neonatal infection 
during pregnancy. For determination of specific IgG avidity commercially available enzyme-linked 
immunosorbert assays (ELISA) are used. Chaotropic agents such as urea reduce effective binding 
between specific antibodies in patient’s serum and antigens coated in the wells of the ELISA plate 
and are employed to break the antigen-antibody bonds. Addition of urea would therefore indicate the 
strength of the antigen-antibody binding when compared to the addition of a buffer. Diluted patients’ 
serum is run in duplicate following the protocol from the manufacturer. An additional incubation step 
is inserted with either urea or phosphate buffered saline (PBS) added to the antigen-bound 
antibodies from the patient’s serum in the respective wells. The avidity result is obtained by dividing 
the values for Absorbances (Urea/PBS) for duplicate tests run with and without urea incubation. 
Ratios of 0% to 100% could be obtained and clinical interpretation (low, equivocal and high) are 
made according to manufacturer’s recommendations, preferably based on validation against a 
reference panel [146].  Low avidity would indicate a recent infection with low binding strength 
between antibodies and antigens while a past infection would be characterised by high avidity. 
Liesenfeld et. al. reported that the IgG avidity test on a single sample taken in the first trimester of 
pregnancy has great value, as being indicative of recent infection, in the diagnosis of Toxoplasma 
gondii infection in pregnant women [51].  
A challenge with the IgG antibody test in pregnant women is that during reactivation of T. gondii in 
HIV-infected women, IgG does not show a rise in titre even when the infants are infected [44].  An 
alternative strategy is to screen neonates for CT and in the USA, this is mostly done on dried blood 
spots which are processed for use in ELISA or PCR [19].  
Recently, Interferon-gamma release assay (IGRA), a T-cell-based test, was introduced as an in vitro 





immunity in diagnosis of toxoplasmosis. IGRA accurately distinguished infected from uninfected 
individuals, showing strong lymphocyte activation after in vitro stimulation with T. gondii antigens, 
even during the first days of life. IGRA is an easy-operation and low-cost method to measure cell 
mediated immunity against T. gondii. The results of a review underline the importance of evaluating 
cellular immunity to establish an early diagnosis particularly for congenital toxoplasmosis. Therefore, 
ELISA-based IGRA holds the potential to become a useful diagnostic tool for early detection of T. 
gondii infection [154]. 
1.3.10 Treatment  
Most healthy individuals with toxoplasmosis do not require treatment. Treatment may however be 
required for people with ocular disease, people with compromised immune systems and in pregnant 
women and neonates. The folate pathway, involved with DNA synthesis, is the main target for anti-
T. gondii drugs. Drugs often used are pyrimethamine and sulfadiazine, plus folinic acid to limit toxic 
effects. Pyrimethamine and trimethoprime inhibits an enzyme which is necessary for synthesis of 
thymidine. It has been used since the 1950’s as antimalarial drug but was discontinued due to 
resistance which developed in malaria parasites. Anti-malarial drugs have been used for treatment 
of T. gondii infection since both organisms are protozoan parasites. Unfortunately, the drug has 
limited seletctivity for the folate metabolic pathway of the parasite and also affects the human host. 
Taken alone, pyrimethamine has limited potency, thus it is administered in combination with 
sulfonamides which block another enzyme in the folate pathway [157]. 
Current treatment regimes have side effects due to myelotoxicity. This is even worse for patients 
who have been congenitally infected who usually need prolonged treatment. Most of all, no current 
drug is able to eliminate T. gondii cysts from the infected host, which remain quiescent, provided that 
the immune system is strong enough to hamper their reactivation into tachyzoites [157]. 
Current treatment options available for T. gondii infection are limited and many have drawbacks of 
high toxicity and low tolerability. No Food and Drug Administration (FDA)-approved treatment is 





There is therefore a need for clinical studies of investigational compounds, which demonstrate in 
vitro growth inhibition of of the parasite [52]. 
Administration of antimalarial drugs to pregnant women to treat T. gondii infection during gestation 
is a challenge. Pyrimethamine inhibits synthesis of folic acid, thus producing reversible depression 
of the bone marrow. Reversible neutropenia is the most frequent toxic effect, although platelet 
suppression and anaemia may occur as well. Folinic acid has been used to protect the bone marrow 
from toxic effects of pyrimethamine [18]. Pregnant women are routinely given folic acid 
supplementation to prevent teratogenic risks like neural tube defects in their infants. However, high 
doses of folic acid counteract the effect of sulfadoxine-pyrimethamine. Therefore, it is recommended 
by CDC that women take only the recommended 0.4 mg daily dose of folic acid.  
Sulfonamide administration to pregnant women is controversial since it is believed to be teratogenic. 
Sulfonamides readily cross the placenta and thus could act as folate antagonists in humans. Folate 
is critical for the development of organs, especially neural tube development. Therefore, there is 
concern about use of sulfonamides early in pregnancy. However, it remains unclear from previous 
studies whether exposure to sulfonamides during pregnancy increases the risk of congenital 
anomalies. A comprehensive study from 2001 to 2008 among 500 000 pregnancies in the USA found 
no greater risk of congenital anomalies among infants exposed to pyrimethamine-sulfonamide during 
the firs trimester than among those exposed to non-teratogenic anti-bacterials (penicillin or 
cyclosporin) or in absence of any drug exposure during the same time period [158]. 
Prenatal treatment is aimed at prevention of materno-foetal transmission of parasites and/or 
reduction of foetal damage [157]. The benefit of prenatal treatment is debated in the literature. A 
prerequisite is to know the accurate time of maternal infection, which is achievable only in countries 
with serological screening programmes in pregnant women, i.e. a limited number of European 
countries [157]. Women in these countries infected during pregnancy (or around conception) are 
generally offered spiramycin, a potent macrolide antibiotic that concentrates in the placenta but does 
not cross it. It has a low rate of adverse effects but is not effective for treatment of established foetal 
infection. Treatment with pyrimethamine-sulfonamide then follows after 16 weeks of gestation 





Spiramycin has been used in foeto-maternal toxoplasmosis prevention and treatment in Canada, 
Latin America and Europe for decades but is classified as “experimental therapy” in the U S. 
Spiramycin monotherapy is effective if administered early in pregnancy as a preventive measure but 
not after foetal exposure to the infection. The efficacy of other foetal-maternal treatments like 
azithromycin, clarithromycin, dapsone and cotrimoxazole is still being debated. In France 24% of 
children born to infected women who were treated with pyrimethamine and sulfadoxine were 
diagnosed with congenital infection [19]. 
New therapies for toxoplasmosis are being investigated and include quinone derivatives, which are 
fairly safe and effective treatment against protozoans like malaria and T. gondii. It targets 
mitochondrial respiration in the parasites. When treated with quinoline, 40-45% of parasites lost their 
apicoplasts [53]. Atovaquone has however, not been approved for use in pregnant women. Another 
compound for possible use in pregnant women is diclazuril (a triazinone antiprotozoal) which targets 
the apicoplast in T. gondii. An apicoplast is an extra-nuclear deoxyribonucleic acid (DNA) organelle, 
which is essential for survival of the parasite [19]. Without the apicoplast the parasites cannot invade 
the host cells. 
For congenitally infected infants identified before birth, either symptomatic or asymptomatic at birth, 
postnatal treatment for 12 months with pyrimethamine and sulfadiazine is indicated. Folinic acid is 
also administered to counteract toxic effects of the medication on red blood cell production. Children 
should be followed up with serial ophthalmologic, auditory and neurologic examinations after 
treatment is discontinued [1]. 
1.3.11 Prevention 
Congenital toxoplasmosis can best be prevented by ensuring that pregnant women who are 
seronegative do not get infected, or by treatment of pregnant women who are diagnosed with a 
primary infection as reflected in seroconversion.  Regulated routine screening programmes for 
toxoplasmosis have been introduced in many European countries (Austria, France, Italy and 





maternal infection with T. gondii during pregnancy or detection of congenital infections in neonates 
at birth [19]. 
There is no vaccine available for T. gondii. Especially pregnant women and immunocompromised 
individuals should be educated on life-style habits, which can prevent infection with the parasite.  
These include proper cooking of meat, washing of hands after handling meat, washing of fruit and 
vegetables, and special precaution when handling cat litter.  Despite the challenges mentioned in 
Section 1.3.10, some European countries do administer treatment to infected pregnant women to 
prevent congenital infections and complications. Infection in foetuses can be prevented by serologic 
testing to identify women at risk, and spiramycin treatment during pregnancy, which lead to an 
approximate 60% reduction in contracting the infection by the foetus, and also to a marked reduction 
in illness in the foetus and infant [18,42]. In European countries where prenatal screening for T. 
gondii is mandatory by law (France, Austria, Belgium), rates and severity of congenital infection have 
been reduced. For populations with greater than 1 case of congenital toxoplasmosis per 10 000 live 
births, (or 2 infected mothers per 10 000) maternal serologic screening is a cost saving strategy. It 
is also argued that prevention options like preconception education reduce the prevalence of T. 
gondii in these countries [42,144]. 
1.3.12 Risk factors 
Risk factors for acquiring T. gondii infection include the following: working with or ingesting raw or 
undercooked meat, not washing raw fruit and vegetables, and handling cat litter. Keeping cats and 
dogs are risk factors according to Cong et. al. (2015). T. gondii can also be acquired through blood 
transfusion or organ transplantion [54]. Poor obstetric history has also been associated with an 
increased risk of T. gondii in pregnant women: toxoplasmosis was found to be more common in 








1.4 Rubella virus  
 
1.4.1 Virus description 
Rubella is a single stranded ribonucleic acid (RNA) virus [1]. It is a member of the Togaviridae family 
[56]. The term “toga” refers to the structure of the virus which looks like it carries a cloak in the form 
of an envelope around the core containing RNA. 
1.4.2 Morphology and biology 
The rubella virus particle is generally a spherical structure, 50-70 nm in diameter. The central 
nucleoid is surrounded by a single layer envelope. The free virus contains positive strand RNA within 
its core, from where structural proteins are translated. Three major structural proteins are E1, E2 
and C. E1 and E2 are envelope proteins and are responsible for the spikes protruding from the 
spherical structure. They are involved in cell entry. The E1 envelope glycoprotein shows remarkable 
antigenic stability [56]. 
Humans are the only known host for rubella virus. Infections typically peaks in spring but could 
circulate any time of the year.  As congenitally infected infants excrete rubella virus for prolonged 
periods, it is possible that congenitally infected infants may provide a reservoir for the virus [56]. 
1.4.3 Epidemiology in developing countries  
Single cases of rubella can occur at any time, but there can be outbreaks involving schools or other 
large groups of children.  Adults (teachers and parents) may also be infected in these outbreaks. 
There is a seasonal pattern, with rubella activity peaking in late spring / summer in neighbouring 
South Africa [57]. A study in Zimbabwe using measles case definition-based surveillance revealed 
that of the 2302 measles IgM-negative samples received over a five-year period, 865 (37.6%) were 
rubella IgM-positive.  Ninety-eight percent of confirmed rubella cases were children younger than 15 
years of age [58]. 
Following rubella epidemics, many infants with congenital rubella syndrome (CRS) have been 






In many developing countries, CRS is an underrecognized public health problem [62]. In South Africa 
it is suspected that most cases of CRS go undetected. The exact incidence of congenital rubella 
syndrome in South Africa is not known, but it is estimated at about 660 cases per annum.  There is 
evidence that CRS may be largely undetected, especially in the upper socio-economic group [63]. 
While neighbouring Zimbabwe is rated by the United Nations as one of the countries highest affected 
by rubella infection, no data were available for Namibia in 2015 when this study was designed. 
Immunity to rubella virus might be due to natural infection or vaccination. While many developing 
countries are still struggling to introduce routine anti-rubella vaccination programmes, immunity to 
rubella virus is mostly attributed to natural infection, mostly during early childhood. The naturally 
acquired immunity to rubella in women of childbearing age in South Africa has been estimated at 
over 90%.[64]. 






Table 2. Immunity to rubella virus in developing countries 




Benin 1995 85.8 Pregnant 
women 
 
ELISA Rodier [28] 
Ghana 1997 92.6 Pregnant 
women 
 
ELISA Lawn [70] 
Mozambique 2002 95.3 Pregnant 
women 
 
ELISA Barreto [74] 
South Africa 2005 97.5 Pregnant 
women 
 
ELISA Corcoran [57] 
DRC 2009 84 Pregnant 
women 
 
ELISA Alleman [73] 
Nigeria 2010 97.9 Pregnant 
women 
 
ELISA Amina [69] 
Namibia 2010 85 Pregnant 
women 
 
ELISA Jonas [10] 









Sudan 2011 72 Pregnant 
women 
 
ELISA Hamdan [67] 
Nigeria 2011 53 Pregnant 
women 
 
ELISA Onakewhor [68] 
Morocco 2012 90.2 Pregnant 
women 
 
ELISA Belefquih [65] 
Burkino Faso 2012 77.0 Pregnant 
women 
 
ELISA Linguissi [71] 
Iran 2013 96 Pregnant 
women 
 
ELISA Honarvar [66] 
Nigeria 2013 91.54 Pegnant 
women 
 
ELISA Adewumi [75] 
Benin 2014 94 Pregnant 
women 
 




2014 58.97 Pregnant 
women 








Transmission of rubella infection occurs via droplet transmission while the virus is detectable in the 
nasopharynx of the host for one week before and one week after onset of the rash [1]. In pregnant 
women, primary infection with rubella causes viraemia.  The virus then spreads from the blood to 
the placenta and may infect the foetus. Reinfection with rubella virus in a pregnant woman rarely 
causes intrauterine transmission [56]. CRS develops in 90% of infants exposed to the rubella virus 
during the first trimester of pregnancy, and in 20-40% of infants exposed during early second 
trimester, the latter usually resulting in deafness only [56,60]. There is a greater risk (80-90%) of 
transmission from a mother with primary rubella infection in the first trimester of pregnancy and 
vertical transmission during this period is associated with the most severe sequelae at birth [1]. 
1.4.5 Pathology 
Little information is available on pathology of rubella infection acquired after birth, since patients 
seldom die of the mild disease. In adults, there is a cellular immune response involving lymphocytes, 
as well as a local immune response in the throat producing IgA. It is possible that lack of the local 
IgA response in cases of rubella vaccination, plays a role in increasing incidence of reinfection in 
vaccinated individuals [56].  
Congenital infection with the rubella virus causes damage to cells, and it also has an effect on cell 
division. Therefore, it is of clinical importance in the developing embryo / foetus. The pathological 
effect of the virus causes progressive necrotizing vasculitis and inflammation in focal areas. It is 
postulated that emboli from the small blood vessels in the placenta break loose and lodge in organs 
of the foetus. These emboli might also cause damage to the foetus by obstructing small blood 
vessels. Furthermore, cytolysis with necrosis has been seen in many organs in the foetus including 
the inner ear (organ of Corti) [1,56].  
1.4.6 Symptoms and signs  
Maternal symptoms include a mild rash, viral pneumonia and infection of the meninges and brain 





devastating effects of rubella infection on infants exposed in the first trimester of pregnancy.  He 
noted that affected infants presented with ocular defects and cardiac lesions [56].   
Today it is known CRS is associated with cataracts and other visual impairments, cardiac defects, 
deafness, microcephaly, and mental retardation.  Classically CRS leads to the triad including 
deafness (80%), congenital cardiac disease (50-70%) and cataracts (30%) [1,56]. Delayed 
manifestation of symptoms includes the development of insulin-dependent diabetes mellitus, thyroid 
disorders, hypertension and behavioural disorders [1,2]. In one study 68% of infected newborns had 
no symptoms at birth. They were followed for the first five years of life and 71% developed 
manifestations of infection. It is said that CR infection is a silent, progressive disease [56].  
1.4.7 Diagnosis of rubella infection 
Enzyme immunoassays (EIA) are the most commonly used and widely available diagnostic test for 
rubella IgG and IgM antibodies. EIAs are sensitive and relatively easy to perform. The IgG level is 
important for indicating susceptibility to re-infection which might occur in women with IgG levels 
below 10 IU/ml. EIA is the preferred testing method for IgM, using the capture technique [76]. In 
contrast, indirect IgM assays on blood of affected infants may give false negative results due to 
competition with high concentrations of maternal IgG.  
It is important to differentiate between an asymptomatic primary rubella infection and re-infection, 
because IgM together with IgG may be present in both cases [77]. Re-infections are mostly 
asymptomatic and pose a low risk to the foetus. Re-infection of vaccinated women is usually 
accompanied by the detection of IgM and IgG. Additional tests used in the clinical diagnosis of 
rubella, are IgG avidity testing and reverse transcriptase PCR in nasopharyngeal swabs, urine, 
cerebrospinal fluid (CSF) and blood at birth. Most pathology laboratories have developed a rubella 
testing algorithm including quantitative cut-off’s for IgG antibodies used for reporting and clinical 
decision making [78]. Rubella testing poses a challenge in low resource settings due to the following 
problems which might arise: false positive rubella IgM results; no access to other assays, such as 
rubella IgG avidity; limited experience of diagnosis and its pitfalls (e.g. persistent specific IgM) and 





1.4.8 Treatment  
There is no specific treatment for infected children available. All infants with CRS are considered 
contagious till the age of one year by which time viral shedding in urine and other body fluids has 
usually ceased [1], although rubella RNA has been demonstrated in ocular fluid from a 28-year old 
woman who was born with CRS.  
1.4.9 Prevention  
Prevention of rubella infection is by vaccination of all adults and children in a population. It is 
important that women of childbearing potential show evidence of rubella immunity, to control the 
incidence of CRS. It is recommended that pregnant women who are not immune or have immunity, 
which is not protective against rubella infection, take post-partum rubella vaccination. However, even 
in immune subjects, due to previous infection or vaccination there is an increase in susceptibility to 
rubella infection over time.  The screening cut-off level (IgG<10 IU/ml) used to identify women at risk 
of transmitting rubella infection to a foetus was determined in 1995, based on early epidemiological 
studies. The Rubella Sub-Committee of the National Committee for Clinical Laboratory Standards 
have proposed that the level to define rubella immunity be lowered from 15 to 10 IU/ml. Proven 
rubella infections have, however, occurred in persons with titres above 15 IU/ml [85].  
The WHO’s Measles and Rubella Initiative aims to eliminate both diseases from at least five of its 
six regions by 2020 [80]. The availability of a vaccine against rubella virus has decreased infections 
in pregnant women significantly [81]. One of the two approaches in rubella vaccination programmes 
is to immunize adolescent girls or women of childbearing age, or both groups [66].  Congenital rubella 
syndrome is completely preventable if an effective vaccination programme in both private and public 
sectors is in place [60]. However, given the increase in susceptibility to rubella infection among 
women of childbearing age in countries with rubella vaccination programmes, this might need further 
intervention by health authorities in the form of revised vaccination efforts.  Nearly a decade after 
Iran’s nationwide measles-rubella vaccination campaign for the population aged 5–25 years, most 
pregnant women up to 34 years of age had humoral immunity against rubella. The authors 
recommend rubella immunity screening or catch-up immunization for women older than 35 years 





programme to inform future planning and found that over a six-year period (2004-2009) the 
frequency of women with anti-rubella IgG <10 IU/ml increased by 60%. Susceptibility to rubella 
infection should be monitored, in order to identify high-risk groups, evaluate control measures and 
to inform policy and service planning [82]. 
In South Africa, Schoub et. al. (2009) postulated that limited administration of measles-mumps-
rubella (MMR) vaccine (not routinely administered in the public sector) in infancy may reduce 
childhood rubella outbreaks, which would have otherwise resulted in high levels of natural immunity 
and thereby gives rise to the development of a group of susceptible females reaching childbearing 
age. These females might be exposed to rubella circulating amongst individuals in the public sector 
who have not been vaccinated. Therefore, incomplete rubella vaccination could paradoxically result 
in an increased occurance of CRS. Currently routine rubella vaccination does not form part of the 
Expanded Programme for Immunization (EPI) in South Africa. It is suggested that selective 
immunisation of girls before puberty should be instituted together with a routine rubella immunisation 
programme of infants to forestall a possible future outbreak of CRS, as occurred in Greece in 1993 
[63].   
In Namibia, since 2005, the measles surveillance programme of the MoHSS in association with the 
WHO includes rubella testing for measles negative cases. Few positive rubella cases were recorded 
in the years preceding this study with a spike in cases in 2015.  
Since 2016 routine rubella vaccination forms part of the vaccination schedule of children in the public 
sector (measles-rubella [MR] at 15 months for male and female children). In 2016 the MoHSS 
conducted a national Special Immunization Activity (SIA) whereby male and female individuals aged 
9 months to 39 years received MR vaccination. The SIA excluded pregnant women. 
Insufficient rubella vaccination coverage results in continued disease transmission [83]. There is an 
urgent need to collect appropriate data to estimate the cost-effectiveness of a potential global rubella 





1.4.10 Risk factors 
Since the incidence of natural rubella infection peaks at the age of 5-7 years in Africa, a risk factor 




1.5.1 Virus description 
Human cytomegalovirus (CMV) belongs to the Herpesviridae family, Betaherpesvirinae subfamily 
and is also referred to as Human betaherpesvirus 5 [86,143]. It has a large dsDNA genome (about 
235 000 bp). Due to numerous mechanisms to modulate the host immune response, infection persist 
lifelong in humans. While the evolution of CMV has been well described, research in the last decade 
outlined the molecular diversity of CMV strains among hosts (interhost variability) as well as within 
the same host (intra-host variability) [87]. The virus also evolves on much shorter time scales, in the 
order of days or months [87]. Compartmentalization of CMV persisting in different tissues (peripheral 
blood and distal compartments) and undergoing mutations while replicating is offered as an 
explanation for intra-host molecular diversity. A case has been described where drug-resistance to 
ganciclovir has been found in the blood of a patient while sensitivity prevailed in the CSF [87].  
1.5.2 Virus properties, replication and immune response 
Infection with CMV results in the formation of greatly enlarged (cytomegalic) cells with nuclear and 
cytoplasmic inclusions. The large cells with owl’s eye appearance was first described in 1881 in the 
kidney of a stillborn infant with congenital syphilis. The virus was first called the cytomegalic inclusion 
disease (CID) and later salivary gland virus. CMV is the largest and structurally most complex virus 
in the family of Herpesviridae. It has three identifiable regions: the capsid containing the double 
stranded DNA (dsDNA) viral genome, the tegument and the envelope. The structure of the capsid is 
very much similar to that of Herpes simplex virus (HSV), although it houses 60% more material than 
HSV. Numerous CMV proteins include epitopes targeted by CD8 and CD4 T cells.  It was reported 





specific T cell responses in seropositive subjects were enormous, comprising on average ∼10% of 
both the CD4+ and CD8+ memory compartments in blood [147]. Cytomegalovirus infections of 
immunocompetent hosts are characterized by a dynamic, life-long interaction in which host immune 
responses, particularly of T cells, restrain viral replication and prevent disease but do not eliminate 
the virus or preclude transmission. The biology of CMV infection in immunocompetent populations 
can be explained as an evolutionarily “negotiated” balance between viral mechanisms of 
pathogenesis, persistence, and immune evasion and the host cellular immune response [147]. Once 
infected, the host retains the infection as a persistent infection, due to immune evasion by the virus. 
Limited information is available on the numerous proteins in the envelope and integument. Envelope 
glycoproteins play an important role in early virus infection and are a potential target for vaccine 
development [86].  
Replication of CMV starts when the virus attaches to the host cell membrane. Specific receptors 
have not been identified beyond doubt. The capsid containing the DNA is transported to the host cell 
nucleus. Viral replication takes place in the nucleus of the host cell and then the new viruses are 
assembled in the cytoplasm. Studies on tissues from autopsies have demonstrated CMV virus in 
almost every cell type of the host [86].  
1.5.3 Epidemiology  
 Cytomegaloviruses are highly species specific, and humans are the only reservoir of human 
cytomegalovirus. Infection with CMV is endemic and does not show a seasonal pattern. 
Seroprevalence differs greatly according to socioeconomic status, ethnic background and 
geographic location.  Of clinical importance is the seroprevalence of CMV among women of 
childbearing age [86].  
Prevalence of CMV infection is about 50% in Europe and North America, while it is close to 100% in 
developing countries in South America and Africa [88,89]. In sub-Saharan Africa, South America and 
Asia, 95-100% of pre-school children were seropositive for CMV, while surveys in Great Britain and 
the US found less than 20% of children of similar age to be seropositive [86].  





Table 3. Prevalence of CMV in developing countries 
Country Year Seroprevalence 
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Prevalence of congenital cytomegalovirus (cCMV) infection was found to be 4.6 /1000 births in 
Sweden and 3.2/1000 births in London [100].  Bonalumi et. al. (2011) reported an incidence of 0.3 – 
2.4 percent in developed countries [101]. The incidence of cCMV infection is highest in developing 
countries (1 – 5 percent of births) and can most likely be attributed to non-primary maternal infections 
[93,102]. A study in South Africa showed that 2.9% of babies born to HIV-positive mothers had cCMV 
[93]. 
1.5.4 Vertical transmission and congenital infection 
CMV can be found in body fluids, genital tract secretions and breast milk. It is generally believed that 
CMV is acquired at mucosal sites. Infections can also be blood-borne in transfusion products or 
organ transplants [86]. In children and adults, transmission of CMV infection is through 
breastfeeding, sexual contact and spread from children through contact with body fluids [92]. Vertical 
transmission of CMV virus may occur during pregnancy via the placenta; during birth via contact with 
the birth canal or after birth through breast milk [88,103].  
CMV infection in pregnant women can either be primary or recurrent. Primary infection is when a 
person gets infected with the CMV virus for the first time and can be demonstrated by seroconversion 
(appearance of antibodies which were not previously present). Recurrent infection is described as a 
past infection and includes, reactivation of latent infections and reinfection with a different CMV 
strain. During latency there is no viral replication, and the virus remains dormant in mononuclear 
leukocytes and cells of organs like the kidneys and heart. The virus may start replicating at any point 
in time, causing a reactivation of the infection [88]. 
In pregnancy, it is useful to distinguish between the types of infections.  Primary maternal infection 
leads to 20-75 per cent of exposed foetuses having cCMV infection while only 1 – 2.2 per cent is 
infected in reactivated CMV [101,104]. In primary maternal infection 32.3 percent of congenitally 
infected neonates are symptomatic at birth while it is 1.4 per cent in case of recurrent infection [105]. 
Primary maternal infection is also associated with increased risk of sequelae associated with CMV 
infection compared to recurrent infection [105,106]. However, many congenitally infected babies do 





infants and found that 11% of those born with cCMV were symptomatic [105]. Congenitally infected 
newborns are at risk for serious long-term sequelae regardless of the presence or absence of 
symptoms at birth [88].  
 Pregnant women who become infected during the first 16 weeks of pregnancy are more likely to 
transmit the virus to the foetus than women who are infected later in pregnancy.  Early infections are 
associated with a higher occurrence of central nervous system (CNS) sequelae, essentially 
sensorineural hearing loss and long-term disability [88,103,106]. 
Recent data demonstrate similar risk of developing sequelae, especially hearing loss, in infants born 
to mothers with CMV primary and re-infection.  There is increasing evidence that non-primary 
maternal infection could lead to symptomatic and severe outcomes. Recent studies in developed- 
as well as developing countries have shown that symptomatic infection occurs with similar frequency 
in children born to women with primary CMV infection and those born to women who were CMV 
seroimmune before pregnancy (nonprimary infection). In addition, the severity of newborn disease 
and the rates of CMV-associated sensori-neural hearing loss also do not differ between primary and 
nonprimary infection groups [86]. This underscores the importance of screening for congenital cCMV 
infection in resource-poor settings.  In well-resourced settings, it is believed that primary maternal 
infection drives cCMV infection – however in resource limited settings with a high prevalence and 
incidence re-infections may contribute to cCMV [101,107]. More recent studies show that women 
who are seropositive can become re-infected with a different strain of CMV and give birth to infected 
infants [108]. 
Congenital infection, as a result of recurrent infection in a seropositive mother, is common in settings 
with high seroprevalence of CMV.  A study in Ivory Coast where seroprevalence of CMV is 100%, 
found a prevalence of cCMV infection in 1.4% of live births [108].  
Intrauterine transmission of CMV after reinfection or reactivation in immune women can possibly 
explain the direct relationship between seroprevalence of CMV and incidence of cCMV infection in 
different countries [86,105]. One study outlined the paradox of maternal CMV infection as a risk 





CMV, nonprimary maternal infections are responsible for the majority of cCMV infections and related 
hearing loss [109]. This finding is supported by Yamamoto et. al. (2011) who found that among 10 
children with sensorineural hearing loss, 6 were born to mothers with non-primary CMV infection 
[108]. Although the individual risk of transmission and cCMV during primary infection is much higher 
than with recurrent infections, recurrent infections are much more common, especially in high 
prevalence settings [105].  
1.5.5 Pathology - Congenital cytomegalovirus infection 
Congenital CMV infection is assumed to take place through the placenta [86]. Once transmitted to 
the foetus, the virus initially infects endothelial cells, and then other target tissues. Consequences of 
placental infection range from no foetal infection to foetal death [88,103].  
Neutrophils do not support viral replication in the host but may carry CMV to different sites within the 
human body. Macrophages derived from blood monocytes have been shown to harbour CMV. 
Endothelial cells in vascular beds support replication of the virus. Cytoplasmic changes are 
characterized by very large cells, 20-35 µm in diameter, and with inclusions in the cytoplasm and 
nucleus. Large inclusions are separated from the nuclear envelope by a clear zone giving the cells 
an owl’s eye appearance. CMV may spread to all organs of the body (disseminated disease), or can 
more commonly be found in the CNS, haematopoietic system, kidneys, gastrointestinal tract and 
lungs. CMV can be found in the placentas of most congenitally infected infants. The most significant 
feature is the presence of inclusion-bearing cells in endothelial cells or in cells attached to the 
capillary walls [86].  
1.5.6 Symptoms and signs 
Ninety percent of adult primary CMV infections are asymptomatic, but may be associated with 
fatigue, myalgia and fever. cCMV is the most common of all intrauterine infections and should be 
considered in all neonates with symptoms of congenital infection [2]. CMV-infected infants showing 
no symptoms at birth are also at risk of developing complications later [105]. CMV infection in the 





Cytomegalovirus has been identified as the main cause of non-inherited hearing loss while long-term 
CNS sequelae include seizures and motor and visual defects [88,101,110].  
Symptomatic as well as asymptomatic cCMV cause hearing loss in children. A study in Flaanders 
established cCMV at birth with PCR or viral culture on urine. In the group with symptomatic cCMV 
63% had hearing loss while in the group with asymptomatic cCMV 8% had hearing loss. Delayed 
onset hearing loss occurred in 10.6% of symptomatic and 7.8% of asymptomatic cCMV cases [111]. 
In 1990 CDC established a national surveillance system to monitor cCMV infections.  In the first four 
years 285 cases were reported.  It was reported that petechiae was the most common clinical 
symptom, presenting in 50% of cases.  It was often seen together with hepatosplenomegaly, 
intracranial calcification, microcephaly and thrombocytopaenia [86,112,113,114]. 
Due to variations in epidemiology and seropositivity in women of childbearing age, prevalence of 
cCMV infection vary between 0.15 – 2.0 percent in different countries. Ten to twenty percent of all 
children with cCMV infections, show signs of neurological damage when followed up [101,102], while 
Enders et. al. (2001) reported that 57.6 percent of congenitally infected live-born infants had 
symptoms of varying degree [104].  
Differential diagnosis is sometimes necessary since clinical signs like cataracts, congenital heart 
defects, certain types of rash, certain lesions to the retina and absence of cerebral calcifications are 
more likely to occur with CRS than with cCMV. Almost all the manifestations described for 
symptomatic cCMV infection are also described in CT. The calcifications in the CNS are usually 
scattered through the brain in toxoplasmosis, while they surround the ventricles in CMV infection. 
Lesions to the retina cannot be distinguished but they are usually accompanied by other 
manifestations in the case of cCMV infection [86]. 
1.5.7 Diagnosis of cytomegalovirus infection  
Laboratory methods used can detect the virus itself (CMV DNA assays, electron microscopy and 
viral culture) or detect antibodies produced in response to CMV virus (serological assays). 





serological testing is used for screening while the PCR of CMV DNA is used for confirmation and for 
risk stratification [115]. 
IgG and IgM serology of a pregnant woman can identify pregnancies at risk for transmission of CMV 
to the foetus. IgG avidity testing adds additional diagnostic value and is complemented by ultrasound 
in the clinical setting [94,116]. IgM positivity and low IgG avidity at < 14 weeks of gestation is a good 
indicator of congenital infection [117]. Antibody kinetics as measured by IgG avidity can be useful to 
predict vertical transmission of CMV. Increase in rate of IgG avidity in consecutive samples is higher 
in pregnant women with congenitally infected foetuses than in mothers with no infection [118].  
Congenital CMV infection is detected by analysis of amniotic fluid, foetal tissue, foetal blood or 
neonatal samples collected within the first two weeks of life [88]. It is possible to predict the risk of a 
foetus with cCMV to be born symptomatic. It can be established with a combination of ultrasound, 
amniocentesis or cordocentesis and laboratory testing of amniotic fluid and foetal blood [119]. 
Invasive antental sampling is however not readily available in developing countries, and it 
furthermore poses a risk of foetal infection or abortion.  After birth confirmation of cCMV infection 
requires detection of virus in neonatal blood, urine or saliva by PCR or virus isolation within the first 
two weeks of life [86]. Saliva or urine are the sample types of choice. Although dried blood spots 
(DBS) have the benefit of sometimes being available for retrospective diagnosis this sample type 
has a sensitivity of only about 30% [120]. 
The best diagnosis of maternal primary infection is by demonstrating seroconversion. CMV IgM is a 
good indicator of recent CMV infection, but CMV IgM can also be detected during recurrent infection 
or primary Epstein-Barr virus (EBV) infection due to cross-reactive antigens or polyclonal activation.  
Detecting maternal CMV IgM does not mean that the foetus will be infected, and further testing is 
needed to determine whether it is a primary or recurrent infection, or an EBV infection [88]. In 
pregnant women, CMV DNAemia is detected during primary infection and it might be useful to 
confirm infection [121]. Cytomegalovirus DNA testing of urine or blood of pregnant women may help 





Interferon-gamma release assays for tuberculosis were the first T cell based immunodiagnostic tests 
in clinical practice. It has rapidly expanded to the diagnosis or risk stratification of other infectious 
diseases including CMV. It is now used for risk stratification of posttransplant CMV infection [159]. 
In newborn infants, computed tomographic (CT) scans showed abnormal findings in 70% of children 
with symptomatic cCMV with intracerebral calcification the most frequent finding [123].  
1.5.8 Treatment 
There is a lack of studies described in the literature which examined either prophylaxis or treatment 
interventions for cCMV. There is a need for high-quality clinical trials to demonstrate the benefit of 
available treatment interventions before they can be recommended for use. This is probably a 
prerequisite for health systems to cover the cost of such interventions [14]. A few antiviral agents 
which are systemically administered have been used in clinical trials of life-threatening or sight-
threatening cases of CMV infection. Agents licenced for use in immunocompromised patients include 
ganciclovir, valganciclovir, cidofovir and foscarnet. Foscarnet decreases viral replication by binding 
at the pyrophosphate binding site and by inhibiting cleavage of the pyrophosphate moiety from 
deoxynucleotide triphosphates, thereby inhibiting viral DNA polymerase, while ganciclovir acts as a 
chain terminator during elongation of the newly formed viral DNA. A study on the prevention of 
hearing loss in congenitally infected infants showed beneficial effects of ganciclovir treatment of 
infants born with neurological symptoms of CMV infection [14,86]. In an open-label study Leruez-
Ville et. al. (2016) provided valacyclovir to pregnant women with moderately infected foetuses and 
showed that the majority gave birth to asymptomatic neonates. This study showed favourable 
outcomes in neonates followed for 12 months but need confirmation by randomized trials [124]. 
Cidofovir is used to treat certain ganciclovir resistant CMV strains, as it does not require 
phosphorylation by the viral UL97 enzyme. However, these drugs are too toxic to administer during 
pregnancy. 
Diagnosis and treatment of CMV infection is very costly in sub-Saharan Africa and calls are going 
out for more affordable health solutions. Moreover, there is limited evidence of benefit of antenatal 





women [14]. Work on new drug development is ongoing and one study showed promising results 
with a combination of drugs in an ex vivo model of floating placental villi in tissue culture [125].  
Cytomegalovirus infections reactivate frequently in the immunocompromised host, which makes it a 
reality in regions hit by high prevalence of HIV infections [126].   
1.5.9 Prevention 
After 30 years of research, a vaccine to prevent cCMV infection is not available. Despite these 
challenges, clinical trials with vaccines, prenatal interventions and prolonged postnatal antiviral 
therapy are underway. Current efforts for elimination of CMV infections are focused on vaccine 
development, which is regarded as a Level 1 priority by the National Academy of Medicine. This 
emphasizes the need for more information on the epidemiology and diagnosis of CMV infections in 
pregnant women and neonates [93,107,148]. Improved understanding of cCMV transmission rates 
resulting from non-primary maternal infections will provide further evidence to study maternal 
immunity as a potential target for vaccine development [148]. 
A protocol has been proposed to identify pregnancies at risk for primary CMV infection [127]. The 
screening may facilitate prevention of congenital infections by preventing infection of seronegative 
pregnant women. Pregnant women could be educated about hygiene and behavioural interventions 
like frequent handwashing, especially if they have regular contact with saliva and urine of small 
children [128].  
1.5.10 Risk factors 
A well-documented risk factor for acquisition of CMV is close contact with young children in crèches. 
This poses a risk for other young children as well as for adults who have contact with these children 
[129]. A strong background of sexually transmitted diseases as well as greater numbers of lifetime 
sexual partners show significant correlation with seropositivity. Low socioeconomic status and lower 
levels of education also appear to be risk factors. Organ transplant and blood transfusion from 






A risk factor for vertical transmission of CMV is CMV immune status [131]. 
Neonates with cCMV are more likely to be co-infected with HIV. The co-infection of HIV and CMV is 
associated with a high mortality rate, especially in male neonates [114].  Another study in Zimbabwe 





In conclusion, this study will focus on seroprevalence and incidence of the three infectious agents 
described above among pregnant women in Namibia. While the description above focused on the 
seroprevalence of infectious agents, the next section describes the application of mathematical 
modelling in order to estimate incidence of infection with the three infectious agents among pregnant 
women. 
1.6 Incidence of infections 
In order to estimate the risk of pregnant women contracting an infection during pregnancy which 
could possibly result in neonates born with congenital infections, it is important to obtain information 
on the number of new infections in a population. Studies on the prevalence of congenital infections 
are invasive and expensive and an alternative method has been offered using mathematical 
modelling to estimate incidence of infection [62, 133, 134, 141]. 
1.6.1  Concept and role of mathematical modelling in public health 
Mathematical modelling is a description of a system and the inter relationships of its components 
using mathematical methods. It makes use of analysis of trends in available data and uses 
mathematical equations in order to make predictions and forecasts regarding future outcomes or 
bigger populations. A mathematical model is an explicit mathematical description of the simplified 
dynamics of a system and allows for conceptual experiments which would be otherwise difficult or 
impossible. It could also be used to predict the impact of changes on the dynamics of a system [149]. 
Public health officials can gain a better understanding of infectious disease epidemiology by using 
mathematical modelling. Mathematical modelling is used in epidemiology and public health to 
understand the dynamics of infections in a population. It is important for health managers to 
understand the transmission rates of infectious diseases and the potential impact of infectious 
disease control programmes. For example, if a decision has to be taken to introduce a national 
immunization programme in a population of 50 million people, an enormous extrapolation is required 
to consider the effect of the immunization programme in such a big population [149].  
Mathematical modelling using smaller datasets and allowing predictions on the outcomes in the 





public health managers to evaluate the need for and effectiveness of a national rubella immunization 
campaign and to plan future interventions like introduction of a routine immunization programme, 
epidemiological data could be used to apply a mathematical model in providing estimates of 
prevalence and incidence of rubella in different years. 
Another application of mathematical modelling in public health is the evaluation of intervention 
programmes to reduce infection rates in populations, taking into consideration available data from 
surveillance systems. In France, incidence and prevalence of T. gondii have decreased markedly 
during the last 30 years [144]. Since 1978, public health authorities in France have implemented a 
CT prevention programme, including monthly serological screening of all pregnant women, and 
treatment in case of seroconversion. However, this programme does not include systematic 
surveillance data on incidence and prevalence. In 2007, a surveillance programme was set up to 
collect information on cases of CT diagnosed by means of amniocentesis during pregnancy or 
diagnosis of newborns and infants less than one year old [144]. 
Nogareda et. al. (2014) used a mathematical model to estimate incidence and prevalence of T. gondii 
infection between 1980 and 2020 in women of childbearing age. They used age- and time-specific 
seroprevalence data obtained from the National Perinatal Surveys. They also estimated incidence 
of seroconversion during pregnancy in 2010 using the National Surveillance of Congenital 
Toxoplasmosis data. Information on 42 208 women aged 15-42 was collected. For women aged 30 
years the modelled incidence decreased from 7.5/1000 susceptible women in 1980 to 3.5/1000 in 
2000. In 2010 the incidence was 2.4/1000. The predicted incidence and prevalence for 2020 was 
1.6/1000 and 27% respectively [144].  
Nogareda et. al. (2014) estimated seroconversion in pregnant women and incidence rate per 1000 
pregnant women per year. Based on this model and considering the same trend and conditions they 
estimated that incidence may continue to decline over the following years. This information is 
essential for epidemiologists and health economists who estimate the impact and the cost-





The application of mathematical modelling in this study could thereforeprovide valuable information 
to policy makers in the health sector about the effectiveness of the T. gondii preventive programme 
among pregnant women in France. 
1.6.2.  Estimation of incidence of infection in this study 
A description of the objectives, methodology used, and suitability of results obtained in the estimation 
of incidence of T. gondii, rubella and CMV among pregnant women attending the antenatal clinic at 
Windhoek Central Hospital follows in Chapter 3. 
The next section describes the study design and methodology for the investigation of seroprevalence 






1.7  Study design and methodology 
The overall goal of the study was to determine seroprevalence of three infectious agents among 
pregnant women in Namibia. The study was a descriptive and quantitative study.  It only included 
pregnant women aged 15-47 years attending the antenatal clinic at Windhoek Central Hospital 
during September and October 2016.  
1.7.1 Rationale and expected results of the study  
There is no information available on the prevalence of congenital infections in Namibia. In view of 
this gap in knowledge in the health sector, the current study aimed at the description of maternal 
seroprevalence of three major infectious agents responsible for congenital infections in neonates. At 
the time of study design, only one study on seroprevalence of T. gondii had been done in Namibia. 
No information was available for the other two infectious agents. Expected results of this study were 
based on literature published in other countries. 
Expected result 1 
T. gondii infections occur among blood donors in Namibia as well as among pregnant women 
attending the antenatal clinic of Windhoek Central Hospital and pose a risk of transfusion transmitted 
infection as well as vertical transmission. Certain risk factors are associated with toxoplasmosis in 
these populations based on reports from other countries. 
Expected result 2 
Rubella immune status is high among pregnant women attending the antenatal clinic of Windhoek 
Central Hospital.  This reduces the pregnancies at risk for vertical transmission of rubella although 
there are pregnant women who are not immune / have low immunity against rubella. 
Expected result 3 
Previous exposure to CMV infection is very high among pregnant women attending the antenatal 
clinic of Windhoek Central Hospital. Mainly recurrent maternal infections pose a risk for the 





1.7.2 Proposed solution / specific aims / objectives / outcomes 
The focus of the research was to begin to unravel the extent to which infectious diseases may be 
impacting on women of childbearing potential in Namibia.  
1.7.2.1 Aims   
The aim of this study was to conduct a study on a group of pregnant women to evaluate exposure 
to infectious agents namely T. gondii, rubella and CMV, as well as the level of anti-rubella immunity. 
The risk of vertical transmission of T. gondii and CMV infections was evaluated. Risk factors 
associated with T. gondii and CMV infections were determined. A pilot study had been conducted to 
determine toxoplasmosis among blood donors in Namibia, in order to get an indication of 
toxoplasmosis among the broader Namibian population.  Results from the pilot study were used to 
determine sample size for the study among pregnant women. Mathematical modelling was planned 
to determine the incidence of rubella, T. gondii and CMV infection, in order to determine the risk of 
vertical transmission of these infections. 
1.7.2.2 Objectives 
The objectives of this study were to test blood samples from study groups in Khomas region to 
determine the following: 
Objective 1:  
Pilot study among blood donors in central Namibia (First publication already published and included): 
1. Seroprevalence of IgG antibodies against T. gondii to determine previous  exposure in the 
general population of Central Namibia 
2. Seroprevalence of IgM antibodies against T. gondii to determine risk of transfusion 
associated transmission 
3. Risk factors associated with toxoplasmosis in blood donors 
The rest of the study was performed among pregnant women attending the antenatal clinic at 





4. Seroprevalence of IgG antibodies against T. gondiito determine previous  exposure of 
pregnant women to toxoplasmosis 
5. Seroprevalence of IgM antibodies against T. gondii among exposed individuals to evaluate 
risk of vertical transmission 
6. Assessment of anti-T. gondii IgG avidity among exposed individuals to evaluate risk of 
vertical transmission. 
7. Calculation of any incident cases of T. gondii infection by using age stratified IgG 
seroprevalence data. 
8. Analysis of association between seropositivity and exposure to risk factors for T.  gondii 
infection to guide future education of pregnant women on prevention strategies 
Objective 2 (Third publication) 
1. Seroprevalence of IgG antibodies to rubella virus mainly to determine anti-rubella 
 immune status  
2. Calculation of any incident cases of rubella infection by using age grouped IgG 
 seroprevalence data. 
3. Level of immunity (IgG measured in international units/ml) among patients testing 
 IgG positive to determine whether immune status is actually protective against 
 congenital infection 
Objective 3 (Fourth publication) 
1. Seroprevalence of IgG antibodies to CMV to determine previous  exposure of pregnant 
women to CMV 
2. Seroprevalence of IgM antibodies against CMV to evaluate risk of vertical transmission. 
3. Assessment of risk of vertical transmission among CMV IgM positive individuals with the 





4. Calculation of any incident cases of CMV infection by using age stratified  IgG 
seroprevalence data. 
1.7.3 Methodology 
1.7.3.1. Collection of samples 
Inclusion criteria: All pregnant women aged 13 years and above attending the antenatal clinic at 
Windhoek Central Hospital between September and October 2016 were included in the study. 
Exclusion criteria: Sampling was planned to be age stratified so once the required number of 
participants in a certain age range had been reached, no further participants would be recruited in 
that age range. 
Sample size was determined according to cost efficiency ensuring optimal benefit in terms of the 
study objectives from available funding. For sample size calculation, the primary objective used was 
T. gondii prevalence: For toxoplasmosis the expected prevalence was 6% based upon previous 
publications in Namibia, and in South Africa (4%-8%).  At 95% confidence level, it needs a sample 
size of 542 to achieve a 2% margin of error for this estimate.  
Calculation of sample size using Cochrane’s formula: 
N = Z2 P (1 - P) / d2 
Z = Z value at 5% level = 1.96 
P = Prevalence 
d = margin of error 
n = 1.962 x 0.06 (1 – 0.06) / 0.022 
    = 3.8416 x 0.06 (0.94) / 0.0004 
   = 542 samples 





In order to achieve optimal efficiency to estimate incidence using mathematical modelling a stratified 
sample across the age range of women of child bearing potential was taken: participants were 
stratified according to five age groups (13-20, 21-25, 26-30, 31-35, 35-48) and 108 pregnant women 
were included in each age group. 5 ml of blood was collected from each participant and transported 
immediately to the laboratory where serum was stored at -80 ºC until testing.  
1.7.3.2 Analysis of samples 
Automated chemiluminescence immunoassays were performed to determine seroprevalence of IgG 
antibodies to T. gondii, Rubella and CMV and IgM antibodies to CMV. Patients testing positive for 
anti-CMV IgM were tested for CMV IgG avidity. Patients testing positive for anti-T. gondii IgG were 
tested for anti-T. gondii IgM followed by IgG avidity testing in patients who tested positive for anti-T. 
gondii IgM.  
Anti-T. gondii IgG, anti-rubella IgG and anti-CMV IgG and IgM testing was performed in a South 
African National Accreditaion Systems (SANAS) accredited laboratory participating in an external 
quality assurance programme, with validation of test methods in place. 
1.7.3.3 Questionnaire 
A questionnaire assessed demographic information, obstetric history, exposure to risk factors and 
vaccination history, and was filled by consenting participants.   
1.7.3.4 Data analysis 
All data were entered into an Excel spread sheet and analysed using Statistical Program for Social 
Sciences (SPSS) statistical software. Assistance from a statistician was obtained to determine 
association between seropositivity and exposure to risk factors. Pearson’s χ2 tests or Fisher’s exact 
tests (when values were lower than 5) was used for categorical data.  Bivariate analyses and 
multivariate analysis assessed associations between population characteristics provided in the 





1.7.3.5 Involvement of a statistician 
Namibia University of Science and Technology provided a mathematician as co-supervisor while 
assistance from two biostatisticians was also available. 
1.7.4 Ethical approval and considerations 
All pregnant women attending the antenatal clinic at Windhoek Central Hospital during the period 
September to October 2016 were approached to participate in the study. The background and 
objectives of the study were explained to each participant and a recruitment information pamphlet 
was handed to each patient. Participation was voluntary and informed consent was obtained from 
each participant and parent/guardian if applicable.  Participants were allowed to opt out of the study 
at any stage. Blood samples were collected, and questionnaires were administered by a nurse 
registered with the Health Professions Councils of Namibia. No incentive was involved in the 
donation of a blood sample as the patients were not required to have an additional visit apart from 
their normal clinic visit. Demographic data and information concerning previous pregnancies, 
exposure to risk factors and vaccination history were collected with the aid of a questionnaire. 
Information was kept safe in a building with access control, and confidentiality was maintained 
throughout the study. Students doing data entry signed a confidentiality statement and were 
registered with the Allied Health Professions Council of Namibia. Questionnaires carried the patient 
codes as well as allocated laboratory numbers. Apart from IgG avidity and anti-T. gondii IgM 
analysis, testing was conducted according to standard laboratory procedures in an established 
diagnostic laboratory. Blood collected was used to test for the infectious diseases as agreed by the 
participant with no extra testing. Samples were transported between the hospital and the laboratory 
by Student Medical Laboratory Scientists in a hamper with a biohazard sign. Samples were stored 
in a building with access control for a period of five years after which they were sent to the incinerator 
at Katutura Hospital.  
Ethical approval for this study was obtained from the Faculty of Health and Applied Sciences of 
Namibia University of Science and Technology; the Health Research Ethics Committee of the 
Faculty of Medicine and Health Sciences, Stellenbosch University as well as the Research Ethics 





Chapter 2: Manuscripts prepared for publication 
 
Four manuscripts were prepared during this study. Three have been published in subsidy generating 
peer reviewed journals. 
2.1 First article 
Van der Colf BE, Noden BH, Wilkinson R, Chipare I. Low seroprevalence of antibodies to 
Toxoplasma gondii in blood donors in central Namibia. South Afr J Infect Dis 2014;29(3):101-
104. 
2.1.1 Reflection on first article 
2.2 Second article 
Van der Colf BE, Van Zyl GU, Noden BH, Ntirampeba D.  Seroprevalence of Toxoplasma 
gondii  infection among pregnant women in Windhoek, Namibia, 2016. S Afr J Infect Dis. 
2020;35(1),a25. https://doi.org/10.4102/sajid.v35i1.25. 
2.2.1 Reflection on second article 
2.3  Third article 
Van der Colf BE, Van Zyl GU, Noden BH, Maposa I. Seroprevalence of rubella among 
 pregnant women after an epidemic in Windhoek, Namibia, 2016. Unpublished.  
2.3.1 Reflection on third article 
2.4 Fourth article 
Van der Colf BE, Van Zyl GU, Mackenzie SBP. Seroprevalence of cytomegalovirus among 
pregnant women in Windhoek, Namibia, 2016. S Afr J Obstet Gynaecol 2019;25(2):52-55. 
https://doi.org/10.7196/SAJOG.2019.v25i2.1441 
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Although emphasis has been placed on research relating to human immunodeficiency virus (HIV), 
tuberculosis and malaria, several researchers in Africa are focusing on other threats to human 
health, such as neglected tropical diseases. Toxoplasma gondii is a possible neglected tropical 
disease in Namibia, although the country has a diversity of climate, ranging from tropical in the 
north to semi-desert in the south. Except for one study in 1978, no recent studies have determined 
the burden of T. gondii infection in Namibia. Three hundred and twelve convenience samples were 
collected from volunteer blood donors in central Namibia. Donors provided informed consent to 
participate in the study, and 5 ml blood was collected. Demographic information was collected by 
means of a questionnaire. Serum was analysed using Captia™ T. gondii immunoglobulin G (Ig) G 
enzyme-linked immunosorbent assay (ELISA) kit. Only samples that tested positive or equivocal 
for IgG antibodies were then tested for IgM antibodies using Captia™ T. gondii IgM ELISA kit. Of 
the 312 samples, 3 (0.961%) tested positive for IgG antibodies to T. gondii. One sample (0.3%) 
tested positive for IgM antibodies to T. gondii. These donors lived in urban areas in central Namibia 
and interacted regularly with animals, such as cats and dogs. The prevalence of antibodies to T. 
gondii in Namibian blood donors was found to be considerably lower than that reported in other 
African countries, but comparable to that in a recent report from South Africa. It is notable that 
most of the donors lived in the arid central regions of Namibia, where the high altitude could also 
affect parasite survival. 







It is estimated that a third of the world’s population is seropositive for Toxoplasma gondii, indicating 
that people have been infected with the parasite at some stage of their lives.1-3 Studies to determine 
the seroprevalence of exposure to T. gondii have been conducted in human and animal populations 
in many countries,4 including blood donors.2, 5-13  
The prevalence of toxoplasmosis has been studied in several African countries, and ranges from 7% 
in Zambia to 80% in Ethiopia.14 In Tanzania, occupationally exposed individuals were identified with 
a seroprevalence of 46%, while 35% and 30.9% of pregnant women were seropositive for T. gondii 
antibodies.15-17 In Nigeria, a seroprevalence of 20.8% was reported in apparently healthy individuals, 
and that of 60% in urban and peri-urban Ethiopian residents.18,19 
Recent studies in southern Africa have reported lower rates of seroprevalence of toxoplasmosis than 
previous studies in the rest of the world. While Kistiah et al noted an unexpectedly low prevalence 
(6.4% in the general population) in neighbouring South Africa, Sitoe et. al. reported 18.7% in 
Mozambique.14,20,21 T. gondii is postulated to be one of the neglected tropical diseases in Namibia.22 
Except for Jacobs and Mason, no recent studies have determined the burden of T. gondii infection 
in humans in Namibia.8  
The objective of this study was to evaluate the exposure by blood donors in Namibia to T. gondii. 
Determining the seroprevalence of antibodies to T. gondii in blood donors might provide an indication 
of the seroprevalence in the broader Namibian population.2,12 Furthermore, it could give an indication 
of the risk of transfusion-transmitted toxoplasmosis in Namibian blood donations.   
Method 
Study design and study population 
A cross-sectional, prospective study was performed in voluntary blood donors in central Namibia. 
Three hundred and twenty-nine blood donors volunteered to participate in the study when they 
donated blood to the Blood Transfusion Service of Namibia between October 2011 to January 2012. 
An additional 5 ml of blood was drawn in a plain tube for each donor. The serum was aliquot and 





purpose of the research, as well as a questionnaire in English or Afrikaans, from which demographic 
data and information on their contact with animals were collected. Only samples with an 
accompanying survey were used for testing. Informed consent was obtained from the donors, 
participation was anonymous and voluntary, and donors could opt out of the study at any stage. 
Permission for the study was granted by the Institutional Research and Publication Committee, the 
Research Committee of the Ministry of Health and Social Services, and by the management of the 
Blood Transfusion Service of Namibia.  
Data collection 
The prevalence of IgG antibodies to T. gondii was determined in 312 samples using the Captia™ T. 
gondii immunoglobulin (Ig) G enzymelinked immunosorbent assay (ELISA) kit (Trinity Biotech, Bray, 
Ireland). The manufacturer’s protocol was followed to determine the outcome of the test results. 
Samples with an equivocal IgG result were retested with the same kit and included in the negative 
results if still equivocal. Serum samples that tested positive or equivocal for IgG antibodies were 
further analysed using the Captia™ T. gondii IgM ELISA kit. Results from the ELISA tests, as well 
as responses from the questionnaires, were entered into a Microsoft® Excel® spreadsheet. Statistical 
analysis was performed using SPSS©version 21. An association between the population 
characteristics in the surveys and the seropositivity results was not calculated owing to a low 




Of a total of 329 samples, only 312 samples were included in the study as accompanying 
demographic information was lacking for the rest. The majority (61.9%) of donors were male. Their 
ages ranged from 16-64, with a mean age of 32.2 ± 11.3 years. Most of the donors (75.7%) were 
aged 40 years and younger. Donors from different regions in Namibia were included in the study, 
although the majority (86.9%) were from the central region. Most participants (81.1%) indicated that 
they lived in urban areas, 95.8% with animals and 32% with animals as part of their occupation. 





owners. Many respondents were farmers who also had contact with other animals, such as cattle, 
goats and horses. The demographic distribution of the donors and their exposure to animals is 
summarised in Table I.  
Seroprevalence 
Of the 312 samples tested, 3 (1%) were positive and three tested equivocal for IgG antibodies to T. 
gondii. All three IgG-positive donors were urban dwellers in central Namibia and had indicated that 
they lived with animals, such as cats and dogs. Their ages ranged from 1861. Two of the three IgG-
positive donors were women (Table II). Of the six samples tested for IgM antibodies, 1 (0.3% of the 





          






Females 119 (38.1) 
Males 193 (61.9) 
Age (years) 
20 and younger 38 (12.2) 
20-29 105 (33.7) 
30-39 93 (29.8) 
40-49 54 (17.3) 
50 and older 22 (7.1) 
Areas* 
North 24 (7.7) 
Central 271 (86.9) 
South 17 (5.8) 
Residence 
Rural 53 (17) 
Urban 253 (81.1) 
Unknown   6 (1.9) 
Interact with animals on a regular basis? 
No 13 (4.2) 
Yes 299 (95.8) 
Work with animals on a farm? 
No 212 (68) 
Yes 100 (32) 
 
  
               
*
Regions:   North (Caprivi, Ohangwena, Oshikoto, Oshana, Omusati and Kunene);  











         





Table II: The seroprevalence of immunoglobulin G and immunoglobulin M antibodies to Toxoplasma gondii 
in Namibian blood donors and the corresponding demographic information 
 











Positive Negative 61 Female Khomas Unknown Unknown Unknown Unknown 
Equivocal Negative 31 Male Khomas Urban Yes Dogs No 




Positive Negative 18 Female Khomas Urban Yes Cats No 
Positive Positive 29 Male Khomas Urban Yes Dogs and 
cats 
No 
               






The low prevalence of T. gondii antibodies in Namibian blood donors was much lower than 7-80% 
reported in other African countries.14 However, the prevalence is comparable to that of toxoplasmosis 
in blood donors in China, which varied from 0.4-20.2%.23 Alvarado-Esquivel et. al. reported a 7.4% 
IgG prevalence of T. gondii in healthy blood donors in Mexico, with an IgM prevalence of 1.9%.2 A 
low prevalence of toxoplasmosis (3% in healthy individuals) was also reported in Thailand.13 
While no specific studies have been published on toxoplasmosis in humans in Namibia, one study 
reported its prevalence using Namibian serum samples. Jacobs and Mason carried out an indirect 
fluorescent antibody survey of the the prevalence of Toxoplasma antibodies using sera from 
southern Africa (Natal, Eastern Cape and Western Cape, South Africa) and south-west Africa 
(Namibia) and Botswana.8 The overall prevalence in that study was 20% of 3 379 sera tested. Serum 
samples were obtained from the San (n = 725) in eastern Namibia, Damara speakers (n = 77) in the 
Erongo region and urban white residents (n = 261) in the Windhoek area, for the Namibian 
component of the Jacobs and Mason study. Prevalence rates were 12% in the white residents of 
Windhoek, 27% in the Damara speakers in Damaraland and 9% in the San. The differences in culture 
were thought to play a role in the variations in the prevalence of toxoplasmosis in the Namibian 
groups.8 
In the current study, the low prevalence in central Namibia indicates a substantial decline from that 
documented by Jacobs and Mason.8 This is in line with the trend in Europe and New Zealand, where 
a decrease in the prevalence of toxoplasmosis has been seen over the past few decades.12 One of 
the reasons for this decline could involve the more common use of frozen meat since the 
consumption of previously frozen meat is associated with a lower risk.24,25 In Europe and America, 
the consumption of raw or undercooked meat, as part of cultural practice, is the main risk factor for 
toxoplasmosis.25,26 This is not the case in certain populations of southern Africa, although some 
restaurants serve rare or underdone beef and game steak, particularly popular with tourists. 
Additionally, the results are comparable to those recently published for South Africa, which also 
describe a lower seroprevalence of T. gondii than that previously reported.14,21 This could be 





Age and the gender distribution of the blood donors compare well to those in other studies. Most of 
the blood donors were recruited in the Khomas region, where the capital city is 1 650 m above sea 
level. High altitude is usually associated with a lower prevalence of toxoplasmosis.2 Furthermore, the 
exceptionally dry conditions encountered in the central regions of Namibia could have also 
contributed to low exposure to Toxoplasma spp. as oocysts are sensitive to desiccation.3 However, 
the situation may differ in other regions, like the Kavango and Caprivi, where warm, humid conditions 
prevail and communities share water resources with livestock and wild animals.    
Five of the possible six T. gondii-positive donors engaged in regular interaction with cats and/or dogs, 
which have been investigated as risk factors for toxoplasmosis, e.g. contact with dogs and farming 
activities, as well as living with cats at home.2,27,25 As toxoplasmosis has been reported in domestic 
and wild animals in Namibia, there is the potential risk of transmission to humans since the reservoir 
for the parasite exists in the country.28,29  
However, it is notable that the majority of respondents in this study were dog and/or cat owners, but 
their exposure to toxoplasmosis was very low. This result is supported by that in another study in 
which an association between the seroprevalence of Toxoplasma spp. and cats in the household or 
contact with dogs was not found.27 One limited but important aspect of this study involves the 
possibility of the transmission of T. gondii via the national blood transfusion service. The transmission 
of T. gondii through blood transfusion has been well documented.30 T. gondii may be transmitted 
through the transfusion of infected blood since trophozoites can survive for several days in blood 
and blood products,  especially leukocytes.31,32 The parasite can survive in citrated blood stored at 
4°C for 50 days. In India, after malaria, toxoplasmosis is the most important protozoan disease that 
is transmitted by blood transfusion.5 While the overall risk is probably low for a donor transmission 
event, the donor who tested positive for IgM antibodies could have potentially been at risk of blood 
safety being compromised through transfusion, especially if the recipient was a pregnant woman or 
an HIV-positive patient.7 T. gondii is currently not part of donor blood screening in Namibia, although 






The small, non-random sample used for the study made it difficult to identify any regional trends and 
establish risk factors based on the questionnaire responses. As most of the study population came 
from the central arid regions, it would be important for future studies to include the northern tropical 
regions, in order to obtain a holistic epidemiological picture of T. gondii in Namibia. However, 
evaluating the exposure of volunteer blood donors is a valuable indicator of the epidemiology of an 
infectious disease in the broader population in the same community.2 Therefore, the low 
seropositivity in central Namibia indicates that the broader population in this area probably has 
limited exposure to T. gondii. 
Conclusion 
This study, while regional in nature, demonstrated that Toxoplasma spp. occurs in Namibia. Further 
studies are needed to evaluate the current status of the parasite in human and animal populations. 
Further point prevalence studies should be conducted in the country, particularly in the areas of high 
prevalence reported by Jacobs and Mason. Occupational risks for abattoir workers, especially those 
handling goats and sheep in the slaughtering process, should also be established. It is anticipated 
that an increase could be indicative of a warming trend accompanied by higher humidity to keep the 
oocysts from desiccating. Ideally, the prevalence of toxoplasmosis in at-risk groups, such as 
pregnant women, their neonates and persons living with HIV, should also be evaluated. 
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2.1.1 Reflection on first article 
This publication is the first on the prevalence of T. gondii in Namibia since 1978.  Worldwide, 
prevalence of T. gondii has declined over the past decades.  Possible reasons could be better 
controlled facilities to process meat, and practices to freeze meat for storage.  Climate change could 
also play a role with severe droughts on the increase in certain parts of the world like Africa and 
South America.  Oocytes of T. gondii cannot survive in dry conditions since they are sensitive to 
dessication.  Namibia has also suffered severe droughts in the past decade.  Therefore, there was 
a need to update information on the prevalence of T. gondii in Namibia.  Prevalence was expected 
to be lower than the 12% recorded among blood donors in 1978. 
Blood donors were selected as the study group mainly for the convenience of sampling.  Another 
project in the department investigated the prevalence of zoonotic and tick-borne diseases among 
blood donors in Namibia.  The same blood samples could thus be used to study the prevalence of 
T. gondii among blood donors. Therefore, a sample size was not calculated for this study.   
This study was a good starting point to pave the way for the actual goal, viz. to study the prevalence 
of maternal infections including T. gondii.  Blood donors could give a good indication of the 
prevalence of an infection in the general population.  Data from this study was used to determine the 
sample size for the bigger study.  
Although the results showed a decline in the prevalence of T. gondii among blood donors since 1978, 
the extremely low prevalence (the lowest found in literature) was possibly not representative of the 
general population.  The sampling was biased since blood donors generally have more affluent 
lifestyles with better hygiene than people in villages in rural areas.  The expectation was that the 
prevalence of T. gondii could be higher in rural areas, as well as in parts of Namibia which have a 
tropical climate. 
The next step was to study the prevalence of T. gondii among pregnant women attending antenatal 
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Background: When a pregnant woman contracts Toxoplasma gondii (T. gondii) infection during 
pregnancy, it may be vertically transmitted to the foetus. Information on the incidence of 
congenital toxoplasmosis (CT) in developing countries is scarce. Most studies focus on the 
seroprevalence of T. gondii infection among pregnant women. This study aimed to determine 
the seroprevalence of T. gondii infection among pregnant women attending public antenatal 
care in Windhoek, Namibia, in 2016. 
 
Methods: In this descriptive study, 344 urban pregnant women attending public antenatal care 
were voluntarily enrolled in the study. Seroprevalence of anti-T. gondii Immunoglobulin G (IgG) 
was determined by automated immunoassay. Samples with a positive T. gondii IgG result were 
tested for T. gondii Immunoglobulin M (IgM) and specific IgG avidity by using an enzyme-linked 
immunosorbent assay (ELISA) test. A questionnaire captured demographic data and exposure to 
risk factors. Data were analysed using Statistical Package for the Social Sciences (SPSS) and R. 
 
Results: Anti-T. gondii IgG was found in nine (2.61%) pregnant women. There was no 
association of anti-T. gondii IgG with demographic characteristics or exposure to risk factors. 
Anti-T. gondii IgM was positive in one (0.3%) woman, while three (0.9%) women had borderline 
anti-T. gondii IgM results. Specific IgG avidity was low, equivocal and high in 0%, 33% and 67% 
of seropositive pregnant women, respectively. 
 
Conclusion: Seroprevalence of anti-T. gondii IgG is much lower in Namibia than is reported in 
other developing countries. Investigation into specific IgM seropositivity and IgG avidity 
showed that pregnant women in the central region of Namibia are at low risk of vertical 
transmission and development of CT. 
 





Toxoplasma gondii (T. gondii) is a protozoan parasite with the only definitive hosts being the cat 
species. Infection occurs via contamination of soil and water, and the parasite can be found in all 
warm-blooded vertebrates and some reptiles. Humans are intermediate hosts. Infections in 
humans occur through the ingestion of raw or undercooked meat, unpasteurised milk or 
contaminated water or by sharing the environment with cats and inadvertently ingesting oocytes 
from cat faeces. Toxoplasmosis can be transmitted from a mother to a foetus and can cause 
deafness, blindness, mental retardation, physical impairment or even stillbirth. If a pregnant 
woman is diagnosed with T. gondii infection, antimicrobial treatment is possible, although the 
success of the treatment will depend on a number of variables like the dose and the route of 
administration.1 Congenital toxoplasmosis (CT) may occur in spite of treatment with spiramycin 
of pregnant women with primary T. gondii infection.2 Furthermore, spiramycin is not available in 




















Immunocompetent and immunocompromised women contracting T. gondii infection for the first 
time during pregnancy run a risk of transmitting the infection to the foetus because of the parasite 
crossing the placenta from the maternal blood. A host that is immunocompetent acquires life-long 
immunity against toxoplasmosis when infected with T. gondii. A new T. gondii infection contracted 
4–6 months before conception will usually not result in mother-to-child transmission of toxoplasmosis 
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Seroprevalence of Toxoplasma gondii infection among pregnant women in Windhoek, 
Namibia, 2016 
Abstract 
Background: When a pregnant woman contracts Toxoplasma gondii (T. gondii) infection during 
pregnancy, it may be vertically transmitted to the foetus. Information on the incidence of congenital 
toxoplasmosis (CT) in developing countries is scarce. Most studies focus on the seroprevalence of 
T. gondii infection among pregnant women. This study aimed to determine the seroprevalence of T. 
gondii infection among pregnant women attending public antenatal care in Windhoek, Namibia, 2016. 
Methods: In this descriptive study 344 urban pregnant women attending public antenatal care were 
voluntarily enrolled in the study.  Seroprevalence of anti-T. gondii IgG was determined by automated 
immunoassay. Samples with a positive T. gondii IgG result were tested for T. gondii IgM and specific 
IgG avidity by ELISA. A questionnaire captured demographic data and exposure to risk factors. Data 
were analysed using SPSS and R.  
Results: Anti-T. gondii IgG was found in 9 (2.61%) pregnant women. There was no association of 
anti-T. gondii IgG with demographic characteristics or exposure to risk factors, although a bigger 
sample size is needed to find possible associations. Anti-T. gondii IgM was positive in 1 (0.3 %) 
woman while 3 (0.9 %) women had borderline anti-T. gondii IgM results. Specific IgG avidity was 
low, equivocal and high in 0%, 33% and 67% of seropositive pregnant women. 
Conclusion: Seroprevalence of anti-T. gondii IgG is much lower in Namibia than is reported in other 
developing countries. Possible explanations are the arid climate and high altitude of the capital, 
Windhoek. Investigation into specific IgM seropositivity and IgG avidity showed that pregnant women 
in the central region of Namibia are at low risk of vertical transmission and development of CT. 
Further studies are needed in rural areas where seroprevalence of T. gondii may be higher. 
 







Toxoplasma gondii (T. gondii) is a protozoan parasite with the only definitive hosts being cat species. 
Infection occurs via contamination of soil and water and the parasite can be found in all warm-
blooded vertebrates and some reptiles. Humans are intermediate hosts. Infections in humans occur 
through ingestion of raw or undercooked meat, unpasteurised milk or contaminated water or sharing 
the environment with cats and inadvertently ingesting oocytes from cat faeces. Toxoplasmosis can 
be transmitted from a mother to a foetus and cause deafness, blindness, mental retardation, physical 
impairment or even stillbirth.  If a pregnant woman is diagnosed with T. gondii infection, antimicrobial 
treatment is possible, although the success of the treatment will depend on a number of variables 
like the dose and the route of administration [1]. Congenital toxoplasmosis may occur despite 
treatment with spiramycin of pregnant women with primary T. gondii infection [2]. Furthermore, 
spiramycin is available in neither the public nor private sector in Namibia. 
 
Congenital toxoplasmosis 
Immunocompetent and immunocompromised women contracting T. gondii infection for the first time, 
during pregnancy run a risk of transmitting the infection to the foetus due to the parasite crossing the 
placenta from the maternal blood. A host that is immunocompetent acquires life-long immunity 
against toxoplasmosis when infected with T. gondii. A new T. gondii infection contracted 4 – 6 months 
before conception will usually not result in mother-to-child transmission of toxoplasmosis on 
subsequent exposures. In immunocompromised women who are HIV positive, T. gondii infection 
may reactivate with resulting vertical transmission [3,4]. In a study in Brazil, 28% of T. gondii IgM-
positive pregnant women with unknown HIV status transmitted the infection vertically [2].  
Only about 30% of infants born to mothers who had seroconversion in pregnancy acquire prenatal 
infection. If the infection in a pregnant woman is not treated, the risk of intrauterine infection increases 
with gestational age, i.e. from 14% for primary maternal infection in the first trimester, to 59% for 
primary maternal infection in the last trimester. [3]. The later in gestation of primary infection, the 





the risk of symptomatic infection and severe disease is high [5]. Clinical signs of toxoplasmosis in 
neonates include the classical triad, namely intracranial calcification, hydrocephalus and 
retinochoroiditis. About 10% of prenatal infections result in abortion or neonatal death.  The surviving 
infants suffer from progressive neurologic complications like mental retardation, learning problems, 
hearing and visual impairment or seizures and have special care and education needs. Children who 
have been infected before birth might be asymptomatic at birth but may develop complications 
associated with toxoplasmosis later in life [3,6,7]. Clinical trials indicate that early treatment of these 
children can decrease manifestations of disease and improve the quality of life [3].  
Congenital toxoplasmosis (CT) can best be prevented by ensuring that pregnant women who are 
seronegative do not get infected, or by treatment of pregnant women who are diagnosed with a 
primary infection, as evident from seroconversion, T. gondii IgM positivity and low IgG avidity.  
Screening programmes for toxoplasmosis have been introduced in many European countries and 
the USA.  These include either diagnosis of primary maternal infection with T. gondii during 
pregnancy or detection of congenital infections in neonates at birth [3]. No routine screening for T. 
gondii is done in Namibia and only two previous studies were done to determine the prevalence of 
toxoplasmosis among blood donors [8,9]. The aim of this study was to determine the prevalence of 
antibodies to T. gondii among urban pregnant women attending public antenatal care in Windhoek, 
Namibia, from September to October 2016. 
 
2. Materials and Methods 
2.1 Study design 
This was a descriptive study aiming to describe the seroprevalence of T. gondii among pregnant 
women in Windhoek, Namibia. 
2.2 Sample size 
At an expected prevalence of 6% of T. gondii infection, using Cochran’s formula, a sample size of 





Estimated prevalence was based on two previous publications in Namibia and the seroprevalence 
in neighbouring South Africa. Funding was available to enrol 344 participants in the study.  
2.3 Exclusion and inclusion criteria 
All pregnant women attending public antenatal care in Windhoek, Namibia, from 12 September to 11 
October 2016 were informed about the study and all women who were identified by the clinic to have 
their blood drawn for routine antenatal testing, were eligible to participate. Five participants were 
excluded due to not signing the consent form by omission and one Ovahimba woman was excluded 
due to not understanding English or Afrikaans.  
2.4 Sample collection 
Participation in the study was voluntary and written consent was obtained from each participant and 
guardian where applicable. A venous blood sample was collected from each consenting participant 
and transported immediately to the testing laboratory.  A questionnaire was administered to collect 
information on demographic characteristics and exposure to risk factors and was filled by consenting 
participants. Questions were derived from the literature. 
2.5 Sample storage 
Blood samples were transported to the laboratory within an hour. Serum was stored for not more 
than a week at 2-8 ºC and then at -80 ºC until testing. 
2.6 Laboratory methods 
An automated chemiluminescent microparticle immunoassay was performed in an ISO 15189 
accredited laboratory to determine seroprevalence of IgG antibodies to T. gondii (Access 
immunoassay systems, Beckman Coulter Eurocenter SA, 22 rue Juste-Olivier, Case Postale 1044, 
CH - 1260 Nyon 1, Switzerland).   Presence of anti-T. gondii IgM antibodies was determined in 
samples testing positive for specific IgG using an ELISA method (Euroimmun Medizinische 
Labordiagnostika, D-23560 Lubeck, Seekamp 31, Germany). Cut-off points were calculated by using 





extinction value of the calibrator defined the cut-off value as recommended by the manufacturer. IgG 
avidity was determined in samples testing positive for specific IgG by performing a manual ELISA 
test with an urea wash step to dissociate antibodies (Euroimmun).  
For interpretation of IgG results, recommendations from the manufacturer were followed. Specimens 
with specific IgG concentration of >10.5 IU/ml were considered positive for T. gondii past or current 
infection. Acute infection with T. gondii was determined by the presence of anti-T. gondii IgM 
antibodies and specific IgG antibodies with low avidity. Recommendations from the manufacturer 
were followed for interpretation of results. For interpretation of IgM results, an extinction ratio (sample 
relative to calibrator) of <0.8 was considered negative, >0.8 to <1.1 was borderline and >1.1 was 
positive. For interpretation of avidity results, the ratio of the enzyme immuno-assay optical density 
when urea-treated relative to untreated was used. Low avidity was defined as a ratio of <40% which 
was indicative of acute T. gondii infection. A ratio of 40-60% was considered equivocal while a ratio 
above 60% was an indication of high avidity antibodies. 
2.7 Data analysis 
Association of demographic characteristics (maternal age, gestational age and parity) with 
seroprevalence of T. gondii infection among pregnant women was investigated. Association of risk 
factors (water source, living with cats or dogs, blood transfusion, as well as consumption of untreated 
water, unpasteurized cow’s milk, goat’s milk, raw/undercooked meat or unwashed fruit/vegetables) 
with seroprevalence of T. gondii infection was investigated. A case-based description of anti-T. gondii 
IgG and IgM seropositivity and IgG avidity was provided for nine participants who tested IgG positive. 
Seropositivity among five age groups was evaluated with the assumption that all age groups had 
had similar exposure to T. gondii. All data were entered into an Excel spreadsheet (Microsoft 
Corporation, One Microsoft Way, Redmond, WA 98052-7329) and analysed using SPSS statistical 
software (version 24, IBM North America, 590 Madison Avenue, New York, NY 10022) and R version 
3.2.2 [10]. Chi-square and Fisher’s exact test (when the expected frequency in any cell of the two-
by-two table was less than 5) were used to assess associations between population characteristics 





linear models using binary logistic regression. Beta-values were used to calculate odds ratios of 
variables while the Wald 95% confidence intervals gave an indication of the width of the odds ratios; 
p-values less than 0.05 were considered statistically significant. 
2.8 Ethical approval 
Ethical approval of the study was obtained from the School of Health and Applied Sciences, 
Polytechnic of Namibia, the Ministry of Health and Social Services in Namibia, and from the Health 
Research Ethics Committee at Stellenbosch University, Cape Town, South Africa. 
 
3. Results 
Three hundred and forty-four pregnant women each donated a blood sample and filled the 
questionnaire. Maternal age at enrolment ranged between 17 and 47 years with the median age of 
27 years. All but two women were residing in the urban area. Forty-one (11.9%) women were in the 
first trimester, 172 (50%) in the second trimester and 130 (37.8%) in the third trimester of pregnancy 
upon enrolment in the study. A hundred and twenty-nine (37.5%) of women were primigravidae, 100 
(29.1%) had one previous pregnancy while 115 (33.4%) had two or more previous pregnancies. 
Overall seroprevalence of anti-T. gondii IgG among pregnant women attending public antenatal care 
in Windhoek was 2.61% (Table 1). Overall susceptibility to T. gondii infection was high (n=335; 97.4 
%). There was no statistically significant difference between seroprevalence of anti-T. gondii IgG in 
different age groups. There was no statistically significant difference between the occurrences of 
anti-T. gondii IgG in different trimesters of pregnancy. There was no statistically significant difference 
between the occurrences of anti-T. gondii IgG in different parities although the highest observed 






Table 1. Association of demographic characteristics with seroprevalence of Toxoplasma gondii 
among urban pregnant women (n=344) attending public antenatal care in Windhoek, Namibia, 2016. 
 
aIncluding borderline positive results 
bAdjusted odds ratios were not calculated as none of the predictors were statistically significant 
cNinety-five percent Wald confidence interval 
dNot available since one predictor equals zero 
 
 
This study found no association between risk factors and seropositivity of anti-T. gondii IgG in 
pregnant women (Table 2). Available data showed that none of own tap versus communal tap as 
water source; living with cats or dogs; or blood transfusion was associated with seroprevalence of T. 
gondii infection.  Consumption of water from a dam or river; unpasteurized cow’s milk, goat’s milk; 












  n (%)     
Overall 344 9 (2.61)     
       
Maternal age       
15-20 38 0 (0) 0.383 0.211 1.08 -0.046-0.209 
21-25 108 3 (2.78)     
26-30 96 5 (5.21)     
31-35 59 0 (0)     
36-47 43 1 (2.33)     
       
Gestational age     
1st trimester 41 0 (0) 0.793 0.999 NAd  
2nd trimester 172 5 (2.91)  0.796 0.84 -1.533-1.176 
3rd trimester 130 4 (3.08)     
       
Parity       
Primigravida 129 6 (4.65) 0.220 0.048 12.16  0.022-4.973 
1 previous 
pregnancy 
100 2 (2.0)  0.334  3.41 -1.262-3.713 
>2 previous 
pregnancies 
115 1 (0.87)     





Table 2. Association of risk factors with seroprevalence of Toxoplasma gondii among urban pregnant 
women (N=344) attending public antenatal care in Windhoek, Namibia, 2016. 
 
 
aIncluding borderline positive results 
bAdjusted odds ratio was not calculated since no predictor was statistically significant 
cNinety-five percent Wald confidence interval of the odds ratio 
dNot available since one predictor equals zero  








  n (%)     
Water source       
Own tap 226 9 (3.98) 0.185 0.998  NAd  
Communal tap 114 0 (0)     
       
Live with cats       
Yes 45 0 (0) 0.612 0.999 NA  
No 299 9 (3.01)     
       
Live with dogs       
Yes 122 4 (3.28) 0.726 0.787 1.24 -1.349-1.779 
No 222 5 (2.25)     
       
Received a blood transfusion   
Yes 6 1 (16.67) 0.172 0.417 3.55 -1.794-4.331 
No 327 8 (2.45)     
       
Consumption        
Water from dam or river      
Yes 55 3 (5.45) 0.160 0.088 4.75 -0.235-3.352 
No 289 6 (2.08)     
       
Unpasteurized cow’s milk    
Yes 39 3 (7.69) 0.070 0.052 7.30 -0.017-3.992 
No 305  6 (1.97)     
       
Goat’s milk       
Yes 7 1 (14.29) 0.171 0.703 1.87 -2.590-3.838 
No 337 8 (2.37)     
       
Raw / undercooked 
meat 
    
Yes 97 2 (2.06) 1.000 0.323 2.71 -0.981-2.972 
No 247 7 (2.83)     
       
Unwashed fruit / vegetables   
Yes 83 0 (0) 0.121 0.998 NA  
No 261 9 (3.45)     





Of the 344 participants, 9 (2.61%) had a positive anti-T. gondii IgG result, while 1 (0.3 %) had a 
positive IgM result and 3 (0.9%) had a borderline-positive IgM result (Table 3). The mean anti-T. 
gondii IgG titre among T. gondii-positive pregnant women was 132.1 IU/ml, ranging between 25.9 
and 298.2 IU/ml.  Specific IgG avidity among infected women was low, equivocal and high in 0 %; 
33 % and 67 %, respectively, of positive IgG cases. 
 
Table 3. Anti-T. gondii IgG and IgM seropositivity, and IgG avidity among pregnant women. 
 
Case IgG IU/ml IgM IgG avidity 
    
5015 38.8 Neg High 
5022 298.2 Neg High 
5040 168.2 Pos Equivocal 
5050 144.2 Borderline Equivocal 
5116 25.9 Borderline Equivocal 
5145 210.5 Borderline High 
5164 83.3 Neg High 
5320 113.6 Neg High 
5328 106.4 Neg High 
 
4. Discussion 
4.1 Seroprevalence of anti-T. gondii IgG 
Very low seroprevalence of anti-T. gondii IgG (2.61%) was found among urban pregnant women 
attending public antenatal care in Windhoek, Namibia, 2016. This is comparable to a previous study 
in Namibia which found 1% seroprevalence of anti-T. gondii among blood donors [9]. Possible 
reasons for this low seroprevalence are the arid climate and high altitude of the capital city, Windhoek 
[11]. Oocysts cannot withstand dry conditions which prevail during extended periods of drought in 
central Namibia. The worst drought since recording of rainfall had started, occurred in Namibia in 
2016. The seroprevalence of anti-T. gondii found in 2016 was lower than the 12.1% recorded among 
blood donors in Windhoek in 1978 [8].  This finding is in line with the worldwide trend of decreasing 
seroprevalence of anti-T. gondii over the previous decades [12]. Factors that could contribute to the 
decreasing trend are urbanization, which is accompanied by better access to safe drinking water and 





Being the driest African country south of the Sahara, Namibia shows much lower seroprevalence of 
T. gondii infection than in other developing countries (Table 4) [8,13-29].  
 






Population N Method Reference 
Namibia 1978 12 Blood 
donors 
261 IFA Jacobs [8] 
Sudan 1991 41.7 General 
population 
386 LAT Abdel-Hameed 
[13] 
Benin 1995 53.6 Pregnant 
women 
211 ELISA Rodier [14] 













180 ELISA Singh [16] 
Ethiopia 2007 60 Urban 
population 
65 MDAT Negash [17] 
Nigeria 2007 20.8 Healthy 
individuals 
144  Uneke [18]                            
Tanzania 2009 46 Occupatio
nally 
exposed 
199 LAT Swai [19] 









Gabon 2010 56 Pregnant 
women 





Mozambique 2010 18.7 Pregnant 
women  
150 ELISA Sitoe [22] 
South Africa 2011 6.4 General 
population 
376 LAT Kistiah [23] 





276 ELISA Deji-Agboola [24] 







323 ELFA El Deeb [25] 





283 ELISA De Paschale [26] 







781 ELFA Doudou [27] 
Namibia 2014 1.0 Blood 
donors 
320 ELISA Van der Colf [9] 
Ethiopia 2015 18.5 Pregnant 
women 
384 LAT Awoke [28] 







It is however comparable to seroprevalence in neighbouring South Africa, with which Namibia shares 
weather patterns [23]. The seroprevalence is the same as in Mexico with similar arid climate [29]. A 
review of studies done in Africa found a median seroprevalence of T. gondii of 37 %, with rates 





In Brazil, Neto et al. (2010) found 0.06% of neonates anti-T. gondii IgG seropositive [30]. It is 
postulated that the high burden of CT in South America can be attributed to more pathogenic 
genotypes that circulate in that part of the world [31].    
In Windhoek, 97.4 % of pregnant women attending public antenatal care remain susceptible to T. 
gondii, posing a risk of vertical transmission and CT if they get infected while pregnant. Infection 
pressure is however low: a large population is at risk, but the probability of exposure is low. In 
hyperendemic settings, acquisition and immunity is likely before women fall pregnant, whereas 
models suggest that when the incidence of T. gondii infection among pregnant women is 4% per 
annum the risk of seroconversion during pregnancy and occurrence of CT would be the highest. This 
correlates with a susceptibility of 40% among pregnant women, which is much lower than the 
susceptibility found in this study [31].  
4.2 Factors associated with seropositivity 
There was no significant difference in prevalence of anti-T. gondii IgG among five different age 
groups of pregnant women. Seroprevalence linearly increased in the lowest three age groups (15-
20 years, 21-25 years and 26-30 years), only to decrease in older women (31-47 years) (Table 1). 
Seroprevalence of anti-T. gondii IgG increased with gestational age although the difference was not 
statistically significant. Primigravidae showed the highest seroprevalence of anti-T. gondii IgG, which 
is in line with the finding of higher seroprevalence among younger women.  
There was no significant association between risk factors and seroprevalence of T. gondii (Table 2). 
Surprisingly, participants with access to own tap showed the highest seroprevalence of T. gondii. 
However, this association was not significant. Another interesting finding was the lack of association 
between consumption of unwashed fruit or vegetables and seropositivity while 3.45% of participants 
denying this consumption showed seropositivity of T. gondii infection. Alvarado-Esquivel et. al. 
(2018) reported a similar finding [29]. These exposures to T. gondii could possibly be due to other 
risk factors like working with raw meat, which were not assessed in our study. 
Magwedere et. al. (2012) included a discussion on T. gondii in their report on zoonoses posing a 





of undercooked game meat could possibly pose a risk of exposure to T. gondii. A previous study 
found presence of T. gondii in lions in Namibia. Among a pride of five lions in a private reserve, four 
showed evidence of T. gondii infection [33]. A high prevalence of T. gondii was also found in feral 
cats in the Western Cape Province in South Africa, providing a reservoir for the parasite and potential 
source of contamination of the environment [34]. In the 1990s a municipality in the Province of British 
Columbia in western Canada experienced an outbreak of toxoplasmosis, with the municipal water 
supply implicated as the source of infection [35,36].  
4.3 Specific IgM and IgG avidity 
Very few pregnant women had possibly been infected during pregnancy so the risk of giving birth to 
an infant with CT was minimal.  Anti-T. gondii IgM antibodies and specific IgG avidity were only tested 
in samples positive for anti-T. gondii IgG. Other studies found very low prevalence of samples 
positive for anti-T. gondii IgM only (0.3% [37], 0.9% [38]).  
It can thus be concluded that the pregnant women who presented with anti-T. gondii IgG antibodies 
were infected before they became pregnant with low risk of vertical transmission. Avidity testing is 
widely used in Europe and increasingly in southern Africa. The French National Reference Center 
for Toxoplasmosis has proposed algorithms for interpretation of serologic testing (IgG, IgM and IgG 
avidity) for T. gondii [39].  
The T. gondii IgG avidity test is useful to distinguish past from present infection in specific IgM-
positive pregnant women. In a study in Brazil presence of anti-T. gondii IgM in an immune pregnant 
woman was often not associated with congenital infection. 20% of infants born to immune mothers 
with specific IgM antibodies and low avidity IgG antibodies were vertically infected while 8% of infants 
born to mothers with specific IgM antibodies and intermediate or high IgG avidity were vertically 
infected [2,40]. Liesenfeld et al. (2001) evaluated the usefulness of testing for IgG avidity in 
association with T. gondii and found that among pregnant women with either positive or equivocal 






4.4 Prevention strategy 
The high rate of T. gondii susceptibility among pregnant women could justify health education 
interventions. Women of childbearing potential found to be susceptible to T. gondii should be 
educated on behaviour to prevent infection [41].  A health promotion strategy should be aimed at 
women of reproductive age, making them aware of preventive behaviour [38].  
 
5. Conclusion 
The study group of urban pregnant women attending public antenatal care in Windhoek, Namibia 
from September to October 2016 had a low prevalence of antibodies to T. gondii. This could possibly 
be attributed to geographical and meteorological aspects. The youngest and oldest age groups were 
least affected by toxoplasmosis. Health education of pregnant women on preventive measures could 
minimize the risk of CT.  Further studies could investigate the seroprevalence of T. gondii in rural 
areas of Namibia, where higher rates of infection might be found. Future investigations could also 
be directed towards a one health approach to focus on T. gondii infection among wildlife like game 
and carnivores, and among abattoir workers. Of interest is the lack of information on genotypes of 
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2.2.1 Reflection on second article 
Funding became available to perform the bigger study, namely the prevalence of infectious diseases 
among pregnant women attending public antenatal care.  Information from the first study, together 
with seroprevalence data from neighbouring South Africa, was used to determine the sample size.  
Due to financial constraints, the calculated sample size could however, not be reached.   
Initially, the ultimate goal was to assess the prevalence of congenital infections in Windhoek, 
Namibia.  There are, however, no surveillance systems for congenital infections available.  It would 
not be feasible to investigate newborns for CT, hence the shift to the investigation of infectious 
diseases among pregnant women.  Pregnant women can transmit infections vertically although this 
does not happen in all maternal infections. 
The prevalence among pregnant women attending antenatal care was a bit higher than the 
prevalence found among blood donors.  Demographic data suggests that this clinic sees the more 
affluent population of clients and that another clinic in Windhoek would have yielded a higher 
seroprevalence since they serve mainly the informal settlements. 
Another goal of the study was to determine associations between seropositivity and risk factors which 
were recorded in a questionnaire.  All 9 seropositive individuals had indicated that they do not have 
cats at home. Owning cats are generally seen as a risk factor for T. gondii infection, especially when 
the owner is handling cat litter. Interestingly, other authors in African countries reported a similar lack 
of association between owning a cat and T. gondii seropositivity [24,27 of the article]. Alvarado-
Esquivel et. al. (2018) conducted a study in Mexico in a similar setting to this study (similar sample 
size, similar seroprevalence of T. gondii of 3.7%) and found no association between owning a cat or 
handling cat litter and seroprevalence [29 of the article]. Cat litter should, however, be handled with 
caution since presence of T. gondii in 20% of privately owned cats’ litter was shown with molecular 
techniques at a teaching hospital in Italy [160 of thesis]. 
Given the low seroprevalence, however, a very large sample size would have been needed to show 





the desired outcome, which was to assess possible associations with meaningful statistical power. 
In retrospect, a sample size of 244 was calculated using Cochran’s formula and the 2.61% 
seroprevalence found among pregnant women.  
Testing for IgG avidity was a strength of this study since it was done for the first time in Namibia.  
Avidity testing is widely used in Europe and is gaining support in South Africa. As specific IgM tests 
are prone to false positivity a low avidity can confirm a recent acute infection in a pregnant woman 
with a positive T. gondii IgM test result.   This would inform whether there is an increased risk of 
congenital infection. However, termination of pregnancy (TOP) in Namibia, in case of intrauterine 
infections, is only allowable by law when it is adjudged to cause a serious risk of mental or physical 
defect to the unborn child and may therefore require additional investigations to determine 
intrauterine infection and the severity of congenital disease. Furthermore, avidity assays are 
relatively unknown in the local industry and may not be justified in local diagnostic laboratories due 
to the small volume of requests expected.  It would, however, be good to create awareness among 
clinicians about the availability of the test in South Africa for possible referral. 
It was reasoned that mathematical modelling could be useful to determine the risk of vertical 
transmission.  Unfortunately, the data obtained was not suitable for mathematical modelling since 
susceptibility did not decrease linearly with age.  After initial possible linear increase in prevalence, 
amongst the younger age groups, the age group of 31 – 35 had no cases with positive T. gondii IgG. 
The study was meaningful to provide updated data on the seroprevalence of T. gondii in Namibia.  It 
will hopefully create awareness of avidity testing among clinicians in order to corroborate a recent 
infection in T. gondii IgM positive cases and confirm this as the likely aetiology in cases with abnormal 
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Background: While rubella and congenital rubella syndrome have been eliminated in the Americas 
through effective vaccination programmes, some countries in Africa are still in the pre-vaccine era. 
Up until 2016, Namibia did not have an immunization programme for rubella. In 2015, a rubella 
outbreak was reported in the Khomas region of Namibia. 
Objectives: The aim of this study was to determine rubella immunity among urban pregnant women 
in Windhoek, Namibia, in 2016. 
Methods: Three hundred and forty-four pregnant women attending public antenatal care during 
September and October 2016 were recruited for the study.  Seroprevalence was determined with 
the Access automated rubella IgG assay. A questionnaire was used to capture demographic data, 
obstetric history and exposure to risk factors. 
Results: The percentage of women with IgG levels of <10 IU/ml, 10-14.9 IU/ml and > 15 IU/ml were 
2.0%, 2.0% and 95.9% respectively. An overall anti-rubella IgG mean level of 164.5 IU/ml (95% CI 
150.4-178.7) was found in five age groups, namely 15-20 (195.8; 159-232); 21-25 (167.8; 143-193); 
26-30 (165.2; 136-195); 31-35 (147.6; 116-179) and 36-47 (150.4; 107-194). Parity was significantly 
associated with high anti-rubella IgG levels (IU/ml) with primigravida showing the highest levels (p = 
0.004) while maternal age, gestational age, immunization history and living with children under 5 
years were not significant.  
Conclusions: A very high percentage of pregnant women in the study were immune to rubella virus 
despite never receiving rubella vaccination. This is likely due to a high rate of natural infection with 
rubella of children before reaching child-bearing potential. The overall anti-rubella IgG titre was much 
higher than the 26.5 IU/ml found in a Canadian cohort of pregnant women where rubella vaccination 
has been in place since the 1970’s. Natural rubella immunity is associated with higher titres that 
persist longer. The small percentage of pregnant women who remained susceptible to rubella virus 
infection is within targets set by WHO. 






Since live attenuated rubella vaccines were licenced in the USA in 1969, the incidence of congenital 
rubella syndrome (CRS) was decreased by well-organized immunisation campaigns [1]. Between 
2000 and 2014, there was a worldwide decline of 95% in reported rubella cases even though the 
number of WHO member states reporting rubella cases increased from 102 to 162.  Rubella and 
CRS interruption was reached in the Americas in 2009 with countries in four WHO regions meeting 
rubella control and elimination goals by December 2014 [2].  In 2010, the second highest estimated 
incidence of CRS was in Africa (116 per 100,000 live births).  The estimate for Namibia was less 
than 150 CRS cases per 100,000 births [3]. The future goal is to eliminate measles and rubella in 
five WHO regions including Africa by 2020 [4-6].   
Before 2016, Namibia did not have a rubella immunization programme in the public sector with 
combined measles, mumps and rubella immunizations (MMR) only given on request in the private 
sector. The first Namibian measles and rubella special immunization activity (SIA) was conducted in 
July 2016 by the Ministry of Health and Social Services, in collaboration with WHO, targeting all 
persons, both male and female, from 9 months to 39 years of age, excluding pregnant women. 
Routine measles and rubella (MR) vaccination of male and female children at 15 months was also 
introduced by the Ministry of Health and Social Services.  Good coverage by the SIA was expected 
based on the wide inclusion of gender and age. The WHO is making available data on vaccine 
coverage by country, but measles and rubella vaccination coverage in Namibia is only included from 
2017 onwards [161]. Endorsed by the World Health Assembly in 2012, the Global Vaccine Action 
Plan calls on all countries to reach ≥90% national coverage with all vaccines in the country’s national 
immunization schedule by 2020. Among countries that offer a second measles vaccine dose during 
the second year of life, coverage increased from 19% in 2007 to 54% in 2018 [162]. Coverage rate 
of a previous measles vaccination campaign in Namibia was 76% in 2009 [7]. 
Currently, the only published record on the seroprevalence of rubella among pregnant women 
attending public antenatal care in Namibia is from a 2010-report with an overall seroprevalence of 





no other information about the seroprevalence of rubella or the incidence of CRS in the Namibian 
population was available. This study, therefore, aimed to determine the seroprevalence of rubella 
among mainly unvaccinated pregnant women who attended a public antenatal clinic in 2016, 
Windhoek, Namibia. 
 
2. Materials and Methods 
This was a descriptive study aiming to describe the rubella immunity status of pregnant women. 
2.1 Study population 
Women aged 15 years and above were eligible to participate in the study. Three hundred and forty-
four pregnant women attending the public antenatal clinic at Windhoek Central Hospital during 
September and October 2016 were included in the study. A minimum sample size of 234 was 
calculated using Cochrane’s formula and a prevalence rate of 97.5% found in neighbouring South 
Africa [9]. A 95% confidence level was used, and provision was made for a 2% error. 5 ml of blood 
was collected from each consenting participant and transported immediately to the laboratory where 
serum was stored for one week or less at 2-8 ºC until testing. A questionnaire was completed by 
consenting participants which assessed demographic information, obstetric history, exposure to risk 
factors and vaccination history.   
2.2 Laboratory methods 
An automated chemiluminescent microparticle immunoassay (Access immunoassay systems, 
Beckman Coulter Eurocenter SA, 22 rue Juste-Olivier, Case Postale 1044, CH - 1260 Nyon 1, 
Switzerland) was performed to measure individual rubella IgG concentrations and determine rubella 
seroprevalence.  All testing was performed in an accredited laboratory which operates according to 







2.3 Interpretation of results 
Following the recommendation from the testing laboratory concerning the cut-off level for rubella 
protection, a rubella IgG value > 15 IU/ml was considered protective.  For the purpose of this study, 
the following IgG cut-off levels were accepted:  0.0-9.9 IU/ml: rubella susceptible; 10-14.9 IU/ml: 
possibly rubella susceptible; > 15 IU/ml: protected/immune. For results interpretation, the first two 
groups were taken as susceptible. 
Participants were asked whether they had been immunized against measles and/or rubella (“Yes”, 
“No” and “Don’t know”). Those who answered “Yes” were further asked when they had been 
immunized.  “In July 2016” was taken as having received the rubella vaccination. Upon 
recommendation from the Ministry of Health and Social services, “As a child” meant that participants 
received the measles vaccination and had never been immunized for rubella. “Don’t know”: It was 
assumed that pregnant women who did not recall being immunized (unknown immunization history) 
were not included in the July 2016 national immunization campaign and had never been immunized 
for rubella. It was further assumed that a person who presented with immunity during the study, 
without having participated in the SIA, had previous natural infection with rubella virus.  
2.4 Data analysis 
All data were analysed using SPSS statistical software (IBM version 24, IBM North America, 590 
Madison Avenue, New York, NY 10022) and R version 3.2.2 [10]. Fisher’s exact test was used to 
determine associations between socio-demographic characteristics and rubella immune status. The 
Kruskal Wallis test was used to assess equality of means for IgG antibody titres in IU/ml between 
different population characteristics provided in the surveys.  95% confidence intervals (CI) were 
calculated for IgG antibody levels. P values less than 0.05 were considered statistically significant.  
Correlations were assessed with Spearman's rank correlation. Difference between continuous 







2.5 Ethical approval 
Ethical approval of the study was obtained from the School of Health and Applied Sciences, 
Polytechnic of Namibia, the Ministry of Health and Social Services (Reference 17/3/3) and from the 
Health Research Ethical Committee at Stellenbosch University (Ethics Reference S16/05/092, 
Institutional Review Board Number IRB0005239). 
 
3. Results 
Maternal age at enrolment ranged between 17 and 47 years with the median age 27 years (Table 
1). The age group with the highest number of participants (108; 31.4%) was 21-25 years. All but two 
participants were residing in the urban area. Most participants (172; 50.0%) were in the second 
trimester of pregnancy. Twenty-four (7.0%) participants indicated that they had been vaccinated in 
the 2016 SIA. One hundred and sixty-nine (49.1%) participants said they had not been vaccinated 
for rubella and 151 (43.9%) did not know whether they had been vaccinated for rubella. These two 
groups were considered not to have received rubella immunizations. Most participants indicated that 
they did not live with small children in the house. For parity, primigravida was the category with the 












Table 1   
Socio-demographic characteristics of pregnant women (n=344) attending public antenatal care in 












Characteristic N (%) 
Age   
15-20 38 11.0 
21-25 108 31.4 
26-30 96 27.9 
31-35 59 17.2 
36-48 43 12.5 
   
Residence   
Urban with own tap 226 65.7 
Urban with communal tap 114 33.1 
Rural 2 0.6 
    
Gestational age   
First trimester 41 11.9 
Second trimester 172 50.0 
Third trimester 130 37.8 
Unknown 1 0.3 
   
Rubella immunization   
Yesa 24 7.0 
No 169 49.1 
Unknown 151 43.9 
   
Live with children <5 
years 
  
Yes 126 36.6 
No 217 63.1 
   
Parity   
Primigravida 129 37.5 
One previous pregnancy 100 29.1 








Overall, seroprevalence of anti-rubella IgG among pregnant women attending public antenatal care 
in Windhoek was 95.9% while susceptibility to rubella virus infection was low (n=14; 4.1%) (Table 
2). The age group with the highest level of rubella immunity (97.9%) was 26-30 years while the age 
group with the highest susceptibility (8.5%) was 31-35 years. There was no significance in the 
association of percentage immunity and age groups.  
The overall level of anti-rubella IgG titre was very high. Anti-rubella IgG mean concentration (95% CI 
for mean) was 164.5 (150.41 – 178.66) IU/ml.  Participants of 15-20 years had the highest (195.8 
IU/ml) mean IgG levels, while participants of 31-35 years had the lowest (147.6 IU/ml). Participants 
in the first trimester of pregnancy had the highest immunity (presence of IgG 100%).   
All participants immunized in July 2016 (7.0%) were immune to rubella virus after the SIA (mean 
anti-rubella IgG 187.1 IU/ml). Of 169 participants (49.1%) who indicated that they had not been 
immunized in July 2016, 160 (94.7 %) were immune to rubella virus, while 5.4% remained 
susceptible. Of 151 participants with unknown immunization history, 146 (96.7%) were immune to 
rubella virus while 3.3% were susceptible (Table 2). Of these participants, 14 (9.2%) indicated that 
they were in the first trimester of pregnancy, meaning that they could possibly have been included 
in the SIA. The majority of participants were already pregnant two months earlier and had not been 
included in the SIA.   
There was a statistically significant difference between the levels of anti-rubella IgG in different 
parities (p = 0.004) with the highest level of rubella IgG in primigravida cases.  As expected, higher 
parity was significantly associated with a higher age (p<0.001). There was an overall significant 
negative correlation between rubella IgG concentration and age (p<0.01), although there were no 
significant differences between the levels of anti-rubella IgG in different age categories (p = 0.085), 






Table 2   
Association of socio-demographic characteristics with rubella immunity among pregnant women (n=344) attending public antenatal care in Windhoek, Namibia, 
2016. 





   
P value 
  n (%) n (%) n (%)  IU/ml                                95 %CI
Overall 344 330 (95.9) 7 (2.0) 7 (2.0)  164.5 150-179  
         
Maternal  age         
15-20 38 37 (97.4) 1 (2.6) 0 0.563 195.8 159-232 0.085 
21-25 108 104 (96.3) 1 (0.9) 3 (2.8)  167.8 143-193  
26-30 96 94 (97.9) 1 (1.0) 1 (1.0)  165.2 136-195  
31-35 59 54 (91.5) 3 (5.1) 2 (3.4)  147.6 116-179  
36-48 43 41 (95.3) 1 (2.3) 1 (2.3)  150.4 107-194  
         
Gestational age       
1st trimester 41 41 (100.0) 0 (0) 0 (0) 0.492 174.6 130-220 0.215 
2nd trimester 172 162 (94.2) 6 (3.5) 4 (2.3)  146.4 129-164  
3rd trimester 130 126 (96.9) 1 (0.8) 3 (2.3)  185.3 160-211  
 
 
        





















a Rubella IgG >15 IU/ml 
b Rubella IgG <10 IU/ml 
c Rubella IgG >10 < 15 IU/ml 
Immunization history        
Immunizedd 24 24 (100) 0 (0) 0 (0) 0.417 187.1 129-246 0.439 
Not immunizedd 169 160 (94.7) 6 (3.6) 3 (1.8)  151.9 134-170  
Unknown 151 146 (96.7) 1 (0.7) 4 (2.6)  175.1 152-199  
         
Live with children <5 years       
      
Yes 126 120 (95.2) 3 (2.4) 3 (2.4) 0.754 175.6 151-200 0.319 
No 217 209 (96.3) 4 (1.8) 4 (1.8)  158.6 141-176  
         
Parity         
Primigravida 129 124 (96.1) 3 (2.3)  2 (1.6) 0.879 190.4 167-214 0.004 
1 previous 
pregnancy 
100 96 (96.0) 1 (1.0) 3 (3.0)  146.4 121-172  
>2 previous 
pregnancies 
115 110 (95.7) 3 (2.6) 2 (1.7)  151.3 127-176  





4. Discussion  
The results from this study revealed that a vast majority of those tested (89.0% of the study group) 
were pregnant during the July 2016 national vaccination campaign directed by the Namibian Ministry 
of Health and had thus been excluded.  Results also indicated that most of these participants were 
immune to rubella virus (n=306; 95.6%).  Only 41 (11.9%) of all participants were in the first trimester 
of pregnancy when they participated in the study so were probably not pregnant at the time of the 
SIA, and a few of those with unknown vaccination history could have received the rubella vaccination.  
High seroprevalence of anti-rubella IgG indicates that most pregnant women were immune with low 
risk of vertical transmission and development of CRS. It also showed that the seroprevalence of anti-
rubella IgG in this region increased from 84% in 2010 [8] to 95.9% among urban pregnant women 
attending the antenatal clinic at Windhoek Central Hospital. This increase in rubella immunity, 
however, could not be attributed to the vaccination campaign alone as rubella outbreaks resulting in 
naturally acquired rubella immunity could have contributed. In 2015, there had been an increase in 
rubella cases identified in the Khomas region.  
Results are in agreement with studies in other parts of the world. Natural infection could result in 
high seroprevalence in the absence of vaccination.  An unvaccinated Turkish pregnant population 
had a rubella IgG positive rate of 93.8% [11]. A worldwide 16-year review of rubella seroprevalence 
studies reported seroprevalence rates of 53.0% to 99.3% [12] while a review of African studies in the 
pre-vaccination era found rubella seroprevalence rates of 52.9% to 97.9% [13].  In this study, 
seroprevalence of anti-rubella IgG among pregnant women was comparable to other developing 
countries although lower levels were reported in Sudan, Nigeria and Democratic Republic of Congo 
[8;9;14-27]. 
The decline in rubella susceptibility among pregnant women in Windhoek, Namibia from 15.0% in 
2010 [8] to 4.1% in 2016 was similar to findings in Brazil where pre-immunization rubella susceptibility 
among pregnant women was 9.4% versus post-immunization susceptibility of 2.8% [28]. In our study 





vaccinated population. Furthermore, our participants were within the WHO target of <5% rubella 
susceptibility [28] ,29].   
In our setting only 2.0% of participants had IgG < 10 IU/mL whereas in Canada where routine 
vaccination has been in place since the 1970’s 12.4% had IgG < 10 IU/ml [30]. The results in Namibia 
could possibly be explained by recent rubella outbreaks prior to the SIA, which probably affected the 
younger age groups. Recent outbreaks could further explain the very high overall level of anti-rubella 
IgG (164.5 IU/ml) among pregnant women in 2016. In this largely unvaccinated population, the 
rubella IgG concentration was much higher than the overall mean concentration of 26.5 IU/ml found 
in the Canadian cohort of pregnant women [30]. This could be since natural infection provide a higher 
and more long-lasting immunity than vaccination [31,32].   
Primigravida had higher anti-rubella IgG levels than multigravida in the study, which can be explained 
by the fact that younger age was associated with higher levels of anti-rubella IgG. This could possibly 
be attributed to younger age groups having had more recent rubella infections. This is in contrast 
with previous studies in Namibia and Spain where primigravidae showed higher susceptibility to 
rubella [8,33]. IgG levels were not significantly different in pre-defined age categories, gestational 
ages, immunization history or co-habitation with children which could result in higher exposure to 
rubella virus.  
A limitation of the study might be the lack of evidence-based information on rubella immunization 
history among participants. It can be concluded that the SIA did not have a meaningful impact on the 
study. It should also be noted that seroprevalence may be different in other geographical areas of 
Namibia. Seroprevalence would be artificially high after a recent outbreak in the geographical area 
studied. Although the study used 10 IU/ml as a cut off and 10-15 IU/ml as doubtful immunity, there 
is a body of evidence that indicates rubella IgG results less than 10 IU/ml are protective [34,35]. 
In this study, women of childbearing age who were susceptible to rubella virus infection formed a 
group of susceptible individuals not reached by the SIA. Even though susceptibility to rubella was < 
5%, continued efforts should be made to limit occurrence of CRS in Namibia. Once a rubella 





vaccination coverage and prevent increase in CRS cases. Incomplete vaccination coverage leads to 
the paradoxical increase in the proportion of girls reaching puberty still susceptible to rubella [36,37].  
Namibia addressed this challenge by introducing routine Measles and rubella (MR) vaccination in 
the public sector in July 2016 for male and female children.  
5. Conclusion 
The study group of urban pregnant women attending antenatal care in Windhoek, Namibia from 
September to October 2016 demonstrated a high prevalence of rubella immunity (IgG > 15 IU/ml), 
despite only 7% of these women being known to be included in the nationwide SIA of July 2016, with 
very high proportion of immunity in unvaccinated individuals. This indicated that the majority of 
pregnant women in this group became immune to rubella due to natural infection.  Of interest, the 
seroprevalence of rubella virus among pregnant women attending the antenatal clinic at Windhoek 
Central Hospital increased from 84% in 2010 to 95.9% in 2016, which can largely be attributed to 
natural immunity after recent rubella outbreaks in Namibia. Few individuals in our study had been 
vaccinated, with the maximum possible proportion that could have been vaccinated being 11.0% (24 
plus 14 which is the number in the first trimester with unknown immunization history). Further 
epidemiological studies could inform policy makers on the need to address persons missed by the 
SIA, although results from this study do not indicate the need for follow-up national rubella 
vaccination campaigns. Further studies could be conducted to assess the occurrence of CRS after 
introduction of rubella containing vaccine into the routine immunization programme in the public 
sector. 
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2.3.1 Reflection on third article 
The initial goal with this study was to determine the seroprevalence and incidence of rubella among 
pregnant women in Windhoek, Namibia.  At the time when the proposal was developed, routine 
rubella immunization had not been introduced in the public sector in Namibia.  When sampling was 
due to start, however, the MoHSS announced a SIA for measles and rubella to take place in July 
2016.  Expanded programmes of immunization (EPI’s) and SIAs are both used to increase coverage 
and the combination should positively impact on herd immunity. More individuals are reached by 
mass immunization which is a programme to control disease by vaccinating large segments of the 
population [149]. It may even be possible to create herd immunity so that transmission is completely 
interrupted because of the high percentage of immune individuals. The natural reproductive number 
(R0) differs between infectious agents therefore requiring different vaccine coverage rates in order 
to achieve herd immunity [149]. Compared to rubella, measles has a higher reproductive ratio (R0) 
which is the number of secondary cases generated from a single infective case introduced in a 
susceptible population [149]. Therefore, measles vaccination programmes would require higher 
coverage (more immune individuals) than rubella vaccination programmes in order to achieve herd 
immunity. 
Namibia was one of the first African countries to include a wide age range of 9 months to 39 years 
male and female in the SIA, supported by WHO.  Pregnant women were not immunized during the 
SIA and thus the majority of participants in this study had missed the immunization campaign.  This 
provided an opportunity to show that there might be a need for follow-up immunization to include 
these participants who have not been immunized during the SIA. 
A major challenge to the study is the fact that many participants could not provide clear information 
about their immunization history.  Questions in the questionnaire included the following: “Were you 
ever immunised against measles and / or rubella? - Yes, No, Don’t know. If yes, when were you 
immunised? – July 2016, As a child, Don’t know”.  Almost half of participants reported unknown 
immunization history.  Only 24 participants had been immunized in the SIA of July 2016.  As 





2016, for the purpose of this study, it was assumed that all the other participants (As a child, Don’t 
know) never received rubella immunization.   
High seroprevalence of rubella is thus ascribed to natural infection during previous rubella outbreaks. 
The 2010 study was performed in antenatal clinics all over the country. This comparison shows the 
2010 results in this specific facility, so the comparison to this study is valid. 
Socio-demographic characteristics did not show meaningful associations with IgG positivity.  
Primigravidae had significantly higher specific IgG concentrations in IU/ml than those participants 
with one or more previous pregnancies.  Primigravidae were also younger than multiparous women.  
Although the decrease in prevalence with increased age category was not statistically significant 
there was an overall significant negative correlation between rubella IgG concentration and age as 
continuous variable (p<0.01). This can be explained by information loss when binning variables in 
cateogries. Hence, it is not surprising that the the model including age as a continuous variable was 
more sensitive to detect a significant drop in seroprevalence with increase age, whereas the 
difference was not significant when binning age into categories.  
Due to the high rate of immunity in all of five age groups, it would not have been meaningful to do 
mathematical modelling to determine incidence of rubella infection. 
The study was meaningful to point out that there is probably no need for follow-up immunization 
among women who were pregnant during the SIA and therefore did not receive the rubella 
immunization.  It also showed that most participants were immune to rubella in any case, so the risk 
of vertical transmission to the foetus in case of maternal infection is very low. Moreover, it suggests 
that vaccination coverage should be maintained at a high level in order not to paradoxically increase 
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Background:  Seroprevalence of cytomegalovirus (CMV) is high in developing countries. However, 
this does not exclude the risk for congenital CMV infection in pregnancies where the mothers have 
pre-existing immunity. 
Objectives:  This study aimed to determine the seroprevalence of CMV among pregnant women 
attending the public antenatal clinic at Windhoek Central Hospital, Namibia, in 2016. Participants 
were evaluated for recent CMV infections to determine the risk for vertical transmission and 
congenital CMV infection. 
Study design:  Three hundred and forty-four pregnant women consented to participate in the study.  
A blood sample was collected, and demographic information was captured using a questionnaire.  
Serum was tested for anti-CMV IgG and IgM using an automated chemiluminescence assay.  
Specific IgG avidity was assessed using an enzyme-linked immunosorbent assay.  Data were 
analysed with SPSS and R. Fisher’s exact test was used to determine associations among variables. 
Results:  Seroprevalence of anti-CMV IgG among pregnant women aged 15-48 years was 100%. 
Eleven participants (3.2%) had a positive or grey zone anti-CMV IgM result. Specific IgG avidity was 
high in all of these cases. Neither maternal age nor gestational age was positively associated with a 
positive or grey zone IgM result.  Parity showed an association with seroprevalence of CMV IgM, 
with the highest seroprevalence observed in women who had one previous pregnancy. 
Conclusion:  This was the first study to investigate seroprevalence of CMV in Namibia. Despite the 
high seroprevalence of CMV among pregnant women, the Namibian population might carry the 
burden of congenital CMV infection among infants. This may contribute to long term disability, 
especially sensorineural hearing loss. Further studies are needed to determine the prevalence of 
congenital CMV in Namibia and neonatal surveillance studies may be important to establish the 
prevalence of congenital CMV disease. Aspects like timing of viral infection should be considered in 
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Introduction 
Cytomegalovirus (CMV) infection in the first trimester of pregnancy is known to cause congenital 
malformation, especially of the central nervous system. CMV has been identified as the main cause 
of non-inherited hearing loss while long-term CNS sequelae include seizures and motor and visual 
defects.[1-3] Between 10% and 20% of all children with congenital CMV (cCMV) infections may show 
signs of neurological damage during follow up,[3,4] and Enders et al.[5] reported that 57.6% of 
congenitally infected live-born infants had symptoms of varying degree. Congenitally infected 
newborns are at risk for serious long-term sequelae regardless of the presence or absence of 
symptoms at birth.[2,6] Transmission of CMV infection occurs through breastfeeding, sexual contact 
and contact with body fluids.[7] cCMV infection may develop when a pregnant woman is infected with 
CMV. Primary or non-primary maternal infection (reactivation or reinfection) at any time during 
pregnancy can lead to CMV crossing the placenta and infecting the fetus.[8] 
Owing to variations in epidemiology and seropositivity in women of childbearing age, prevalence of 
cCMV infection varies across countries. In the USA, epidemiologic studies suggest that CMV 
infection occurs in approximately 1% of all births or affects about 40 000 infants annually. These 
CMV infections are asymptomatic in most cases.[9] Prevalence of cCMV infection was found to be 
4.6/1 000 births in Sweden and 3.2/1 000 births in London.[10] Bonalumi et al.[3] reported an incidence 
of 0.3 - 2.4% in developed countries. The incidence of cCMV infection is highest in developing 
countries (1 - 5% of births) and can most likely be attributed to non-primary maternal infections.[4,11,12] 
CMV infection in pregnant women can be either primary or recurrent. Primary infection occurs when 
a person is infected with the virus for the first time and can be demonstrated by seroconversion 
(appearance of antibodies that were not previously present). Recurrent infection is described as a 
past infection and includes reactivation of latent infections and reinfection with a different CMV strain. 
During latency there is no viral replication, although viral products may be transcribed during this 
time. The virus remains dormant in mononuclear leukocytes and cells of organs such as the kidneys 





Recent data demonstrate a similar risk of developing sequelae, especially hearing loss, in infants 
born to mothers with primary CMV infection or CMV reinfection. There is increasing evidence that 
non-primary maternal infection could lead to symptomatic and severe outcomes. This underscores 
the importance of screening for cCMV infection in resource-poor settings. In well-resourced settings, 
it is believed that primary maternal infection drives cCMV infection; however in resource-limited 
settings with a high prevalence and incidence, reinfections may contribute to congenital 
infections.[3,13]  
Methods 
A total of 344 pregnant women attending public antenatal care in Windhoek, Namibia during 2016 
were enrolled in the study. Serum was tested for CMV IgG, CMV IgM (Access immunoassay 
systems, Beckman Coulter Eurocenter SA, 22 rue Juste-Olivier, Case Postale 1044, CH - 1260 Nyon 
1, Switzerland) and IgG avidity (ELISA, Euroimmun Medizinische Labordiagnostika, Germany). The 
reference range for negative CMV IgG was <6.0 AU/mL. For specific IgM, a grey zone value meant 
that the value was not negative but also not high enough to confidently call it positive. Software for 
statistical analysis included SPSS (version 24) and R (version 3.2.2).[14] Fisher’s exact test was used 
to determine p-values while a p-value of <0.05 was considered significant.  
Ethical approval 
Ethical approval was granted by the School of Health and Applied Sciences, Polytechnic of Namibia; 
the Namibian Ministry of Health and Social Services (Reference 17/3/3) and by the Health Research 
Ethics Committee of Stellenbosch University (Ethics Reference S16/05/092, Institutional Review 
Board Number IRB0005239). 
Results  
The seroprevalence of anti-CMV IgG was 100% among all participants (Table 1). Results from 11 
women (3.2%) were positive (or in the grey zone) for IgM. Neither age group nor gestational age was 
associated with IgM activation. A significant association was found between parity and CVM IgM 





could possibly be attributed to a higher probability of risky behaviour and higher exposure to CMV in 
younger age groups.  
 
 
Table 1.  
 
Anti-cytomegalovirus IgM in relation to sociodemographic and antenatal characteristics 




samples, n/N (%) 
IgM-positive 
samples, n/N (%)* 
p-value 
All participants 344/344 (100) 11/344 (3.2)  
Maternal age (years)    
15 – 20 38/38 (100) 1/38 (2.6) 0.613 
21 - 25 108/108 (100) 5/108 (4.6)  
26 - 30 96/96 (100) 2/96 (2.1)  
31 - 35 59/59 (100) 3/59 (5.1)  
36 - 48 43/43 (100) 0/43 (0.0)  
Gestational age    
1st trimester 41/41 (100) 1/41 (2.4) 1.000 
2nd trimester 172/172 (100) 6/172 (3.5)  
3rd trimester 130/130 (100) 4/130 (3.1)  
Parity    
Primigravida 129/129 (100) 5/129 (3.9) 0.027 
1 previous pregnancy 100/100 (100) 6/100 (6.0)  
>2 previous 
pregnancies 
115/115 (100) 0/115 (0.0)  
*Including grey zone results 
 
 
Evidence of longstanding CMV infection was found in all samples. All IgM-positive samples (n=11) 

















Table 2.  
 
Anti-cytomegalovirus IgG and IgM seropositivity, and IgG avidity among pregnant women 
 
Case IgG concentration 
(AU/mL) 
IgM status IgG avidity 
5011 241.2 Grey zone High 
5014 140.0 Grey zone High 
5020 46.0 Positive High 
5049 >250.0 Grey zone High 
5127 181.7 Positive High 
5133 205.3 Grey zone High 
5165 >250.0 Positive High 
5188 248.3 Grey zone High 
5287 >250.0 Positive High 
5295 213.5 Positive High 




Seroprevalence of anti-CMV IgG was higher than the prevalence of CMV infection in Europe and 
North America (approximately 50%) but similar to the prevalence seen in South America and 
elsewhere in Africa.[2,7,15-18] In high-prevalence settings, most primary CMV infections occur in 
infancy. In a recent study in South Africa, polymerase chain reaction (PCR) analysis of saliva 
samples showed 2.9% of newborns from HIV-positive mothers to be CMV infected.[11] Another recent 
study in South Africa revealed that cCMV was prevalent in 5.96% of births with no significant 
association with HIV-status of the mother.[29] A population-based study of 460 healthy infants in 
Zambia showed 83% CMV seroprevalence by 18 months of age.[19,20] Early infection (i.e. before 
reaching childbearing potential) could therefore explain the 100% prevalence in our study across 
age strata.  
Despite all pregnant women shown to have pre-existing anti-CMV antibodies, they remain at risk of 
CMV reactivation or reinfection during pregnancy and subsequent vertical transmission to the fetus.  
High maternal seroprevalence of CMV therefore does not exclude the threat of cCMV infection. 
Although individual risk is highest with primary infections, Omoy and Diav-Citrin[21] concluded that 
cCMV infection occurs in infants born to previously infected mothers. More than 60% of infants 





and who experienced reactivation of latent virus or reinfection with a new strain during pregnancy. 
An increasing number of studies show severe sequelae in these infants.[8] Maternal IgG positivity 
alone does not eliminate the risk of cCMV infection. It is thought that the cytotoxic T-lymphocyte 
response –another arm of the adaptive immune response – is more important than antibodies in 
preventing CMV reactivation, and therefore treatment or conditions that result in a decreased cellular 
immunity is associated with CMV reactivation even in the presence of high titres of IgG.  
Leruez-Ville and Ville[22] reported that the burden of cCMV infection can be attributed to secondary 
maternal infection to a larger extent than previously thought. Unfortunately, there are still no validated 
tools to accurately diagnose and differentiate maternal reinfection and reactivation.[22] 
CMV IgM is a sensitive marker of primary CMV infection but can also be detected during recurrent 
infection. False positives may develop owing to polyclonal activation or the presence of cross-
reactive antigens in the case of a primary Epstein–Barr infection.[23] In the case of a primary CMV 
infection, the individual risk of transmission is highest, but in high-prevalence settings most cases of 
true CMV-IgM positivity would be due to secondary infections when the individual transmission risk 
is lower. Taken together, detecting maternal CMV IgM does not mean that the foetus will be infected, 
and further testing is warranted in an attempt to differentiate a primary or recurrent infection, or to 
identify another cause of CMV-IgM reactivity (e.g. primary Epstein–Barr infection).[2,24]  
IgG and IgM serology of a pregnant woman can identify pregnancies at risk for transmission of CMV 
to the foetus. Finding CMV IgM antibodies with low IgG avidity supports a primary infection and a 
high risk of transmission, whereas in cases with high avidity, the individual risk of transmission is 
lower.[25] When maternal primary infection has been diagnosed or when high-definition ultrasound 
and magnetic resonance imaging suggest congenital infection, CMV DNA can be detected by means 
of PCR using amniotic fluid taken at 21 weeks of gestation.[3] Neonatal diagnosis of cCMV infection 
is by viral culture or PCR on blood or urine within 2 weeks of birth. Cases with asymptomatic cCMV 
infection may require more frequent follow-up to diagnose sensorineural hearing loss early and to 





However, the costs of comprehensive diagnosis and treatment of CMV infection is prohibitive in sub-
Saharan Africa and there is a need for more affordable solutions. Moreover, there is limited evidence 
of the benefit of antenatal antiviral therapy, which, owing to its toxicity, is seldom considered during 
pregnancy. In neonates, there is uncertainty about the indications for and duration of therapy.[26] 
Studies on newer, less toxic drugs are ongoing.[27] CMV reactivation is common in 
immunocompromised hosts. Therefore, in settings with a high prevalence of HIV infections, the risk 
of reactivation is increased.[28] Despite these challenges, clinical trials with vaccines, prenatal 
interventions and prolonged postnatal antiviral therapy are underway. This emphasises the need for 
more information on the epidemiology and diagnosis of CMV infections in pregnant women and 
neonates.[13]  
Conclusion 
All pregnant women in our study presented with IgG antibodies for CMV. Of the women, 11 showed 
IgM antibodies for CMV, which could have been a result of reactivation of the infection or reinfection 
with a new strain of CMV. IgG avidity was high in all cases, indicating absence of primary infections. 
However, pre-existing immunity does not exclude vertical transmission of the virus during pregnancy. 
Despite the high seroprevalence of CMV among pregnant women, the Namibian population might 
carry the burden of cCMV infection among infants. This may contribute to long-term disability, 
especially sensorineural hearing loss. Further studies are needed to determine the prevalence of 
cCMV in Namibia and neonatal surveillance studies may be important to establish the prevalence of 
cCMV disease. Availability of this information could lead to health interventions aimed at the 
reduction of disabilities such as hearing loss. Furthermore, emphasis should be on factors to be 
considered in designing further studies, for example the timing of viral infection. 
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2.4.1 Reflection on fourth article  
This was the first study in Namibia to assess seroprevalence of CMV in any population.  Given 
information in the literature on seroprevalence in other African countries, it was expected to be high 
in Namibia as well, but the 100% seroprevalence still came as a surprise. The first impression would 
be that there is no risk of vertical transmission in this population, because of pre-existing 
seropositivity to CMV.  Further investigation of the literature revealed that secondary infections are 
now getting more attention regarding vertical transmission to the foetus.  There is increasing 
evidence that secondary infections are the most important contributor to cCMV infection, either due 
to reactivation of maternal infection, or maternal infection with a new strain of CMV.   
Most CMV transmission from mothers, either post-natally through breast feeding, which is by far the 
most common route of mother to child transmission, or intrauterine infection occurs in mothers with 
reinfection or reactivation of CMV infection.  
Avidity testing was performed on all IgM positive and equivocal cases.  No case of low avidity was 
found. It is therefore unlikely that these IgM positive or equivocal cases represented true recent or 
reactivated infections and were therefore unlikely to transmit CMV.  In addition, the IgM assay may 
have missed some cases of reactivation.  CMV IgM assays may be false positive due to a number 
of factors including polyclonal activation, rheumatoid factor (depending on the assay design), 
molecular mimicry with cross-reactive antigens such as in the case of a primary Epstein–Barr 
infection. The latter is, however, unlikely since seropositivity for Epstein-Barr virus is probably also 
close to 100% in Africa. An IgM capture enzyme immunoassay is preferred as this would reduce the 
impact of rheumatoid factor and improve the sensitivity of IgM assays in the presence of high 
concentrations of IgG 
Although younger age groups might have a higher risk of sexual CMV reinfection, as the incidence 
of other sexually transmitted infections, such as HIV is highest in this group,  high IgG avidity in all 
IgM seropositive individuals rather suggests that infections were acquired long ago, possibly in 
childhood. In conclusion, I could not offer a plausible explanation for the higher IgM prevalence in 





Due to the nature of the data, it would not be possible to do mathematical modelling to determine 
incidence of CMV infection.  None of the participants was susceptible to primary CMV infection, so 
there is no linear decrease of CMV susceptibility over the five age groups.  
More than 60% (and probably close to a 100% in Africa) of infants infected with CMV in utero appear 
to be born to mothers who were seropositive before conception and who experienced reactivation of 
latent virus or reinfection with a new strain during pregnancy. In fact, reactivation of CMV in pregnant 
and breastfeeding mothers is very common.  
It can be concluded that despite high seroprevalence of 100%, pregnant women might still run the 
risk of transmitting the virus to the foetus, and the possibility of cCMV exists. The literature suggests 
that in high prevalence developing countries about 1-5% of children are born with cCMV, most likely 
as a result of maternal non-primary infections. Nevertheless, screening programs for cCMV are not 
in place in the region. Clinicians should be made aware of this, and neonatal assessments should 
be followed up, especially to detect sensorineural deafness as early as possible to facilitate 
treatment. 
Future perspectives should focus on assessment of cCMV burden in Namibia, especially with 
technology which uses saliva or urine (rather than blood) for CMV PCR to determine the prevalence 







Results presented in this chapter focused on seroprevalence and risk factors associated with T. 
gondii, rubella and CMV infections among two study populations, namely blood donors, and pregnant 
women in Namibia.  
In conclusion of this chapter it can be said that a strength of this study is the three articles which 
have been published in peer-reviewed journals which are indexed in widely accessed databases 
such as PubMed (in progress) and African Journals Online. 
The next chapter describes the progression and outcome of mathematical modelling applied to the 
seroprevalence data obtained in this study in order to estimate the rate of new infections in the study 






Chapter 3: Incidence of Infection 
 
3.1 Definitions 
Prevalence of an infectious agent:  The percentage of the study group who previously had or 
currently has an infection with the infectious agent. This can be determined by the presence of 
specific IgG antibodies. 
Incidence of an infectious agent: The rate of new infections among the susceptible population with 
the infectious agent over a time period.  This can be determined prospectively by identifying new 
infections in previously uninfected individuals or by cross sectional markers of recent infection. 
However, specific IgM has relatively low accuracy and the period of low IgG avidity varies resulting 
in inaccurate estimations. Prospective studies are costly and markers of recency, even when 
accurate may require very large sample sizes to accurately estimate incidence.  
Force of infection: Force of infection is a per capita rate of acquisition of infection that gives an 
indication of the incidence of infection in the seronegative population. Force of infection is estimated 
as the slope of the log-linear regression line when we have the seronegative prevalence (percentage 
susceptible) as the dependant variable (Y-axis) and the age as the independent variable (X-axis). 
Herd immunity: Herd immunity refers to the percentage of a community that needs to be immune to 
an infection in order to contain spread of the infection. This concept is used to determine the need 
to vaccinate a community for an infectious agent like rubella. Rubella is less infectious than measles, 
so a lower level of herd immunity would be required to interrupt rubella transmission than for measles. 
Infectiousness: An infectious agent is highly infectious if the infection spreads fast in a community. 
The natural reproductive number R0 is used to measure this, which is the average number of cases 
infected, in a susceptible population, by a single infected case.  
Virulence: Virulence refers to the likelihood that an infectious agent would cause serious disease. 





qualify for inclusion; infectiousness and virulence are totally different concepts – some viruses are 
highly virulent but have low infectivity.  
Prior infection: Pregnant women may present with specific IgG antibodies in the absence of IgM 
antibodies, indicating that they had been infected with the infectious agent before becoming 
pregnant. 
Affinity: The binding force between an individual specific antibody and its antigen. 
Avidity: Avidity is the net effect of all the different antibodies binding to their specific antigens with a 
certain affinity. 
Vertical transmission:  transmission from an infected mother to her child, either in-utero, perinatally 
of post-partum. 
Congenital infection: An infection acquired before birth through vertical transmission from the mother.  
Neonate: A newborn baby during the first 28 days of life. 
An infection can either be endemic or epidemic.  An endemic infection is found consistently over time 
in a specific population or in a certain geographical area.  CMV infections occur worldwide in an 
endemic pattern and in countries with a high prevalence of T. gondii endemic transmission is also 
observed. Infections with an epidemic pattern of occurrence, however, do not occur evenly spread 
over time in a population.  Rubella is an example of such an infection with a seasonal peak 
occurrence, with some years having much larger outbreaks than other years. 
In case of infections that are associated with protective immunity, in any population there would be 
three different groups of individuals regarding their immune status to an infectious agent.   
1. The first group would be recovered or immune since they may have been naturally infected 
or if a vaccine is available could have been vaccinated.  
2. The second group is currently infected with the agent.   
3. The third group are susceptible either because they have never been exposed to the agent 





of some chronic or latent infections, the immune response is not fully protective against 
reinfection or reactivation [81].  
Seroprevalence of an agent refers to the first group and may be measured by the presence of IgG 
antibodies to the agent. The presence of IgG antibodies to an agent indicates past infection and lasts 
for life.  In some cases, like CMV infection, reactivation or reinfection may occur. 
Incidence refers to the rate at which new infections occurred in the susceptible population over the 
study period.  Incident cases could be detected by the presence of IgM antibodies against an agent, 
indicating current or recent infection.  Immunoglobulin M antibodies are the first to appear upon 
exposure to an infectious agent but diminish within a couple of months. However, IgM is not an ideal 
marker to estimate incidence for the following reasons:  
1. it be could also be positive in secondary infections;  
2. the duration of IgM positivity is short and therefore estimates of recent infections would 
require large sample sizes if the incidence is low;  
3. IgM testing may be prone to false positivity and the false positive rate could be high relative 
to the true positive rate when the prevalence of acute infections (i.e. incident cases) is low.   
Recent infections could further be corroborated by the presence of specific IgG antibodies with low 
avidity.  Upon exposure to an infectious agent, specific IgG antibodies are formed, which are however 
not yet exactly fitted for the epitope on the antigen.  This would be reflected in antibodies with low 
affinity – which would result in a low avidity when assayed (avidity is the net effect of individual 
antibody affinities and is measured by the proportion of antibodies that are disrupted by a chaotropic 
agent such as urea).  With time antibodies develop that have a higher binding affinity.  This would 
be reflected in a high avidity, and thus points at non-recent infection. The mechanism of avidity 
testing is described in Chapter one, section 1.3.9 Diagnosis of T. gondii infection. 
Age-prevalence data refer to designation of age groups within the study group.  It would require 
stratification of sample collection to ideally include the same number of participants in each of the 
selected age groups.  After testing of the samples, data analysis could reveal the prevalence or 






Incidence of an infection could give an indication of the force of infection, and how easily it spreads 
in a community.  Measuring the incidence of an infection among pregnant women could be useful to 
give an indication of the risk of congenital infection occurring.  If an agent that is associated with 
intra-uterine infections shows high incidence in a pregnant population, there would be an increased 
risk of vertical transmission.  It would then follow that the prevalence of congenital infections with 
adverse sequelae would be high.  Knowledge of the incidence of infections would be useful in 
Namibia since there is no information available on the prevalence on congenital infections. 
3.3 Mathematical modelling 
The direct measurement of incidence is neither feasible nor practicable as very large sample sizes 
and repetitive testing would be required to find new cases of infection. Moreover, in the context of a 
low prevalence of recent infections (incident cases) any assay aimed at detecting these incident 
cases with specificity that is not very close to 100% would result in the greater proportion of positive 
tests being false positive. For example, if at any time the expected prevalence of recent infections is 
1% (this would translate to an incidence of > 3 % as the expected window for IgM positivity is < 4 
months for most agents) and the specificity of a test is 99%, ~50% of positives will be false positive 
(positive predictive value of ~50%).  
Therefore, rather than attempting to directly measure incidence, mathematical models may be helpful 
in estimating incidence from cross-sectional age-prevalence data. Such a model would hold true if 
the following conditions are met:   
1) The incidence is stable across the age range studied; and  
2) the infection does not affect the probability of dying during this observed period.   
These assumptions are likely to hold true for CMV and T. gondii – as infections are mostly 
asymptomatic and the incidence is likely not very variable across child-bearing age. However, in the 
case of rubella an epidemic pattern of transmission may require a large sample size due to the 





shows a significant negative log-linear relationship with high correlation coefficient it is likely that the 
age-prevalence models would be valid. 
It was expected that the prevalence of exposure (presence of specific IgG antibodies) to these agents 
would increase with age, and it followed that the number of susceptible pregnant women would 
decrease with age. Studying the relationship between these two variables would enable the 
mathematician to make predictions on what the incidences of these infections would have been 






The following calculations can be done to estimate incidence mathematically: 
Sj: Number susceptible at time j 
j: number of years 
i: incidence – number of new cases in the susceptible population 
S0: number of susceptible individuals at start 
Susceptible individuals decrease at a constant proportion: 
𝑆j=S0 (1 − 𝑖)𝑗  
For each interval (year) the ratio of 𝑆j / 𝑆j-1= 1-i 
As ratio of Sj to Sj-1 is constant; one has to log transform Sj: (𝑙𝑛(𝑆𝑗)) for linear regression with j: 
It follows that the gradient: 
𝑙𝑛(𝑆𝑗) − 𝑙𝑛(𝑆𝑗−1) = 𝑙𝑛(1 − 𝑖) = 𝑚 
where m = gradient of regression line for Sj = mj+c 
e-m = 1-i 
Solve i: 
𝑖 = 1 − 𝑒𝑚 
 






3.4 Examples from literature 
In a previous study, Cutts and Vynnycky modelled the incidence of congenital rubella syndrome in 
developing countries.  They developed a formula to determine estimates of the incidence rate of 
infection in pregnant women, as well as estimates of the incidence of congenital rubella syndrome.  
They tested the formula using data from two big reviews and papers from a Medline search.  Included 
in the research were studies of women attending antenatal clinics. Data were required on the number 
studied and the numbers seropositive for rubella in at least two age groups between the ages of 15-
49 years. There was an excellent agreement between model predictions and the prevalence of 
seronegativity to rubella virus in different WHO regions. The estimated incidence rate of congenital 
rubella syndrome in the WHO Africa region was found to be 104 per 100 000 live births.  The number 
of CRS cases in the same region was estimated at 22 471 in 1996 [62,133]. 
In another study, Colugnati et. al. used CMV seroprevalence data from a national survey to estimate 
CMV incidence among the general United States population and among pregnant women. They 
employed models that used age specific CMV seroprevalence data as cumulative markers of 
previous infections in order to derive mainly the force of infection. Force of infection is a per capita 
rate of acquisition of infection that gives an indication of the incidence of infection in the seronegative 
population. Force of infection is estimated as the slope of the log-linear regression line when we 
have the seronegative prevalence (percentage susceptible) as the dependant variable (Y-axis) and 
the age as the independent variable (X-axis). Age groups selected for the study were 12-19, 20-29, 
30-39 and 40-49. The percentages of seronegative women in these age groups were 42.6, 17.8, 
13.4 and 5.3.  The corresponding numbers of women with primary infection during live-birth 
pregnancies were calculated at 4150, 1867, 621 and 14. The force of infection among blacks in the 
USA was found to be 5.7 – this is the number of primary CMV infections per 100 seronegative 
persons per year. It was estimated that 27 000 new CMV infections occur among seronegative 
pregnant women in USA each year [134].  
In preparation of this study, age-stratified seroprevalence data in several published studies were 





described above.  Using an Excel spreadsheet, prevalence % in each age group was tabulated and 
susceptibility % in each age group was calculated. Susceptibility % was converted to decimals which 
were used to calculate logarithms of susceptibility. These were used to create a graph with mean 
age of each age group on the X-axis and logarithm of susceptibility on the Y-axis. The trendline was 
drawn and the formula y=mx+c was applied in order to find m which was used in the mathematical 
model to calculate incidence. Line graphs are shown in Figures 2,3 and 4 while Table 4 tabulates 
data including age intervals used in the calculations. 
 
Figure 2. Mathematical modelling of age prevalent T. gondii susceptibility from the literature 
 
 






Figure 4. Mathematical modelling of age prevalent rubella susceptibility from the literature 
 
In all these cases the data followed a specific trend with a negative trendline. This means that 
prevalence increased with age while it follows that susceptibility decreased with age. This is shown 
by negative slopes (m-values) for all three graphs. When these negative m-values are used in the 
model, it yields positive incidence values meaning that the probability or risk of new infections 
occurring in a future time period increases by the calculated incidence rate. 
Table 4 depicts data from the literature and mathematical modelling applied to it in order to 





Table 4. Mathematical modelling to calculate incidence from published data 
 
Rodier et. al. [28]: Toxoplasma gondii 
   
    
Age Expected age Prevalence 
% 
Susc % Suscept LN(susc)  
15-19 17.5 20 80 0.8 -0.22314  
20-29 24.5 48 52 0.52 -0.65393  
30-39 34.5 60.8 39.2 0.392 -0.93649  
39+ 44.5 66.6 33.4 0.334 -1.09661  
       
 m=slope of graph  y=mx+c   
 -0.2903      
       
Incidence 0.251960878 25.19%  R2 0.9583   
       
       
       
A study done in India reported by Cannon et. al. [130]: CMV  
  
Age Expected age Prevalence Susc LN(Susc)   
16-25 21 80 0.2 -1.60944   
26-35 31 94 0.06 -2.81341   
36-42 39 98 0.02 -3.91202   
       
m=slope of graph  -1.1513    
Incidence = 1 - em  0.683775 68% R2 0.9993 
      
      
       
Corcoran [57]: Rubella      
      
Age Expected age Prevalence Susc LN(Susc)   
15-24 19.5 95.3 0.047 -3.05761   
25-34 29.5 97.5 0.025 -3.68888   
35-45 40 98 0.02 -3.91202   
       
m=slope of graph  -0.4272    
Slope: y=mx+c      
c= intercept with y axis      
Incidence = 1 - em  0.347667 34.80% R2 0.9293 
       
    
    
     






These calculations using data available from previous studies, showed that the mathematical model 
could be used to predict incidence of the respective infectious agents. In some studies, however, the 
age-prevalence data did not show a linear decline in susceptibility. While the data could be used for 
linear regression analysis in most cases, the assumptions discussed below in 1.6.5 were not always 
met.  
For T. gondii, Sitoe et. al. conducted a study among 150 pregnant women in Mozambique.  Among 
HIV-negative women they presented the following IgG prevalences: <17 (1%); 17-22 (9%); 23-27 
(20%); 28-35 (22%). Among HIV-positive women: <17 (16%); 17-22 (25%); 23-27 (39%); 28-35 
(38%). These data met the requirements of modelling and would give meaningful results since 
susceptibility declined in a linear fashion over increasing age ranges. 
For rubella, Belefquih et. al. [65] presented the following susceptibility data among 2284 pregnant 
women: 14-24 years (9.1%); 25-34 years (11.0%); 35-44 years (7.9%); >45 years (8.1%). These 
data would probably result in a low R2 when modelled. In another study, Onakewhor et. al. [68] found 
IgG negativity among 270 women: <35 years (47%); >35 years (47%). In this case mathematical 
modelling was not possible since there was no trend in the susceptibility among age groups. Rodier 
et. al. [28] presented the following IgG prevalence data: 15-19 (80%); 20-29 (87%); 30-39 (84.7%); 
>39 (83.3%). Although there was no linear increase in seroprevalence with increasing age, the data 
met the requirement of decreased susceptibility with age. 
For CMV, Rodier et. al. [65] presented the following IgG prevalence data among pregnant women: 
15-19 (80%); 20-29 (99%); 30-39 (95.6%); >39 (100%). These data also met the requirement of 
decreased susceptibility with age. 
Mathematical modelling nevertheless poses a solution to the challenging task of determining the 








In order to use the mathematical model to predict incidence of infection, certain assumptions 
regarding the epidemiology of the three infections studied in this research will be discussed. 
3.5.1 Uniform risk 
One of the assumptions for mathematical modelling is that the risk of infection is spread uniformly 
over the test period, or that exposure to the infection is the same over the five age groups [62].  This 
would probably be true for T. gondii and CMV.  However, rubella infections are seasonal with most 
outbreaks in southern Africa occurring during late spring which is during October to November. 
Chimhuya et. al. [58] reported on rubella incidence rates found in the WHO measles/rubella 
surveillance programme in Zimbabwe. They reported peaks in late spring with a sharp decline in 
December through April associated with the rainy season. Laboratory confirmed rubella cases 
among the suspected cases were 37.5% during the rainy season and 62.5% during the dry season. 
They further reported that 95% of rubella cases were among children up to 14 years of age, with a 
peak from 4-14 years. Once the first individuals get infected, the infection spreads rapidly especially 
among school children and in institutions like hostels.  The relative proportions of Rubella infections 
in various age strata cwould thus be influenced by an epidemic occurring in a specific year, which 
depending on the transmission setting might have affected younger age groups (attending school) 
more than older ones The assumption of uniform risk may therefore not hold true.  
In the case of CMV, the epidemiology of the infection in sub-Sharan Africa is such that almost all 
infections had likely beenacquired long before females reached childbearing potential, Therefore, it 
was not feasible to assess an age seroprevalence relationship.  In other geopgraphical settings, 
where CMV is acquired later in life, through sexual tranmssion, an age seropevalence model may 
be useful to estimate incidence, although the exposuse risk may not be uniform, as in additional to 
sexual exposure, exposure to the urine or respiratory secretions of infants or young children, such 
as in daycare settings may be another source of infection for mothers having young children or 






3.5.2 Mortality rate 
Another assumption is that the infectious agent is not causing a high mortality rate among patients.  
This needs to be taken into consideration in cases where the infection itself is likely to cause the 
death of the patient during the test period.  In this study, however, the mortality rate due to the 
infection itself could be negated since the infections are not life-threatening under normal 
circumstances in healthy individuals.  
3.5.3 False-recent results 
It is further assumed that the three infectious agents do not show a high rate of false positive results. 
Some diagnostic tests may show false positive or persistent positive results, especially in the case 
of specific IgM antibodies. In this study, seroprevalence data were based on IgG antibody testing, 
which is less prone to false positive results. 
3.5.4 Decrease in susceptibility over age 
To make mathematical modelling meaningful for the purpose of this study, it was expected that 
susceptibility to the three agents would decrease linearly over the five age groups selected. Most of 
the published studies described in 3.4 showed decreasing susceptibility to the three infections among 
increasing age groups. The expectation for this study was thus that the susceptibility to an agent 
would decrease with increasing age. 
In conclusion, the age-prevalence data found in the literature for the three infectious agents provided 
meaningful results when incidence was estimated using the mathematical model presented above. 
However, no age-prevalence data obtained in Namibia of the three infectious agents investigated in 
this study could be found in the literature. Therefore, this study aimed to determine seroprevalence 








3.6 Mathematical modelling using data from this study 
For all three infectious agents, one of the objectives was to estimate the incidence of these infections 
as this would provide an indication of the potential or risk for congenital infections to occur.  
During the planning stage a modelling study of published age-prevalence data was done and 
incidences of the three infections could be calculated using age-prevalence data from published 
articles. The mathematical model used as well as the suitability for the model of age-prevalence data 
presented by different authors were described in 3.4.  Chapter Three, 3.5, also described certain 
assumptions or requirements for the data obtained in this study to deliver epidemiologically 
meaningful results when the model was applied to it. In 3.5.1. the assumption of uniformity of risk 
was described. In 3.5.4 the expectation that age-prevalence in this study would also follow a specific 
pattern of prevalence increasing with age was described.  
The seroprevalence data obtained in this study were presented in Chapter Two. The data did not 
show an age-prevalence trend and the incidences obtained when the model was applied, were not 
epidemiologically meaningful. It was concluded that the model was not applicable to our data since 
some of the assumptions were not met. The main and most important reason was that the sample 
size (cases different from 100% or 0 in each age stratum) was too small to calculate this with any 
precision; secondly no age-prevalence trend could be demonstrated as discussed below.   
Unlike the expectation that prevalence of infection would increase with age and susceptibility would 
decrease with age, both T. gondii and rubella showed a decline in seroprevalence with increasing 
age. This means that the susceptibility of participants increased with age which was contradictory to 
what was expected. The trendlines on the graphs in Excel showed positive slopes. Results obtained 
with the model thus yielded a negative incidence rate which indicated decreased risk with increased 
exposure or increased age.  
In the case of T. gondii prevalence increased linearly over the first three age groups only to decrease 
as age increased further. However, considering the small number of cases (9/344) that were T. gondii 
IgG positive random error could play a role and differences in prevalence between the different age 





decrease in susceptibility with increased age. There could thus have been a cohort effect which 
indicated that risk of infection was not uniform over the five age groups as it appeared that the risk 
of infection decreased in older individuals. Urbanization could have played a role with younger 
individuals growing up in the urban areas and older individuals moving from rural areas. This is 
contradictory to a previous study in Namibia [7] which reported higher prevalence of T. gondii in rural 
areas. The expectation would be that rural people would be more exposed to T. gondii due to their 
culinary habits. They are more likely to consume untreated water and milk and they frequently handle 
raw meat during slaughtering of their animals. As there were too few cases with T. gondii IgG, our 
study did not have the statistical power to investigate associations with being seropositive and the 
lack of age-prevalence trend remains unexplained. 
In the case of rubella, seroprevalence among five age groups ranged from 91% to 97% with small 
differences between age groups. With such a high frequency of immunity and as there were only 7 
cases out of 344 who were susceptible to rubella, we could not reliably assess differences in 
seroprevalence between various age categories. This was unexpectedly high and higher than the 
expected prevalence and effectively decreased our statistical power to assess differences between 
groups, and in this instance different age strata.  It is therefore not surprising that we failed to observe 
a consistent increase in seroprevalence of rubella IgG with increased age. A much larger sample 
size would have been needed to accurately assess differences between age categories, with such 
a high overall immunity rate.  
Mathematically deriving incidence from age- seroprevalence data also assumes that different age 
cohorts would have had relatively uniform exposure risks with the cumulative risk of exposure and 
immunity increasing in older individuals. Interestingly, younger individuals had statistically significant 
higher antibody titres supporting recent infection; a proportion of these infections could have 
occurred during a recent rubella epidemic.  
The Windhoek region has seen rapid recent urbanization and older individuals who moved from less 
dense rural areas may have had lower exposure risks. However, Alleman et. al. [73] reported 84% 





rural settings. Chimhuya et. al. ascribed a measles and rubella outbreak in 1977 in Zimbabwe to the 
movement of people during the war [58]. It seems like the model would be more applicable in stable 
populations where more uniform risk over age groups would be expected. Chimhuya et. al. further 
reported a peak of rubella infection in children from 4-14 years. In their report on measles and rubella 
surveillance data 95% of rubella cases were found in children up to the age of 14 years. This finding 
is supported by Alleman et. al. [73]. It supports the statement above that younger participants were 
probably exposed while in school, while older participants probably had less exposure.  Children only 
became liable to attend school after Namibian independence in 1990. Furthermore, the cohort effect 
found in the rubella data could possibly have been influenced by the recently introduced rubella 
vaccination, although only 27 of the 344 participants had indicated that they had been vaccinated. 
Cutts and Vynnycky [62] only included data from studies prior to wide-scale vaccinations in the 
country when they developed their model. 
The mathematical modelling expectation was not realised for CMV since all age groups had 
seroprevalence of 100%, even though we used an age stratified sample collection to attempt to 
ensure that we may have some young individuals who were not yet infected. Vynnycky et. al. [141] 
excluded data sets where the best-fitting force of infection was zero and where the upper limit on the 
95% CI was 100%. In this study it was expected that seroprevalence would be high, but the 100% 
seroprevalence in all age groups was unexpected.  This finding is however, in line with a previous 
finding in Zambia that most children are seropositive for CMV at the age of 18 months [137]. This 
previous study indicated that individuals in Africa get infected at an early stage of life and would 
exhibit very high seroprevalence by the time they reach reproductive potential. Another previous 
study in DRC concurred that most CMV exposure and seroconversion occur before the age of 15 
years [73]. 
It can be concluded that although using data from the literature we were able to model incidence of 
the three infections, the data obtained in this study were however not sufficient and suitable for age-
prevalence models. The first challenge faced was the very low seroprevalence of T. gondii IgG and 





was no increased seroprevalence with age, but in case of both T. gondii IgG and rubella, a trend, 
suggesting that the seroprevalence might decrease with age, which was unexpected.  
Alleman et. al. used data from 1605 pregnant women aged 15-46 years to estimate incidence of 
CRS per 100 000 live births and the number of CRS cases born in 2013 in DRC [73]. In Chapter One 
of this study data from a study in India [reported in 130] were used to apply the model to CMV 
infection. Although only a small sample size was used in the study (16-25: N= 172; 26-35: N=119; 
36-41 N=49) a perfect fit of R2 = 0.9993 was obtained when we applied the model to the data.  
 
3.7 Conclusion 
In summary, datasets obtained in our study proved unsuitable to do mathematical modelling as 
described in the study design. Although the model could be applied to data from the literature and 
produced meaningful estimates of incidence rates, the results from this study did not provide answers 
which could be applied epidemiologically. 
Results from the study do, however, contribute to knowledge about seroprevalence of infectious 
diseases among pregnant women and possible risk of vertical transmission of infections.  
The next chapter discusses seroprevalence results obtained in this study and concludes on the 







Chapter 4:   Overall Discussion and Conclusion 
In the absence of a surveillance system for congenital infections in Namibia a study on vertically 
transmissible infections among pregnant women was conducted. The study focussed on assessment 
of seroprevalence (IgG) of infections and further aimed to identify pregnancies at risk of vertical 
transmission of infections by determining IgM and IgG avidity. It also investigated the association of 
risk factors with infections. The study design included the calculation of incident cases by using age-
prevalence data in mathematical modelling in order to assess the probability of congenital infections 
to occur. 
This chapter presents several aspects, including a narrative of the approach followed showing how 
the methodology relates to the objectives. It is followed by a summary of the main findings relating 
them to the objectives and an evaluation of the contribution of the study to existing knowledge and 
contextualization.  Limitations of the study are discussed.  A description of how the study impacts on 
health with a focus on Namibia is followed by a reflection on the future perspectives. A conclusion is 
giving a short summary of main findings and the way forward, highlighting the remaining gaps in 
research. 
4.1 Approach followed 
 
The ultimate goal of the study was to assess the prevalence of congenital infections in Windhoek, 
Namibia.  In the absence of surveillance systems for congenital infections and given the high cost of 
PCR testing among newborn babies for research purposes, the study focused on seroprevalence of 
infectious diseases among pregnant women attending public antenatal care.  An effort was made to 
assess risk of vertical transmission through IgM and IgG avidity testing and initially mathematical 
modelling to calculate incidences of the infections had been planned.  
4.1.1  Methods  
This was a cross-sectional descriptive study. A descriptive study was selected as the method of 
choice since the aim of the study was to investigate the immune status of pregnant women and 





samples were collected once only and there were not sufficient funds for follow up testing of mothers 
and babies.  We chose this approach due to the challenge to access patient records and scarcity of 
information on laboratory tests in a retrospective study. In addition, a retrospective study would have 
ruled out laboratory testing to determine seroprevalence and risk of vertical transmission and 
administration of the questionnaire to determine risk factors associated with infection. 
A pilot study was performed on a group of blood donors in central Namibia (Van der Colf et al., 2014, 
attached).  Seroprevalence of antibodies to T. gondii was 1% in that group, the lowest that could be 
found in the literature.  It was estimated that a higher seroprevalence would be found in the bigger 
study among pregnant women attending antenatal care, since blood donors originate from a more 
affluent population while patients attending a public health facility might have different living 
conditions and culinary habits.  
4.1.2 Sample size  
The results from the pilot study of toxoplasmosis among blood donors informed the calculation of 
sample size for the study among pregnant women and gave an indication of toxoplasmosis among 
the broader Namibian population.  This was necessary because the only previous study on T. gondii 
in Namibia (South West Africa) was reported in 1978 and the information was outdated [7]. For 
calculation of sample size, the prevalence of toxoplasmosis in Namibia (1978 and 2014) was 
combined with the prevalence found recently in neighbouring South Africa [41] and a prevalence of 
6% was used in Cochran’s formula. The ideal sample size was calculated to be 542 participants 
based on seroprevalence of T. gondii. Smaller sample sizes were calculated for the other two 
infectious agents based on the high seroprevalence found in neighbouring South Africa. No 
information on seroprevalence of rubella and CMVs in Namibia was available at the time of study 
design. The aim of the study was to include results from 542 participants for all three infectious 
agents respectively.  Eventually a sample size of only 344 could be reached due to lack of funding. 
4.1.3 Sample collection  
The pilot study was published in 2014 and paved the way for the bigger study involving the 





was obtained for the study among pregnant women.  In January 2016 the study was registered for a 
PhD with Stellenbosch University. Ethics approval was obtained in July 2016 from the MoHSS as 
well as from the Human Research Ethics Committee of Stellenbosch University. Sample collection 
took place from September to October 2016 but was terminated due to lack of funding.  The funding 
agency was not in a position to imburse the whole amount which had been allocated to the study.  
To facilitate calculation of incidence according to age-prevalence, a stratified sample collection 
method was used, with the target 108 participants in each of five age groups (13 - 20; 21 - 25; 26 - 
30; 31 - 35; 36 - 48). At the time when sample collection was interrupted the first age group of 21 – 
25 years had been filled with 107 participants. It means that up till that time, the stratified sampling 
approach had not been implemented and for the purpose of this study it can be said that sampling 
was sequencial. The youngest participant was 15 years old and the oldest participant was 47 years 
old. The mean age of participants was 27 years.  All participants gave consent and minors (persons 
under 18 years) gave assent while consent was obtained from the parent / guardian.  In five cases 
participants did not sign the consent form and these participants were excluded from the study. One 
Ovahimba woman was excluded due to not being able to understand English or Afrikaans. The 
remaining 344 participants were included in the study. 
4.1.4 Sample analysis  
A SANAS accredited pathology practice analysed the samples and all results were received in one 
week. Testing of T. gondii IgM (in IgG positive cases) and IgG avidity (T. gondii and CMV) were 
performed by the researcher in the NUST laboratory which is a teaching laboratory.  For the pilot 
study among blood donors, all sample analysis was performed in the NUST laboratory by the 
researcher. 
4.1.5 Questionnaire 
A questionnaire was designed using information from previous publications in the same field 
(Addendum G). The questionnaire addressed demographic information like maternal age, 
gestational age, parity and obstetric and perinatal history. It also addressed risk factors like living 





five and handwashing. The questionnaire was successful to collect demographic data and data on 
risk factors.  It was, however, not able to collect unambiguous data on rubella vaccination history.  
The reason being the additional goal to do further studies on seroprevalence of measles among 
pregnant women after completion of the PhD study. The question on rubella vaccination history tried 
to capture data about measles vaccination as well, rendering it ineffective for the purpose of this 
study. The essential information from this question is that only 7% of participants had been 
vaccinated in the SIA due to the rest being pregnant at the time. For the purpose of this study, the 
SIA was deemed as not having had a significant influence on the results.  
Information on risk factors associated with toxoplasmosis were useful for this study. However, 
information on obstetric history as well as exposure to risk factors could not be fully utilized due to 
low seropositivity of T. gondii IgG. A much larger sample size would be needed in order to have good 
statistical power to determine meaningful associations. The association of risk factors with CMV 
infection could not be analysed due to 100% seropositivity. 
Overall, as the effective sample size was small (few individuals diferent from the majority: low 
seroprevalence in the case of T. gondii IgG and high or very high in the case of rubella and CMV 
infection), there was insufficient power to assess the impact of multiple possible risk factors collected 
through a very comprehensive questionnaire. 
4.1.6 Data analysis 
Data collected with the questionnaire as well as test results were entered in an Excel spreadsheet 
and analysed with SPSS version 24 and R. Participants were divided into five age groups. Mean 
seroprevalence, mean rubella IgG concentration and 95% confidence intervals were calculated. P-
values were calculated using the Fisher’s exact test with p-value <0.05 deemed significant. The 
Kruskall-Wallis test was used to determine associations between demographic data and rubella IgG 
concentrations. This is a non-parametric test and an extension of the Mann Whitney test of ranks. 
The R statistical package was used in cases where there were too many variables in a model for a 
Fisher’s exact test (typically 2 by 2) to be performed. Involvement of a biostatistician is acknowledged 





It is concluded that the methodology followed was appropriate to address the objectives set during 
study design. The following section gives a summary of the main findings of the study. 
4.2 Summary of Main Findings 
This study focused on seroprevalence of three infectious agents namely T. gondii, rubella and CMV 
among pregnant women attending antenatal care at Windhoek Central Hospital, Khomas Region, 
Namibia.  A pilot study was conducted to determine seroprevalence of T. gondii among blood donors. 
In the first publication, 1% seroprevalence of T. gondii was found among blood donors from mainly 
urban settings in Central Namibia. Of 312 samples tested, 6 had positive or equivocal IgG results. 
Blood donors had limited exposure to T. gondii, and this result could possibly be extrapolated to the 
broader Namibian population. One blood donor exhibited both IgG and IgM antibodies against T. 
gondii and could possibly pose a risk of transfusion transmitted infection.  This donor had indicated 
that he lived in an urban area and kept cats and dogs. Association of risk factors with T. gondii 
infection could not be determined due to the low rate of positive cases among blood donors.  
In the second publication, 2.61% seroprevalence of T. gondii was found among pregnant women 
attending the antenatal clinic at Windhoek Central Hospital. Of 344 participants, 9 had IgG antibodies 
against T. gondii (including borderline positive results). Of these 9 participants, 1 had IgM antibodies 
against T. gondii with IgG avidity giving an equivocal result.  The other 8 IgG positive cases also had 
high or equivocal IgG avidity. This means that there had been limited previous exposure of pregnant 
women to toxoplasmosis while the risk of vertical transmission of toxoplasmosis was also low.  
Among 9 risk factors for T. gondii infection evaluated, none showed a significant association (p-value 
<0.05). Surprisingly, all 9 IgG positive participants indicated that they use water from their own tap 
as opposed to water from a communal tap indicating that risk factors other than those investigated 
could have contributed to the infection.  Calculation of incident cases of T. gondii infection by using 
age stratified IgG seroprevalence data was not possible due to the lack of a linear increase in 
seroprevalence among pregnant women in five age groups. Seroprevalence increased linearly in the 
first three age groups, only to decrease after the age of 30. Although the number of infections were 





suggest that different age cohorts had different exposure risks. Without a relative uniform exposure 
risk in different age cohorts a mathematical model of age-prevalence ratio to calculate incidence 
would be invalid.  
The third article described the very high overall rubella seroprevalence of 95.9% among pregnant 
women. There was no statistically significant (p-value <0.05) difference between seroprevalence in 
five age groups. High seroprevalence and the small number of individuals remaining susceptible 
might have caused a lack of statistical power to calculate any differences. Seroprevalence in five 
age groups were 97.4; 96.3; 97.9; 91.5 and 95.3 percent suggesting that younger age groups may 
have been more affected by rubella outbreaks.   The mean anti-rubella IgG level was highest in the 
age group of 15 – 20 years (195.8 IU/ml) only to decline to 150.4 IU/ml in the age group of 36 – 48 
years. This finding was supported by the finding that primigravidae had significantly (p-value <0.05) 
higher anti-rubella IgG levels than multiparous women indicating that participants probably acquired 
naturally infected at a young age. Shortly before the study a rubella outbreak occurred in the Khomas 
region, and in addition, a national SIA took place including male and female persons aged 9 months 
to 39 years but excluding pregnant women. Only 7% of participants had been included in the rubella 
and measles SIA of July 2016 while the rest of the participants were pregnant at the time. Therefore, 
immunity was ascribed to natural immunity acquired in previous rubella outbreaks. The recent 
outbreak prior to the study could also explain the very high mean anti-rubella IgG concentration of 
164 IU/ml found among participants. IgM and IgG avidity testing were not done for rubella since very 
few if any incident cases were expected. Rubella is a seasonal infection which occurs mainly in 
spring and in retrospect, it was found that there had been no outbreak in the spring of 2016. Once 
again, incidence of rubella infection could not be calculated due to the small proportion of non-
immune individuals in each age category. Differences in seroprevalence among the five age strata, 
although not statistically significant, suggest they did not have similar exposure to rubella infection.  
Younger age groups are probably more susceptible to rubella infections during outbreaks due to 
crowded conditions in schools increasing the risk of being infected. 
The fourth article focussed on seroprevalence of CMV among pregnant women attending the 





comprehensive previous CMV exposure, probably at a young age. All participants were tested for 
anti-CMV IgM with 11 positive or grey zone results. Of these 11, all had high IgG avidity showing 
that it had been past infections and not secondary infections (possibly with a different strain) during 
pregnancy. These pregnant women, therefore, were not at risk for primary infection during pregnancy 
and consequent cCMV. It was however, noted from the literature that secondary infections during 
pregnancy result in 1-5% cCMV prevalence in neonates in developing countries where high 
seroprevalence of CMV prevails. The majority of these cases are however asymptomatic of which a 
small proportion may have sequelae [100]. Calculation of incident cases of CMV infection by using 
age stratified IgG seroprevalence data was not possible due to 100% seropositivity in all five age 
groups. For the same reason association of risk factors like blood transfusion, living with children 
under the age of five or handwashing practices with CMV infection could not be established. 
4.3 Contribution of the study to existing knowledge 
Results from this study contribute to knowledge about the prevalence of vertically transmissible 
infections among pregnant women in Southern Africa. This information is scarce in the region and 
Africa as a whole, while considerable work in this regard has already been done and reported in 
Europe, China, northern and southern America as well as India.  
The originality of the study revolves around the scarcity or absence of information about the 
seroprevalence of infectious diseases among pregnant women in Central Namibia or the country as 
a whole. The two studies on T. gondii were the first to investigate seroprevalence of T. gondii in 
Namibia since 1978.  It was the first study to determine risk factors associated with toxoplasmosis 
among pregnant women in Namibia. This was only the second study to determine seroprevalence 
of rubella among pregnant women in Namibia. This study was the first done in Namibia on 
seroprevalence of cytomegalovirus in any population.   
 
There had been a lack of local access to IgG avidity testing in Namibia and this had only recently 
become available. There remains limited availability and it is not clear whether awareness of its 





The study furthermore resulted in four manuscripts which have either been published or have been 
submitted to peer-reviewed journals. Findings described in these four publications are evaluated and 
contextualized in this section. 
4.3.1  Toxoplasma gondii 
The two study groups, namely of blood donors in Central Namibia and of urban pregnant women 
attending public antenatal care in Windhoek, Namibia from September to October 2016 had low 
prevalence of antibodies to T. gondii. This could possibly be attributed to geographical and 
meteorological aspects.  
The first publication on the study among blood donors showed that they had not been exposed to T. 
gondii to a greater extent. One blood donor who had IgM antibodies to T. gondii could possibly pose 
a risk of transfusion transmitted infection. Since he lived in the urban area it is postulated that he got 
infected by eating undercooked meat. Many restaurants in Windhoek serve venison and it is popular 
to order it rare. The very low overall seroprevalence of T. gondii among blood donors, however, does 
not justify routine screening of blood donors for T. gondii infection. Therefore, a minimal risk of 
transfusion transmitted infection remains.  
Seroprevalence of T. gondii among blood donors could further give an indication of the prevalence 
of T. gondii among the general population of Namibia. The rate of 1% was much lower than the 12% 
found in the same region in 1978. This finding is in line with the decline in toxoplasmosis found world-
wide over the past centuries. This could possibly be due to climate changes like droughts and flash-
floods which do not favour the survival of oocytes. Also, freezing facilities for raw meat have become 
more widely available, eliminating live oocytes from meat products. In addition, access to clean 
drinking water is hopefully improving world-wide. 
In the subsequent study on seroprevalence of T. gondii among pregnant women the result was also 
very low, indicating that residents in the central part of Namibia are not greatly exposed to T. gondii 
while pregnant women carry little risk of transmitting the infection to the foetus. Therefore, low 
prevalence of CT could be expected in the Khomas region. The youngest and oldest age groups 





the highest exposure with seroprevalence of 5.21%. It once again shows that different age groups 
did not have similar exposure to infection. 
Seroprevalence of T. gondii in different parts of the world vary greatly. Seroprevalence in Namibia 
was comparable to that in neighbouring South Africa [41], and the prevalence in Mexico [135], with 
similar weather patterns. The study in Mexico similarly did not find any association between 
toxoplasmosis among women and raw meat consumption, cow raw milk consumption, goat raw milk 
consumption, unwashed raw vegetables consumption or untreated water consumption.  
4.3.2  Rubella 
In the third manuscript the study group of urban pregnant women attending antenatal care in 
Windhoek, Namibia from September to October 2016 had high prevalence of rubella immunity (IgG 
> 15 IU/ml), despite only 7% of these women being known to be included in the nationwide SIA of 
July 2016. This indicates that the majority of pregnant women in this group had rubella immunity 
probably due to natural infection.  A previous study found that seroprevalence of rubella virus among 
pregnant women attending the same antenatal clinic was 84% in 2010 [10]. In our study 
seroprevalence had increased to 95.9% in 2016 after an outbreak in 2015 and after the national 
rubella vaccination campaign in July 2016.  As few individuals in our study had been vaccinated, this 
increase was probably due to naturally acquired immunity obtained during previous rubella outbreaks 
in Namibia and could not be attributed to the SIA vaccination campaign alone.   
In our study, the average level of rubella IgG (IU/ml) was determined in five different age groups with 
no significant difference of infection among the age groups. The overall level of anti-rubella IgG was 
much higher than the level found among pregnant women in Canada where rubella vaccination had 
been implemented in the 1970s [30]. A recent study among pregnant women in Iran found a mean 
concentration of anti-rubella IgG of 14.9 IU/mL after a nation-wide mass vaccination campaign [66]. 
It is possible that the anti-rubella IgG concentration in our study was artificially elevated after a recent 
rubella outbreak. This could explain the extremely high overall anti-rubella IgG concentration in this 
mainly unvaccinated population. It underscores previous findings that natural immunity elicits a much 





Our finding that primigravidae had higher rubella antibody concentrations could indicate that younger 
age groups had been more affected by recent rubella outbreaks.   
Overall, high seroprevalence found in all age groups could indicate low risk of vertical transmission 
of rubella since very few cases of re-infection in previously immune individuals have been reported. 
The high seroprevalence found in our study was similar to the seroprevalence reported in South 
Africa [57] while it is comparable to seroprevalence found in other developing countries. 
4.3.3  Cytomegalovirus 
The seroprevalence of IgG to CMV was also comparable to the seroprevalence found in other 
developing countries with one other African country also reporting seroprevalence of 100% [108]. All 
pregnant women in our study had IgG antibodies for CMV (100% seroprevalence). Five participants 
had IgM antibodies for CMV with 6 participants having grey zone results.  This seropositivity could 
have been associated with reactivation of the infection, or re-infection with a new strain of CMV or 
false positive IgM results.  IgG avidity was high in all cases indicating absence of primary infections. 
Pre-existing immunity does, however, not exclude vertical transmission of the virus during 
pregnancy. Despite the high seroprevalence of CMV among pregnant women, the Namibian 
population might carry the burden of congenital CMV infection among infants [108,140]. This may 
contribute to long term disability, especially sensorineural hearing loss [111]. In Windhoek deaf adults 
are seen begging in parking lots and the question arises as to the cause of the hearing disability. To 
what extent is deafness in the Namibian population attributable to congenital infection? Further 
studies are needed to determine the prevalence of cCMV in Namibia and neonatal surveillance 
studies may be important to establish the prevalence of cCMV disease. Since surveillance studies 
involving PCR testing would be costly, mathematical modelling could still be considered in future as 
more epidemiological data become available.  
4.3.4  Mathematical modelling 
For all three infectious agents, one of the objectives was to calculate incidence of infections in order 
to get information on the potential for congenital infections to occur. That was the reason for including 





mathematical modelling as described in the literature [144]. Main findings when the model was 
applied to data obtained in this study, were presented in Chapter three. This objective could not be 
met due to the nature of the data obtained. 
The following section focuses on the strengths and limitations of the study. 
4.4 Strengths and Limitations of the Study 
The study was successful in describing seroprevalence of three infectious agents among pregnant 
women in Namibia. This information could be useful to policy makers in the health sector to determine 
future diagnosis and treatment policies for pregnant women in order to address the possible burden 
of congenital infections. 
4.4.1 Challenges faced 
The study did face challenges in terms of financial constraints which made it impossible to reach the 
carefully calculated sample size. Furthermore, the results were not exactly as expected when the 
research questions were phrased. In both study populations the seroprevalence of T. gondii was 
very low, making it difficult to reach enough statistical power to establish meaningful associations 
between risk factors and infection. It is however, postulated that a much larger sample would have 
been needed in order to be able to establish associations and that the outcome would not have been 
much different.  For the rubella study, the major challenge was ambiguity regarding vaccination 
history.  It is however, concluded that the SIA did not have a meaningful effect on the study. 
Participants were able to indicate clearly whether they had been included in the SIA since it only took 
place two months prior to the study. Since no rubella vaccination had been done in the public sector 
prior to the SIA, the rest of the participants were deemed not to have received any vaccination. The 
CMV study posed a challenge due to 100% seropositivity among participants. Similar studies in 
developing countries created the expectation of a high seropositivity in this population, but such 
comprehensive seropositivity was not expected.  Unfortunately, this rendered the study unsuitable 
to consider risk factors for CMV infection. Finally, the objective of calculating incidence of the three 






4.4.2 Strengths and limitations 
A strength of the study is the inclusion of a pilot study of T. gondii seroprevalence among blood 
donors. Results from this study could inform the sample size which would be needed for the 
consecutive studies in the absence of relevant data from Namibia.  
A further strength of this study was the submission of a PhD by publication and due to its nature, it 
implied the publication of 4 – 5 manuscripts in peer-reviewed journals. The first achievement was 
the publication of the study among blood donors in a peer-reviewed journal. Three more articles had 
been prepared for publication of which two have been published by peer-reviewed journals which 
are indexed in widely accessible databases. Within three months the CMV manuscript had attracted 
more than 300 views.  To further enhance international visibility of study findings, an abstract on the 
seroprevalence of T.gondii among pregnant women had been accepted by the International 
Conference on the HIV Treatment Pathogenesis and Prevention Research in Resource-Limited 
Settings (INTEREST) 2020 which is the largest international platform for HIV-related studies from 
Africa.  
It is thus envisaged that results from this study will be useful to clinicians and health administrators 
within Namibia but also beyond its borders, especially in other resource-limited settings. 
Furthermore, results from this study contribute to the growing body of evidence-based information 
becoming available in Namibia. Before Independence in 1990, isolated studies performed by the 
South African Defence Force based in then South West Africa were published in local journals. It 
was only after the establishment of the Medical School at the University of Namibia (2009) and the 
Faculty of Health and Applied Sciences at NUST (2010) that medical research was conducted on 
limited scale in Namibia. Although a lot of data are available, publication in reputable journals outside 
the African continent still poses a challenge to many African researchers. Furthermore, securing 
funding for medical research remains a challenge in economies which are hardly hit by other 
disasters like the HIV, malaria and tuberculosis burdens and severe droughts. 






4.4.2.1 Validity and reliability of the study 
In the absence of any recent information on the seroprevalence of the three agents in Namibia, it 
was important to get an indication of the current seroprevalence of at least one of them. Therefore, 
seroprevalence of T. gondii was assessed among blood donors in preparation of the study on 
seroprevalence of three infectious agents among pregnant women. This information was used in the 
calculation of the sample size for the bigger study among pregnant women. It also gave a preliminary 
impression of results which could be expected for toxoplasmosis in the study among pregnant 
women. 
Pregnant women are often used in nation-wide studies to determine seroprevalence of infections. 
An example is the statistics on HIV infection rates in different regions, which are derived from the 
testing of blood collected from pregnant women (HIV sentinel surveys). Data obtained in this 
population are generally accepted as representative of the general population.  
Validity and reliability of data were also ensured. As far as validity of the questionnaire is concerned, 
a pilot assessment was performed with a woman of childbearing potential to ensure that the 
questions are clear and unambiguous. Data obtained in the questionnaire were entered in a 
spreadsheet by senior Medical Laboratory Sciences students. Data were encoded and cleaned by 
the researcher. Spot checks were done to ensure that data were transferred correctly from the 
questionnaires to the spreadsheet. All positive laboratory results were double checked for correct 
transcript.  
Laboratory testing was done in a SANAS accredited laboratory which operates according to ISO 
15189 standards. The test method used for IgG and IgM testing utilizes the latest technology and is 
seen to be adequately sensitive and specific. For interpretation of results, reference ranges either 
from the manufacturer of the kits or the pathology laboratory were used. 
To ensure validity of statistical analysis, a biostatistician was involved from an early stage in the 
study design and data analysis of the study. He also critically reviewed the manuscript on rubella 
before submission to the journal. A second biostatistician assisted with multivariate analysis for T. 





For all manuscripts, co-authors from other Universities and from industry were involved in the critical 
review process. Submissions were made to peer-reviewed journals which are listed in widely 
accessible databases. 
4.4.2.2 Limitations of the study 
Similar to most studies in health research, there were limitations to the study. Firstly, this study was 
only done at one public antenatal clinic in Central Namibia, so the data were not representative of 
the whole country.  Especially in the case of T. gondii which is dependent on social and 
environmental factors, other regions of Namibia could yield different results. Namibia has diverse 
ecosystems ranging from the oldest desert in the world to a semi-tropical climate in the north. 
Furthermore, rural communities have different lifestyles from urban communities. 
The study among blood donors was possibly biased due to blood donors probably living a healthier 
and more affluent life than citizens in remote villages of the country. An attempt was made to improve 
on this by conducting the bigger study in a population of state patients attending public health care. 
A major setback for the study was the premature termination of funding. This led to a situation where 
the calculated sample size could not be reached. It is, however, believed that a larger sample size 
would not have changed the outcome of the study. Due to the very low seroprevalence of T. gondii 
a huge sample size would be needed in order to identify significant associations with risk factors. In 
Namibia funding and resources are not available to facilitate a study with such a large sample size.  
For rubella and CMV, seroprevalence was very high or 100% and a larger sample size would not 
have changed the results. 
The validity of the IgG avidity testing could not be established. This was the first time that the 
methodology was used in Namibia and there are no reference laboratories available in country.  
Contact was established with a private laboratory in Pretoria in South Africa, who use the same 
manufacturer’s reagents for CMV IgG avidity testing.  Furthermore, NHLS laboratories in Cape Town 
in South Africa were willing to test serum for T. gondii IgG avidity. However, regulations regarding 





compromised due to a power failure in the NUST laboratory during the summer recess. Therefore, 
efforts to validate the test method for IgG avidity testing were not successful.  
For rubella the questions in the questionnaire regarding immunization history were not well designed.  
The reason for this was the recommendation that the protocol be written in such a way as to facilitate 
further testing for other infectious agents when this study is completed.  The questions on 
immunizations were thus phrased to include measles immunization history in addition to rubella 
immunization history.  However, for the purpose of this study the researcher focused on the answers 
to the question whether participants were immunized in July 2016. This was the first rubella 
immunization campaign in Namibia. Therefore, if they were not immunized in 2016 due to being 
pregnant at the time, it means that they had never received rubella immunization. 
Another limitation for the rubella study was the publication a few weeks before sample collection 
started, of a comprehensive study on rubella seroprevalence covering the whole country using HIV 
sentinel survey samples as discussed in Section 4.3.2 of this chapter.  Therefore, the current study 
was not the first to be published on rubella in Namibia as planned in the protocol. 
Our findings also highlight how difficult it is to determine incidence of maternal infections that could 
pose intrauterine infection risks. We attempted to use an age-prevalence model, as this would have 
been most cost-efficient and affordable, but in the case of CMV, women of child bearing potential 
had already been infected and we had no reliable way to determine the rate of reinfections (assays 
to detect these are not freely available and have not been validated).  
Another limitation of the age-prevalence ratio approach to determine incidence is that it may only 
work in populations with relatively high stability and very similar exposure risks amongst age cohorts. 
The T. gondii and rubella age-prevalence trends suggest that the different age cohorts in our study 
may have had different exposure risks. As developing countries often experience large population 
movements including immigration or emigration or urbanisation, with accompanied different living 
conditions, population density and exposure risks, this approach may not be feasible in many 
developing countries. An alternative approach is to screen large numbers of blood samples that are 





acute or recent acute infections. If one assumes a 1% annual incidence, and IgM remaining 
detectable for 6 weeks, it would require a cross sectional sample size of > 140 000 for a precision 
(95% confidence interval) of 30% or smaller around the estimate (binomial probability test).  Similarly, 
prospective cohorts of pregnant women are very costly. Moreover, IgM assays in cases with a low 
pre-test probability have very low positive predictive values, which would result in many more false 
positives than true positives.  Therefore, additional confirmatory testing of IgM positive samples to 
determine IgG avidity would be required to partially overcome this. Lastly relying on reporting of 
congenital infections are also inadequate as this would rely on diagnostic screening of infants to 
detect congenital infections, which is not feasible in most resource limited settings.  
Despite these limitations the study was able to identify areas for further investigation.  
4.5 Impact of the study: Health with a focus on Namibia 
Results from this study indicates that congenital infections with T. gondii, rubella are probably not a 
huge public health concern in Central Namibia. While there may be an underdiagnosis of mild or 
asymptomatic congenital CMV in children from mothers with reinfection or reactivation, it is not clear 
to what extent asymptomatic cCMV impacts on long term child development. We found a low 
seroprevalence of T. gondii and high immunity to rubella and high proportion of CMV seropositivity 
among pregnant women. It is significant to note that T. gondii is not highly prevalent in Central 
Namibia. The results from this study do not justify routine screening of blood donors or pregnant 
women for T. gondii, although a previous study indicated that maternal screening could save cost in 
terms of support of disabled persons [42].  
The results from the rubella study were useful to inform policy makers that a group of women were 
missed during the first rubella SIA due to being were pregnant at the time of the SIA. In Central 
Namibia, however, unvaccinated women exhibited high immunity to rubella, with the percentage of 
susceptible women within the acceptable range determined by WHO. Women missed during the SIA 
probably pose minimal risk for CRS in future outbreaks and do not justify follow-up nation-wide 





A 100% seroprevalence of CMV among pregnant women probably indicates no further public health 
action is required. It is, however, evident from previous studies that non-primary CMV infection also 
poses a risk for cCMV to develop. Policy makers and clinicians should be made aware of this. 
There is limited access to IgG avidity testing in many resource-limited settings. Availability of avidity 
testing may assist clinicians in differentiating risk of congenital infections as primary rubella infection 
or CMV infection are both associated with an increased risk of transmission to the foetus. Moreover, 
as IgM assays performed in patients with a low pre-test probability of infection have low positive 
predictive values a concurrent low avidity would increase support for a recent acute primary infection.   
 
The question could be asked about the application of the CMV IgM and IgG avidity tests in a setting 
with very high seroprevalence of CMV. According to Prince and Lape-Nixon (2014) the IgG avidity 
test is useful to determine the time of infection in case of a primary CMV infection during pregnancy. 
This information is useful to indicate further testing and treatment if it is available. IgM detection is a 
sensitive marker of primary CMV infection, but its specificity is poor because CMV IgM is also 
produced during viral reactivation and persists following primary infection in some individuals [163]. 
CMV IgG avidity is both a sensitive and specific method for identifying a pregnant woman with recent 
primary infection and thus at increased risk for vertical CMV transmission [163]. Results from our 
study showed that primary CMV infection is not likely in this study population.  Although all CMV IgG 
avidity tests showed a high avidity, it is possible that reactivation or reinfection with CMV could have 
occurred. A review of studies in 5 medical centres in Europe summarized the following IgG avidity 
results among pregnant women: (i) primary infection (seroconversion/virus isolation) >85% low 
avidity; (ii) past infection (CMV IgG positive IgM negative) >90% high avidity; (iii) CMV reactivation 
(four-fold increase of CMV IgG levels with or without detectable IgM); or IgG positive IgM positive for 
more than a year >90% high avidity; (iv) at risk group of pregnant women (first prenatal serum IgG 
positive IgM positive precluding determination when primary infection occurred) 50% high avidity. All 
women who had CMV-infected offspring exhibited low CMV IgG avidity [163]. However, two other 





offspring [163,164]. This finding is supported by the demonstration of cCMV in settings with very high 
CMV seroprevalence where reactivation of latent infection probably predominates. 
In conclusion, there is no routine screening programme for maternal CMV in any country and the 
reasons are postulated: (i) unjustified pregnancy termination due to anxiety of the mother; (ii) lack of 
interventions proven to reduce or prevent transmission even in primary infection; (iii) inability of 
screening programmes to identify the small percentage of women who exhibit CMV antibodies before 
conception but transmit the infection to their foetuses [163]. 
 
4.6  Future perspective  
 
4.6.1 T. gondii 
Further studies could be conducted on the seroprevalence of T. gondii in rural areas in Namibia. T. 
gondii might show higher seroprevalence in rural areas as reported by a previous study in Namibia 
[7]. Animals which are raised in a free-range setting are more likely to get infected [138] and rural 
populations live in closer contact with animals than the population studied in this research. 
It could be useful to study the prevalence of T. gondii in the sub-tropical savannah areas of Namibia. 
This study was conducted in the dry central area of Namibia and it is expected that seroprevalence 
of T. gondii will be higher in the northern regions where rainfall is higher and more favourable 
conditions for the survival of oocysts prevail.  
Information on genotypes of T. gondii circulating in Africa is scarce. It seems like there are two T. 
gondii population structures in Africa: one in desert and semi-arid North and East Africa and one in 
the tropical zone of Central and West Africa. No genotyping studies of T. gondii have been done in 
Southern Africa [139]. Genotyping of T. gondii in Southern Africa is recommended in view of the 
possible development of a vaccine. 
In France, where high seroprevalence of T. gondii prevailed in the previous century, the reduction of 





habits (the Ministry of Agriculture and Food reported a 30% decrease in beef consumption between 
2000 and 2010) and preventive education [15,144].  Even in a country with low seroprevalence like 
Namibia, preventive strategies like the education of pregnant women to create awareness of hygienic 
practices like hand washing and safe water could be promoted. This would prevent primary infection 
of susceptible pregnant women and reduce the risk of CT with the social and economic burden which 
it carries. CDC recommendations for prevention of toxoplasmosis in pregnant women can be found 
at: http://www.cdc.gov/parasites/toxoplasmosis/prevent.html. 
Parasites-toxoplasmosis (Toxoplasma infection). Available at: 
http://www.cdc.gov/parasites/toxoplasmosis/gen_info/pregnant.html. Accessed November 2018. 
Routine maternal testing for toxoplasmosis could save cost.   Despite the low prevalence of 
toxoplasmosis among pregnant women in the central region of Namibia, routine maternal testing 
could be indicated should data about the prevalence of CT in Namibia become available in future 
and should safe and effective treatment for pregnant women be developed and become available in 
Namibia. Despite the cost of early diagnosis and treatment of toxoplasmosis, it could be a cost-
saving strategy in the long run. In European countries like France, where routine maternal screening 
for T. gondii is mandatory by law, a reduction in rates and severity of CT has occurred. In France 
where relatively high seroprevalence of T. gondii prevails, screening for CT is mandatory since 1992. 
Seroprevalence of T. gondii decreased from 84% in the 1960’s to 54% in 1995 and further to 44% in 
2004 [42,144]. Stillwagon et al. (2011) compared the cost of pre- and postnatal diagnosis and 
treatment, versus estimates of lifetime societal costs of developmental disabilities. They postulated 
that for populations with rates of CT greater than 1 infected child per 10 000 live births or 2 infected 
mothers in 10 000, maternal serologic screening is a cost-effective strategy. This is much lower than 
the 2.61 infected pregnant women in 100 found in Central Namibia. Although the cost of diagnosis 
and treatment in Namibia is not known, maternal screening for toxoplasmosis could possibly also 
save lifelong costs, especially in rural areas where seroprevalence may be higher [7]. Early 





No information on the prevalence of CT in Namibia is available. An important intervention to control 
the occurrence of CT is the implementation of a CT surveillance system. This is however very rare 
in developing countries and researchers use data from literature reviews to model incidences of CT. 
Global estimated incidence of CT is 1.5 cases per 1000 live births or 190 100 annual cases. 
Incidence of CT in the WHO Afro region is 2.4 per 1000 live births or 37 000 cases annually [43].    
Due to the vibrant wild-life industry in Namibia, a One Health-approach should be followed to curb 
toxoplasmosis in human populations. Closer collaboration between health care providers and 
veterinarians would be beneficial to address zoonotic diseases like toxoplasmosis. 
The findings of this study in the setting of a developing African country are greatly underscored by 
the European CDC Report on Congenital Toxoplasmosis from 2016 [151].  They raised a concern 
about the cost benefits for prenatal screening programmes mainly because of the low prevalence of 
CT in European countries and lack of effective treatment. However, considering recent 
epidemiological studies in non-reporting countries, changes in eating habits (e.g. the consumption 
of undercooked meat), increased travel and therapeutic developments, the significance of this 
infection in European countries warrants a better estimation. Congenital disease should be better 
investigated to assess severity, urban vs. rural setting and prevalent risk factors in a specific region. 
Prevention options for CT should be reinforced. Information for pregnant women should include 
information about T. gondii risk factors [151]. Diagnostic capabilities in the clinical as well as in the 
food sector should be regularly assessed against the changing epidemiology of the disease and 
circulating pathogen genotypes. They raised a concern about the introduction of exotic genotypes 
through imported food, causing severe disease in immunocompetent adults as already reported in 
France.  Therefore, the One-Health approach is mentioned [151]. In Namibia, collaboration with CDC 
could be expanded beyond the classical agenda of HIV, Tuberculosis and malaria, to include 






It is important for public health care providers to ensure that the newly implemented MR vaccination 
of all children at the age of 15 months be maintained comprehensively to prevent further outbreaks 
of rubella in future, and to mitigate the risk of CRS. 
All available information on the seroprevalence of rubella among pregnant women in Namibia 
originates from the public sector.  Co-ordinated involvement of the private sector is needed to ensure 
sufficient vaccination coverage to protect the population against CRS.  
4.6.3 CMV 
Further studies are needed to determine the prevalence of cCMV among newborns in Namibia. Only 
then can it be established whether public health care interventions are needed to counteract the 
effect of secondary CMV infection among pregnant women. A recent study in the Eastern Cape in 
South Africa where high seroprevalence of CMV also prevails, established that 6% of babies born in 
an academic hospital, were PCR positive for CMV. This finding was similar to results in other 
resource-limited settings [140]. 
Further studies in Namibia could also focus on determination of the age of infection with CMV in the 
population. 
4.6.4 Mathematical modelling 
Mathematical modelling could be explored in future to determine incidence of CRS, should more 
seroprevalence data and immunisation coverage data of rubella become available [141]. In the report 
by Cutts and Vynnycky, estimates of the incidence of infection among pregnant women were 
calculated using the average susceptibility to infection and the incidence of infection during gestation 
[62]. Since there is no data available on the occurrence of CRS in Namibia, mathematical modelling 
could provide valuable information without costly and invasive research methodology.  
Given the very low rate of T. gondii in Namibia, very large sample sizes would be needed to estimate 
likely transmission rates to the foetus. In a study in France, where relatively high seroprevalence of 





Surveys and the National Surveillance of Congenital Toxoplasmosis were used. Data were collected 
from 42 208 pregnant women. In addition, procedures like amnioscentesis are done to establish 
foetal infection [144]. This is not achievable in low income countries. 
4.7 Conclusion 
This study investigated the extent of vertically transmissible infections among pregnant women in 
Central Namibia. Seroprevalence results (IgG) indicated that previous exposure to T. gondii was very 
low among participants. Previous exposure to rubella and CMV had been very high with 95.9% of 
participants being immune to rubella and 100% of participants found to be CMV IgG seropositive. It 
is concluded that very low risk of vertical transmission of the infections existed in the study 
population.  
This was further supported by results from IgM and IgG avidity testing which indicated that no current 
infection with either T. gondii or CMV occurred among participants during the study period. Further 
investigation into the incidence of infections by employing mathematical models did not prove 
successful due to data being unsuitable for age-prevalence modelling. Participants in five age groups 
did not exhibit equal exposure to T. gondii and rubella and furthermore, the seroprevalence did not 
follow a linear increase over age as expected and as had been found in previous studies. In the case 
of CMV 100% seroprevalence in all age groups rendered the data unsuitable for modelling. The ideal 
method to investigate incidence would have been to use a very large sample size like HIV sentinel 
survey samples and determine IgG avidity in IgM positive cases. This is, however, not plausible in 
resource-limited settings.  
Another objective which could not be explored to its full potential was the association of risk factors 
with maternal infection due to either very low or very high seroprevalence found among participants.  
In the case of rubella, primigravidae showed a positive association with anti-rubella IgG levels 
indicating that younger age groups had higher antibody titres to rubella. This was attributed to 
younger persons being more exposed to rubella outbreaks in crowded situations like schools and 
hostels. Although risk factors for CMV had been included in the questionnaire they could not be 





The very high overall mean rubella IgG concentration found among participants was attributed to 
natural immunity acquired during previous rubella outbreaks. The mean anti-rubella IgG level among 
participants was much higher than those reported by two post-vaccination studies in other countries. 
It underscores the belief that antibody production due to vaccination may wane and it showed that 
the study population in Namibia was highly protected against future rubella outbreaks.  
In conclusion routine testing of pregnant women for T. gondii, rubella and CMV IgG may not be 
justified based on the results of this study. This concurs with recommendations from a previous study 
done in South Africa [142]. Furthermore, results from this study do not indicate the necessity of 
follow-up rubella vaccination campaigns after pregnant women missed the SIA in July 2016. This is 
due to high naturally acquired rubella immunity found in this study. It should, however, be 
emphasized that the newly introduced rubella vaccination of all children at 15 months be maintained 
in order to avoid development of the paradoxical effect of insufficient rubella vaccination coverage. 
Health care providers should also be made aware of the occurrence of cCMV in developing countries 
despite very high seroprevalence of CMV among pregnant women as described in the literature.  
Although a surveillance programme may not be justified, future investigations into congenital 
infections with T. gondii, rubella and CMV might prove useful to establish the extent of congenital 
infections impacting on the Namibian population.  Although this study was able to report on the 
prevalence of maternal infections with these three agents in Central Namibia, it was for various 
reasons not completely able to evaluate the risk of vertical transmission and congenital infection.  
Immunoglobulin M positive cases were few and IgG avidity was high or equivocal in all IgM positive 
cases indicating low risk of transmission to the foetus. The low positive predictable value of IgM tests 
for these infections poses a further challenge and much larger samples sizes would be needed to 
effectively evaluate transmissible intra-uterine infections.   
If a better understanding of the extent of infectious diseases amongst pregnant women is achieved, 
it could lead to improved management of this group of patients and assist to identify possible 
interventions needed in the Namibian healthcare system. Further investigations are needed to 





Although seroprevalence of T. gondii among pregnant women was very low, the preventive effect of 
hygiene education given by health authorities to susceptible women during pregnancy could be 
considered. 
Better understanding of the immune status of pregnant women might guide expanded immunisation 
programmes including rubella vaccination, possibly linking it to the national measles campaigns by 
the MoHSS.  
Improved understanding of cCMV transmission rates resulting from non-primary maternal infections 
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Addendum D: Recruitment Advertising Leaflet 
 
Dear Patient 
Did you know that infections other than HIV (for example German measles) can affect you and your 
unborn child? 
Infectious diseases contribute to the high death rate and illness of pregnant women and their children 
in Africa.  Several infectious diseases may be transmitted from a pregnant woman to her unborn 
child having bad effects on the newborn baby which include deafness, blindness, mental retardation, 
physical impairment or even spontaneous abortion or stillbirth. Information about these infections is 
essential for health care workers to either treat or prevent these diseases. Some of these infections 
can be prevented by vaccination before pregnancy (German measles and chicken pox) or through 
reduction of exposure risk before or during pregnancy (toxoplasma and cytomegalovirus). 
Information on the prevalence of infections in newborn babies in Namibia is limited. Therefore, this 
study aims to determine the prevalence of some important mother-to-child transmitted infectious 
diseases in women of childbearing age in Namibia. You are kindly invited to participate in a research 
project on infectious diseases other than HIV which can be transmitted from a mother to an unborn 
child. 
Please ask the sister for more information and she will hand you an information pamphlet explaining 
the study to you. She will also explain what you need to do should you choose to participate in the 





Addendum E: Participant Information Leaflet and Consent 
Form 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT: Seroprevalence and incidence of Toxoplasma 




REFERENCE NUMBER:  
 
PRINCIPAL INVESTIGATOR: Ms E van der Colf 
 
ADDRESS: Department of Health Sciences, Faculty of Health and Applied Sciences, 
Namibia University of Science and Technology 
 
 
CONTACT NUMBER:  00264 61 207 2872 
 
 
You are being invited to take part in a research project.  It will take about twenty minutes. 
Please take some time to read the information presented here, which will explain the details 
of this project.  Please ask the study staff or doctor any questions about any part of this 
project that you do not fully understand.  It is very important that you are fully satisfied that 
you clearly understand what this research entails and how you could be involved.  Also, your 
participation is entirely voluntary and you are free to decline to participate.  If you say no, 
this will not affect you negatively in any way whatsoever.  You are also free to withdraw from 
the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research.  This study is funded 
by the National Commission on Research, Science and Technology. 
 
 
What is this research study all about? 
➢ 540 participants will be recruited at the antenatal clinic of Windhoek Central Hospital 
➢ This is a study on the prevalence of infectious diseases in pregnant women.  The 
infections I am investigating are Toxoplasma gondii (a parasite), rubella (German 
measles), measles, cytomegalovirus (causes flu-like symptoms), varicella (chicken 
pox) and hepatitis B virus (jaundice).  If a woman contracts one of these infections 
during pregnancy, the infection can be passed on and have serious effects on the 
unborn child. It can cause abnormalities like deafness or other disabilities or even 
stillbirth 
➢ If you agree to participate, the sister will ask you a few questions and take a blood 





above with no extra testing. Your blood sample will be stored in a building with access 
control for a period of five years, after which it will be incinerated. 
➢ 108 patients in each age group will be selected, so once that number has been 
attained, no more patients in that age group will be recruited 
 
Why have you been invited to participate? 




What will your responsibilities be? 




Will you benefit from taking part in this research? 
➢ This study will give information to the Ministry of Health and Social Services, on the 
prevalence of these infections in pregnant women, and hopefully lead to better diagnosis 
and treatment of these patients, as well as improved immunisation programmes for state 
patients.  
 
Are there in risks involved in your taking part in this research? 
➢ There is only minimal risk associated with the collection of a blood sample. This will 
be done by a qualified phlebotomist/nurse. 
 
 
If you do not agree to take part, what alternatives do you have? 
➢ You may discuss it with the doctor at the clinic if you feel that you are at risk for any 
of these infections. 
 
 
Who will have access to your medical records? 
The information collected will be treated as confidential and protected.  If it is used in 
a publication or thesis, the identity of the participant will remain anonymous.  Student 
Medical Laboratory Scientists who do data entry will sign a Confidentiality Statement.  
 
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
➢ No medications are involved  
 
 
Will you be paid to take part in this study and are there any costs involved? 
 
➢ No, you will not be paid to take part in the study. There will be no costs involved for 







Is there anything else that you should know or do? 
➢ You can contact Ms E van der Colf at tel 061-207 2872 if you have any further queries 
or encounter any problems. 
➢ You can contact the Health Research Ethics Committee at 002721-938 9207 if you 
have any concerns or complaints that have not been adequately addressed by your 
study doctor. 
➢ You will receive a copy of this information and consent form for your own records. 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled “Seroprevalence and incidence of Toxoplasma gondii, rubella and 
cytomegalovirus in Namibian women of childbearing potential”. 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written 
in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced 
in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 




Signed at (place) ......................…........…………….. on (date) …………....……….. 20   . 
 
 ...............................................................  ............................................................. 
Signature of participant Signature of witness 
……………………………………………………………………….. 
Signature of Parent/Guardian if Participant is under the age of 18 years 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 






• I did/did not use a interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 20  . 
 
 ...............................................................  ............................................................. 
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………………………………………. to explain 
the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Oshiwambo. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
 




 ...............................................................  ............................................................. 












FACULTY OF HEALTH SCIENCES  
 
 
PARTICIPANT INFORMATION LEAFLET AND ASSENT FORM 
   
 
TITLE OF THE RESEARCH PROJECT: Seroprevalence and incidence of Toxoplasma gondii, 
rubella and cytomegalovirus in Namibian women of childbearing potential. 
 
RESEARCHERS NAME(S):  Ms E van der Colf 
 
ADDRESS: Department of Health Sciences, Faculty of Health and Applied Sciences, Namibia 
University of Science and Technology (NUST) 
 
CONTACT NUMBER:   61 207 2872 
 
What is RESEARCH? 
 
Research is something we do to find new knowledge about the way things (and people) work.  We 
use research projects or studies to help us find out more about disease or illness. Research also 
helps us to find better ways of helping, or treating children who are sick. 
 
What is this research project all about? 
This is a study on the prevalence of infectious diseases in pregnant women.  The infections we are 
investigating are Toxoplasma gondii (a parasite), German measles, measles, cytomegalovirus 
(causes flu-like symptoms), chicken pox and hepatitis B virus (jaundice).  If a woman contracts one 
of these infections during pregnancy, the infection can be passed on and have serious effects on the 
unborn child. It can cause abnormalities like deafness or other disabilities or even stillbirth. 
 
Why have I been invited to take part in this research project? 
The researchers want to test the blood of pregnant women attending the antenatal clinic at 
Windhoek Central Hospital, while including people of the age group 13 to 45.   
 
Who is doing the research? 
Ms Van der Colf and Professor Reju are lecturers at NUST and we are working with Professor Van 
Zyl at the University of Stellenbosch and Professor Noden at Oklahoma State University.  Once we 
have the information on the prevalence of infections in pregnant women, we shall share the 
information in the form of publications and also advise the Ministry of Health and Social Services. 
 
 
What will happen to me in this study? 
If you agree to participate, the sister will ask you a few questions and take a blood sample.  The 
blood taken will be used to test for the infectious diseases mentioned above with no extra testing.  
 





The sister will just give you a small prick to withdraw one blood sample.  Please inform your 
parents should you experience any discomfort after the blood sample has been withdrawn. 
 
Can anything good happen to me? 
This study will give information to the Ministry of Health and Social Services, on the prevalence of 
these infections in pregnant women, and hopefully lead to better diagnosis and treatment of these 
patients, as well as improved immunisation programmes for state patients.  
 
Will anyone know I am in the study? 
The information collected will be treated as confidential and protected.  If it is used in a publication 
or thesis, your identity will not be made known.  Information might be given to the NCRST who is 
funding this research. 
 
Who can I talk to about the study?  
You can contact Ms E van der Colf at tel 061-207 2872 if you have any further queries or encounter 
any problems.  
 
What if I do not want to do this? 
Participation is entirely voluntary, and you can refuse to take part even if your parents have agreed 





Do you understand this research study and are you willing to take part in it?   
YES  NO 
 
Has the researcher answered all your questions? 
 
YES  NO 
 
Do you understand that you can pull out of the study at any time? 
 
YES  NO 
 
 
_________________________  ____________________  







Addendum G: Questionnaire 
 
QUESTIONNAIRE 
    
Age        
 
Where do you live?    Windhoek house with own tap 
 Windhoek house with communal tap 
       Farm / village 
 
Month of pregnancy     1 to 3 
       4 to 6 
       7 to 9 
 
Number of previous pregnancies?    None 
One 
       Two or more 
 
Did you have problems with previous births if you had any?   
No problems with previous pregnancies 
Premature baby 
       Baby with jaundice 
       Emergency caesarean section 
       Stillbirth / miscarriage 
       Baby died within four weeks 
 
Do you live with animals around the house?  None 
Cat 
       Dog 
       Goat 



























Do you consume any of the following:  Water other than running tap water 
Unpasteurized cow’s milk or products of it 
Goat’s milk or products of it 
Raw or undercooked meat 
Fruit and vegetables which have not been 
washed 
 
Were you ever immunised against measles and /or rubella? 
 
       Yes                  No                 Don’t know 
 
If yes, when were you immunised?   July 2016 
As a child 
       Don’t know  
 
Did you ever receive a blood transfusion?  Yes                   No 
 
Do you have children less than five years of age in the house?          Yes             No 
 
If yes, kindly record the number and ages: 
Number of children less than five years  
Age of first child     
Age of second child     
Age of third child     
Age of fourth child     
 
How many times per day do you wash your hands? 
Three times or less  
More than three times   
 





























I ___________________________________________________  (full names and surname) 
 
_____________________________  (Identity number) 
hereby declare that I am aware of the obligation to keep patient records containing any demographic 
or other personal and clinical information confidential. 
 
I shall at all times maintain confidentiality when handling patient data for the research project titled: 
“Seroprevalence of Toxoplasma gondii, rubella and cytomegalovirus among pregnant women 
attending the antenatal clinic at Windhoek Central Hospital.” 
 
I shall not share any information collected during the course of this research project with any other 
medical staff, fellow students or members of the public. 
I shall ensure safekeeping of records at all times, and only use the information as instructed by the 
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